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The present disclosure provides compositions for inhibiting 
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methods of using the disclosed protease inhibitors. Aspects of 
the disclosure include a peptidyl propenoyl hydrazide com-
positions that inhibit proteases, for example cysteine pro-
teases, either in vivo or in vitro. 
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PROPENOYL HYDRAZIDES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims benefit of and priority to U.S. Pro-
visional Patent Application No. 60/545,354 filed on Feb. 18, 
2004, and which is incorporated by reference in its entirety 
where permissible. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
Aspects of the work disclosed herein were support in part 
by the National Institutes of Health. Therefore, the U.S. gov-
ermnent may have rights in the claimed subject matter. 
BACKGROUND 
1. Technical Field 
This disclosure relates generally to protease inhibitors and 
applications thereof, more specifically to peptide inhibitors of 
cysteine proteases, even more specifically to propenoyl 
hydrazides, methods of their use, and methods of their pro-
duction. 
2. Related Art 
Protease inhibitors are important therapeutics in the treat-
ment of a variety of disease conditions including viral infec-
tions such as HIV infection. Proteases are enzymes that 
cleave proteins or peptides and are classified into several 
groups. For example, cysteine proteases form a group of 
enzymes involved in numerous disease states, and inhibitors 
of these enzymes can be used therapeutically for the treat-
ment of diseases involving cysteine proteases. 
Cysteine Proteases. 
Cysteine proteases employ a thiolate residue, which per-
forms a nucleophilic attack on the amide bond of the peptide 
backbone to form a tetrahedral intermediate. The intermedi-
ate collapses to release the first product and the resulting acyl 
enzyme then undergoes hydrolysis. Based on their sequence 
homology cysteine proteases are divided into several clans 
and families. Clan CA and clan CD contain the majority of 
cysteine proteases. The majority of cysteine proteases, such 
2 
the action of various caspases. Indeed, many of the pro-
caspases are activated by other caspases, which selectively 
cleave at Pl Asp residues in their recognition sites. 
At present, there are 11 homologous members of the 
caspase family in humans. Some caspases are important 
mediators of inflammation, where they are involved in the 
production of inflammatory cytokines, and others are 
involved in apoptosis, where they participate in signaling and 
10 effector pathways. Group I caspases ( caspases-1,-4, -5, -11, 
-12, -13, and -14) are primarily mediators of inflanimation 
and are involved in proteolytic activation of proinflammatory 
cytokines. Caspase-1 is also involved in the Fas and TNFR 
apoptotic pathway. Group II caspases ( caspases-2, -3, and -7) 
15 
are late phase effectors of apoptosis and are involved in the 
cleavage of key structural and homeostatic proteins. Caspase-
3, also known as CPP32 (cysteine protease protein 32-kDa), 
Yama or apopain, is believed to be one of the major effectors 
20 in apoptosis. This enzyme is a key executioner because it is 
responsible either partially or totally for proteolytic cleavage 
of key apoptotic proteins. It functions to decrease or destroy 
essential homeostatic pathways during the effector phase of 
apoptosis. Caspase-3 cleaves or activates nuclear enzymes, 
25 such as poly(ADP-ribose)polymerase (PARP), the 70 kDa 
subunit of the Ul small ribonucleoprotein, the catalytic sub-
unit of DNA-dependent protein kinase, and protein kinase 
Co. Group III caspases (caspases-6, -8, -9, -10) are involved 
30 in the upstream early activation of effector caspases. Studies 
have shown that caspase-8 and -10 can cleave radiolabeled 
precursors for caspase-3. Caspase-6 is the only known 
caspase that cleaves the lamins, the major structural proteins 
in the nuclear envelope. Proteolysis oflamins is observed in 
35 cells undergoing apoptosis. Caspase-8 (MACH/FLICE), 
which can cleave all other known caspases, is suggested to lie 
in the pinnacle of the apoptotic cascade, at least when apop-
tosis is initiated by some stimuli such as Fas-L and TNF. 
40 Accordingly, the present disclosure encompasses composi-
tions and methods of altering, inhibiting, or reducing the 
formation of enzymatic reaction products involving cysteine 
proteases. Inhibiting the formation of cysteine protease reac-
tion products in vivo can provide therapeutic effects to 
patients suffering from unregulated or undesired protease 
activity. 
Caspases have a specificity for at least four amino acids to 
the left of the cleavage site (P side). The S4 subsite is the 
as papain, cal pains, cathepsins, and cruzain belong to the clan 
CA. According to the crystal structure of papain, clan CA 45 
proteases are unique for their catalytic triad formed by Cys, 
His, andAsn. The oxyanion hole is created by a preceding Gin 
residue. Clan CA enzymes are inhibited by E-64, a natural 
inhibitor of cysteine proteases, and cystatin. The substrate 
specificity of clan CA enzymes is primarily controlled by the 50 single most important determinant of specificity among 
caspases after the Pl Asp. The optimal sequences of the S2 enzyme subsite. Clan CD enzymes are unique for their 
lack of inhibition by E-64 and their specificity for the Pl 
amino acid residue. Even though clan CD is the smallest of 
the clans, it contains some very important enzymes. Among 
them are caspases, legumains, gingipains, clostripain, and 55 
separase. 
Caspases are a recently discovered family of cysteine 
endoproteases, which are highly selective for Asp at the Pl 
residue. As a result, this newly emerging family of proteases 
has been called caspases (cysteinyl aspartate-specific pro- 60 
tease). All caspases contain the conserved pentapeptide active 
site motif Gln-Ala-Cys-X-Gly (QACXG)(SEQ. ID NO. 1), 
where X=Arg, Gin, Gly (R, Q, G), and are synthesized as 
inactive proenzymes. The only other mammalian protease 
with specificity for Asp is the lymphocyte serine protease, 65 
granzyme B. Many of the proteolytic cleavages that are 
observed during apoptosis and cytokine maturation are due to 
caspases were obtained using a positional-scanning combi-
natorial substrate library (PS-CSL). The optimal recognition 
sequences for these enzymes are closely related to the 
sequences found in known macromolecular substrates. 
Group I caspases' optimal sequence is Trp-Glu-His-Asp 
(WEHD) (SEQ. ID NO. 2) with S4 favoring hydrophobic 
amino acids. Group II caspases' optimal sequence is Asp-
Glu-X-Asp (DEXD) (SEQ. ID NO. 3) with a requirement for 
Asp in S4. Group III caspases' optimal sequence is N-Glu-
X-Asp where N=Val or Leu, and X can be any amino acid 
( (V,L )EXD) (SEQ. ID NO. 4) with a preference for branched, 
aliphatic side chains in S4. The S3 subsite prefers glutamic 
acid (E) in most of the caspases, which could be explained by 
the salt link betweenArg-341 (involved in stabilization of the 
Pl aspartic acid) and the glutamic acid in P3. 
US 7,482,379 B2 
3 
Legumains (EC.3.4.22.34, asparaginyl endopeptidase) 
form a another important family (C13) of clan CD proteases. 
They are related to caspases and other clan CD enzymes by a 
shared catalytic-site motif and a common scaffold within 
their catalytic domains. They were first identified in legumi-
nous plants, and later in mammalian cells. In mannnalian 
cells legumain has been linked to osteoclast formation and 
bone resorption, and the processing of bacterial antigens and 
the potential autoantigen, myelin basic protein, in the major 
histocompatability (MHC) class II system. In S. mansoni the 10 
legumain protease (SmAE, Sm32) is dissimilar to the other 
proteinases and may process gut-associated clan CA 
zymogens to their active forms, thus facilitating the digestion 
of ingested host serum proteins. S. mansoni legumain is not 
inhibited by the clan CA cysteine protease inhibitor E-64 or 15 
the diazomethane inhibitor Cbz-Phe-Ala-CHN2. Irreversible 
protease inhibitors would have great potential for the short-
term therapeutic administration against parasitic infections. 
So far there has been no success in the determination of a 
crystal structure of the asparaginyl endopeptidase. Like all 20 
clan CD proteases, the substrate specificity of legumain is 
controlled by the interactions of the S 1 subsite. Legumains 
selectively hydrolyze substrates with an asparaginyl residue 
in the Pl position. Legumain is less selective with respect to 
the P2 and P3 positions, but prefers Ala or Thr. The synthetic 25 
substrate Cbz-Ala-Ala-Asn-AMC was effectively cleaved by 
S. mansoni legumain and human legumain with KM's of 90 
and 80 µM respectively. 
Next to caspases and legumains, the family of separases 
has gained increasing attention among the clan CD enzymes. 30 
Separases play an important role during mitosis at the 
metaphase to anaphase transition. When the sister chromatids 
are aligned at the onset of the anaphase, separase initiates the 
segregation of the chromosomes by facilitating the break-
down of a cohesion complex between the individual sister 35 
chromatides. 
4 
addition, a number of viral processing enzymes, which are 
essential for viral infection, are cysteine proteases. Inhibitors 
of cysteine proteases would have multiple therapeutic uses. 
Other important cysteine proteases are the bacterial 
enzymes clostripain and gingipain. Gingipain causes tissue 
destruction during periodontal diseases. 
Cysteine Protease Inhibitors. 
To date, a structurally diverse variety of cysteine protease 
inhibitors have been identified. Palmer, (1995) J. Med. 
Chem., 38, 3193, discloses certain vinyl sulfones, which act 
as cysteine protease inhibitors for cathepsins B, L, S, 02 and 
cruzain. Other classes of compounds, such as aldehydes, 
niitriles, a-ketocarbonyl compounds, halomethyl ketones, 
diazomethyl ketones, (acyloxy)methyl ketones, ketomethyl-
sulfonium salts and epoxy succinyl compounds have also 
been reported to inhibit cysteine proteases. See Palmer, id, 
and references cited therein. Many irreversible cysteine pro-
tease inhibitors have been described in the review by Powers, 
Asgian, Ekici, and James (2002) Chemical Reviews, 102, 
4639. See Powers, id, and references cited therein. However, 
most of these known inhibitors are not considered suitable for 
use as therapeutic agents in animals, especially humans, 
because they suffer from various shortcomings. These short-
comings include lack of selectivity, cytotoxicity, poor solu-
bility, and overly rapid plasma clearance. 
Several types of Michael acceptor warheads have been 
employed as inhibitors for cysteine proteases. Among the 
most effective inhibitors are vinyl sulfones and a,~-unsatur­
ated carbonyl derivatives against various cysteine proteases. 
Hanzlik, (1984) J. Med. Chem., 27, 711 has replaced the 
carbonyl group of a good substrate with a moiety, that would 
trap the enzymatic nucleophile (Ser-OH or Cys-OH) without 
altering the structural features required for enzyme recogni-
tion and binding. The fumarate derivative of the epoxy suc-
cinate E-64c, which is one of the first Michael acceptor 
inhibitors reported, extends the a,~-unsaturated carbonyl by 
Neural tissues, including brain, are known to possess a 
large variety of proteases, including at least two calcium-
stimulated proteases termed calpains. Calpains are present in 
many tissues in addition to the brain. Calpain I is activated by 
micromolar concentrations of calcium while calpain II is 
activated by millimolar concentrations. In the brain, calpain II 
is the predominant form, but calpain I is found at synaptic 
endings and is thought to be the form involved in long term 
potentiation, synaptic plasticity, and cell death. Other Ca2+ 
activated cysteine proteases may exist, and the term "calpain" 
40 an additional carbonyl for possible structural recognition and 
binding requirements within the enzyme active site. The 
fumarate derivative of E-64c (trans-HOOCCH=CH-CO-
Leu-NH(CH2)2CH(CH3)2) inhibits cathepsin B (kapp=625 
M- 1s- 1 ), cathepsin H (kapp =M- 1s- 1 ), and cathepsin L 
45 (kapp =2272 M-1 s- 1) irreversibly. Both the fumarate analog of 
E-64c and the epoxide parent compound do not inhibit clan 
CD proteases. Caspases, legumains, gingipains and clostri-
pain are members of clan CD, while papain, cathepsins, and 
calpains are members of clan CA. Therefore, because of the 
50 aforementioned deficiencies in the art, there is a need for new 
compounds and methods for inhibiting proteases, in particu-
lar cysteine proteases. 
is used to refer to all Ca2+ activatedcysteineproteases, includ-
ing calpain I and calpain II. The terms "calpain I" and 
"calpain II" are used herein to refer to the micromolar and 
millimolar activated calpains, respectively, as described 
above. While cal pains degrade a wide variety of protein sub-
strates, cytoskeletal proteins seem to be particularly suscep-
tible to attack. In some cases, the products of the proteolytic 
digestion of these proteins by calpain are distinctive and 
persistent over time. Since cytoskeletal proteins are major 55 
components of certain types of cells, this provides a simple 
method of detecting calpain activity in cells and tissues. Acti-
vation of calpains and/or accumulation of breakdown prod-
ucts of cytoskeletal elements have been observed in neural 
tissues of mannnals exposed to a wide variety of neurodegen- 60 
erative diseases and conditions. For example, these phenom-
ena have been observed following ischemia in gerbils and 
rats, following stroke in humans, following administration of 
the toxins kainate, trimethyltin, or colchicine in rats, and in 
human Alzheimer's disease. 
Cathepsin Bis involved in muscular dystrophy, myocardial 
tissue damage, tumor metastasis, and bone resorption. In 
SUMMARY 
Aspects of the present disclosure provide compositions for 
inhibiting proteases, methods for synthesizing the composi-
tions, and methods of using the disclosed protease inhibitors. 
One aspect provides a hydrazide comprising an aza-amino 
acid residue in a Pl site. The compositions described herein 
can inhibit proteases, for example cysteine proteases, either in 
vivo or in vitro, by contacting a cysteine protease with a 
propenoyl hydrazide, which acts as a Michael acceptor. The 
65 disclosed compounds, pharmaceutically acceptable salts, 
pharmaceutically acceptable derivatives, prodrugs, or combi-
nations thereof can be used to treat disease or pathological 
US 7,482,379 B2 
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conditions related to the activity of proteases associated with 
a specific disease or condition. Such treatable conditions 
include viral infections, stroke, neurodegenerative disease, 
and inflammatory disease, among others. Methods disclosed 
herein for treating diseases include administering an effective 
amount of a propenoyl hydrazide to a host in need thereof to 
inhibit or reduce protease activity in the host, particularly 
cysteine protease activity, more particularly activity of 
caspases, calpains, cathepsins, papain, gingipain, clostripain, 
separin, or legumain. One or more propenoyl hydrazides of 10 
the present disclosure can also be used alone or in combina-
tion with each other, other protease inhibitors, or another 
therapeutic agent including anti-viral compounds such as 
anti-viral nucleosides including nucleoside analogs. 
One aspect of the disclosure provides propenoyl hydrazide 15 
compositions, for example a compound or pharmaceutically 
acceptable salt or pharmaceutically acceptable derivative 
thereof according to Formula I below. In some aspects of the 
present disclosure, propenoyl hydrazide inhibitors are spe-
cific for cysteine proteases and do not inhibit serine proteases 20 
or aspartyl proteases. In another aspect of the present disclo-
sure, these propenoy 1 hydrazide compounds potently and spe-
cifically inhibit clan CD cysteine proteases. Although the 
compounds of the present disclosure are usually specific for 
cysteine proteases of clan CD, they are also inhibitors of other 25 
proteases. Exemplary differences between propenoyl 
hydrazides disclosed herein and other cysteine protease 
inhibitors include different mechanisms of inhibition of the 
6 
Another aspect of the disclosure provides propenoyl 
hydrazides containing basic residues at the Pl position. Such 
propenoyl hydrazides inhibit proteases such as gingipain, 
separase, and clostripain. Propenoyl hydrazide inhibitors of 
gingipain can be used for treatment of periodontal diseases. 
Propenoyl hydrazide inhibitors of separase are useful for 
stopping, modulating, or interfering with cell division. 
In another aspect, this disclosure provides a method to 
identify proteolytic enzymes and a method to prevent pro-
teolysis. 
BREIF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows two exemplary aza-amino acids. 
DETAILED DESCRIPTION 
The present disclosure may be understood more readily by 
reference to the following detailed description of the disclo-
sure and the Examples included therein. 
Before the present compounds, compositions and methods 
are disclosed and described, it is to be understood that this 
disclosure is not limited to specific synthetic methods, spe-
cific pharmaceutical carriers, or to particular pharmaceutical 
formulations or administration regimens, as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular cysteine residue and the binding modes. 
Some propenoyl hydrazides of the present disclosure can 
30 embodiments only and is not intended to be limiting. 
Cysteine Proteases. 
One embodiment provides propenoyl hydrazide composi-
tions that inhibit enzymatic cleavage of proteins or peptides, 
or a combination thereof. Exemplary enzymes inhibited by 
propenoyl hydrazides include cysteine proteases, for 
example, caspases, legumains, gingipains, clostripain, and 
separase. 
The present disclosure includes all hydrates, solvates, 
complexes and prodrugs of the compounds of this disclosure. 
The term prodrug refers to a pharmacologically inactive com-
pound that is converted to an active drug by a metabolic 
biotransformation. Prodrugs include compounds wherein an 
be constructed to selectively inhibit individual cysteine pro-
teases or groups of cysteine proteases. These propenoyl 
hydrazides can, for example, contain acidic aza-amino acid 
residues in the Pl site. Such propenoyl hydrazides are potent 35 
inhibitors of caspases. Propenoyl hydrazide caspase inhibi-
tors are useful for the treatment of stroke and inflammatory 
diseases, and as inhibitors of apoptosis. Thus, another aspect 
provides a method of treating stroke, inflammatory disease, or 
inhibiting apoptosis including administering an effective 40 
amount of a propenoyl hydrazide to a patient in need thereof. 
Such patients can include any mammal, for example a mam-
mal exhibiting symptoms characteristic of a protease related 
pathology or disease condition such as stroke, inflammatory 
disease, or pathology related to apoptosis. 45 amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently 
joined through an amide or ester bond to a free amino, 
hydroxy or carboxylic acid group of compounds of Formula 
I. Additional types of prodrugs are also encompassed. For 
Another aspect of the present disclosure provides a prope-
noyl hydrazide composition containing an aza-asparagine 
residue at the Pl position. Propenoyl hydrazides having an 
aza-asparagine residue at the Pl position inhibit legumain 
and can, therefore, modulate the immune system through 
such inhibition. Cleavage of antigens by proteases such as 
legumain and related proteases is a step in antigen presenta-
tion including the display of MHC class II peptides. Thus, 
another aspect of the disclosure provides a method of modu-
lating the immune system of a patient by administering to a 
host an effective amount of a propenoyl hydrazide composi-
tion. The propenoyl hydrazide can modulate the immune 
system by inhibiting the cleavage of antigens in the patient 
and thereby reducing the display of antigen peptides on cell 
surfaces. 
Yet another aspect of the disclosure provides a method of 
treating autoimmune disease by administering an effective 
amount of a propenoyl hydrazide to a host in need thereof. 
The host can be any mammal, including primates, which 
demonstrates symptoms associated with any number of 
autoimmune diseases including but not limited to lupus, for 
example lupus erythematosus, and cancers. 
50 instance, free carboxyl groups can be derivatized as amides or 
alkyl esters. The amide and ester moieties may incorporate 
groups including but not limited to ether, amine and carboxy-
lic acid functionalities. Free hydroxy groups may be deriva-
tized using groups including but not limited to hemisucci-
55 nates, phosphate esters, dimethylaminoacetates, and 
phosphoryloxymethyloxycarbonyls, as outlined in D. 
Fleisher, R. Bong, B. H. Stewart, Advanced Drug Delivery 
Reviews (1996) 19, 115. Carbamate prodrugs of hydroxy and 
amino groups are also included, as are carbonate prodrugs 
60 and sulfate esters of hydroxy groups. Derivatization of 
hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl 
ethers wherein the acyl group may be an alkyl ester, option-
ally substituted with groups including but not limited to ether, 
amine and carboxylic acid functionalities, or where the acyl 
65 group is an amino acid ester as described above, are also 
encompassed. Prodrugs of this type are described in R. P. 
Robinson et al., J. Medicinal Chemistry (1996) 39, 10. 
US 7,482,379 B2 
7 
The subject disclosure also includes isotopically-labelled 
compounds, and the pharmaceutically acceptable salts 
thereof, which are identical to those recited in Formula I, but 
for the fact that one or more atoms are replaced by an atom 
having an atomic mass or mass number different from the 
atomic mass or mass number usually found in nature. 
Examples of isotopes that can be incorporated into com-
pounds of the disclosure include isotopes of hydrogen, car-
bon, nitrogen, oxygen, phosphorous, fluorine and chlorine. 
10 Compounds of the present disclosure, prodrugs thereof, and 
pharmaceutically acceptable salts of said compounds or of 
said prodrugs which contain the aforementioned isotopes 
and/or other isotopes of other atoms are within the scope of 
this disclosure. Certain isotopically-labelled compounds of 15 
the present disclosure, for example those into which radioac-
tive isotopes such as 3 H and 14C are incorporated, are useful 
in drug and/or substrate tissue distribution assays. Tritiated, 
i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly 
preferred for their ease of preparation and detectability. Fur- 20 
ther, substitution with heavier isotopes such as deuterium, 
i.e., 2 H, can afford certain therapeutic advantages resulting 
from greater metabolic stability, for example increased in 
vivo half-life or reduced dosage requirements and, hence, 
may be preferred in some circumstances. Isotopically labeled 25 
compounds of Formula I of this disclosure and prodrugs 
thereof can generally be prepared by carrying out the proce-
dures disclosed in the Schemes and/or in the Examples and 
Preparations below, by substituting a readily available isoto-
30 pically labeled reagent for a non-isotopically labeled reagent. 
8 
Anlino acid residues and blocking groups are designated 
using standard abbreviations [see J. Biol. Chem. 260, 14-42 
(1985) for nomenclature rules; incorporated herein by refer-
ence]. An amino acid residue (AA) in a peptide or inhibitor 
structure refers to the part structure -NH--CHR1--CO-, 
where R1 is the side chainofthe amino acid residue AA. It will 
be appreciated that at least one of the amino acid residues of 
the propenoyl hydrazides of the disclosure may be substituted 
by one of the well known non-naturally occurring amino acid 
residues. Alterations such as these may serve to increase the 
stability, bioavailability and/or inhibitory action of the pep-
tides of the disclosure. Moreover, any of the propenoyl 
hydrazides described herein may, additionally, have a non-
peptide macromolecular carrier group covalently attached to 
their amino and/or carboxy termini. Such macromolecular 
carrier groups may include, for example, lipid-fatty acid con-
jugates, polyethylene glycol, or carbohydrates. The term 
MeAA describes an N-methylated amino acid, as for example 
MePhe, which is phenylalanine, where the nitrogen is substi-
tuted with a methyl group. 
FIG. 1 shows two examples of aza-amino acids. An aza-
amino acid residue (structures top and bottom right) is an 
alpha-amino acid residue (structures top and bottom left) 
where the alpha-carbon has been replaced by a nitrogen atom. 
It will be abbreviated as the three letter code for the amino 
acid preceded by an "A". Therefore, substituting the a-carbon 
of an aspartate residue with a nitrogen converts an aspartic 
acid residue (Asp) to an aza-aspartic acid, which will be 
abbreviated as AAsp, and a lysine residue (Lys) to aza-lysine 
(ALys). 
If a chiral center or another form of an isomeric center is 
present in a compound of the present disclosure, all forms of 
such isomer or isomers, including enantiomers and diastere-
omers, are intended to be covered herein. Inventive com-
pounds containing a chiral center may be used as a racemic 
mixture, an enantiomerically enriched mixture, or the race-
mic mixture may be separated using well-known techniques 
and an individual enantiomer may be used alone. An enantio-
merically enriched mixture means a mixture having greater 40 
than about 50% of a single enantiomer. In cases in which 
compounds have unsaturated carbon-carbon double bonds, 
both the cis (Z) and trans (E) isomers are within the scope of 
this disclosure. The compositions of the present disclosure 
can be substantially optically pure. Substantially optically 45 
pure means a composition having greater than 90%, prefer-
ably greater than 95%, most preferably greater than 98% of a 
single optical isomer. 
Another embodiment provides a propenoy 1 hydrazide hav-
35 ing the following formula 
It must be noted that, as used in the specification and the 50 
appended claims, the singular forms "a," "an" and "the" 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "an aromatic com-
pound" includes mixtures of aromatic compounds, reference 
to "a pharmaceutical carrier" includes mixtures of two or 55 
more such carriers, and the like. 
Nomenclature. 
Propenoyl Hydrazide 
Moiety 
Aza-Amino 
Acid Residue 
Propenoyl Hydrazide 
Moiety 
Aza-Amino 
Acid Residue 
or 
The R3 or R4 group would be abbreviated as C02 H, C02Et, 
C02R, CONHR, CONRR', or CO-AA-T if the propenoyl 
In discussing the interactions of peptides with cysteine 
proteases, we have utilized the nomenclature of Schechter 60 
and Berger [Biochem. Biophys. Res. Commun. 27, 157-162 
(1967); incorporated herein by reference]. The individual 
amino acid residues of a substrate or inhibitor are designated 
Pl, P2, etc. and the corresponding subsites of the enzyme are 
designated Sl, S2, etc. The scissile bond of the substrate is Sl 65 hydrazide contains a fumarate moiety in its structure. Other-
-Sl '. The most important recognition sub sites of scysteine 
proteases are Sl and S2. 
wise, the structure of the R3 or R4 group would be drawn or 
abbreviated. 
US 7,482,379 B2 
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Another embodiment provides propenoyl hydrazides hav-
ing abbreviated structures according to the following: 
0 
0 ~ 0 (NH, ~ )l ~'( _.....N~COOBzl 
Ph 0 N N 
H H 
~C-ar-bo-x-yb-e-nz-o-yl~ 0 0 
(Cbz) aza-asparagine 
(AAsn) 
COOR 
(COOH 
0 0 0 
OH'--------' 
aza-aspartic acid 
(AAsp) 
H O /NH, 
Ph~N'¢H_.....N~COOEt 
0 0 
Phenylpropanoyl 
(PhPr) aza-lysine 
(Alys) 
tetrahydro-
isoquinoline 
10 
Cbz-Ala-Ala-AAsn-CH=CHCOOBzl 
Cbz-Leu-Glu-Thr-AAsp-CH=CHCOOEt 
PhPr-Leu-ALys-CH=CHCOOEt 
Cbz-Ala-Ala-AAsn-CH=CHCO-
tetrahydroisquinoline 
Cbz-Asp-Glu-V al-AAsp-CH =CHCO 
N(Bzl)-2-CH2-Napth 
US 7,482,379 B2 
11 12 
There can be three structural isomers at the double bond 
moiety, if the appropriate substituents are present, two trans 
isomers (E and Z) and one cis isomer. The cis and trans 
nomenclature is used for simple alkenes with similar substitu-
ents. A C=C double bond is referred to as cis, when the 
substituents are on the same side of the double bond, and 
trans, when the substituents are on opposite sides. The E and 
Z terminology applies to compounds that contain a C=C 
double bond with more than two substituents. The Cahn-
Prelog-Ingold selection rules are used to assign priorities to 
the various substituents. If the two substituents with the high-
est priority are on the same side, the double bond is given the 
designation Z (from zusammen) and E (from entgegen), if 
they are on opposite sides. 
Exemplary isomers according to one embodiment of the 
present disclosure have the following structural formulae: 
Cbz-Leu-Glu-Thr-AAsp-cis-CH =CHCOOEt 
(This is the cis or Z isomer) 
Cbz-Ala-Ala-AAsn-trans-CH=CHCOOEt 
(This is the trans or E isomer) 
(Z)-Cbz-Asp-Glu-Val-AAsp-CH=C(Cl)CON(Bzl)-2-CH-Napth 
(This is the Z isomer) 
(E)-PhPr-Leu-ALys-CH=C(OH)COOEt 
(This is the E isomer) 
US 7,482,379 B2 
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The numbering of the carbons of the double bond is shown 
above. 
The term "amino," as used herein, refers to -NH2 or 
derivatives thereof formed by independent replacement of 
one or both hydrogen atoms thereon with a substituent or 
substituents independently selected from alkyl, alkanoyl, 
aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, het-
eroarylalkyl, and an amino protecting group. 
14 
of the Formula I that are acidic in nature, are capable of 
forming base salts with various pharmacologically accept-
able cations. Examples of such salts include the alkali metal 
or alkaline earth metal salts and particularly, the sodium and 
potassium salts. 
The term "pharmaceutically acceptable derivative" refers 
to any homolog, analog, or fragment corresponding to the 
propenoyl hydrazides of the present disclosure provided 
herein which inhibits protease activity and is relatively non-The term "C1 _10 acyl," as used herein, refers to aC1 _10 alkyl 
group, as defined herein, having an attached carbonyl group. 10 toxic to the subject or host. 
The term "C1_10 alkoxy," as used herein, refers to a C1 _10 
alkyl group, as defined herein, attached to the parent molecu-
lar group through an oxygen atom. 
The term "pharmaceutically acceptable" means a material 
that is not biologically or otherwise undesirable, i.e., the 
material may be administered to an individual along with the 
selected propenoyl hydrazide without causing any undesir-The term "C1 _10 alkyl" as used herein refers to a branched 
or unbranched hydrocarbon group of carbon atoms, such as 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, I-butyl, 
and the like or branched or unbranched hydrocarbon groups 
15 able biological effects or interacting in a deleterious manner 
with any of the other components of the pharmaceutical com-
position in which it is contained. 
of carbon atoms that either contain double or triple carbon 
bonds. 
As used herein, and without limitation, the term "deriva-
tive" is used to refer to any compound which has a structure 
The term "C1 _10 alkylamino," as used herein, refers to a 
C1 _10 alkyl group, as defined herein, to which is attached at 
least one amino substituent. 
20 derived from the structure of the compounds of the present 
disclosure and whose structure is sufficiently similar to those 
disclosed herein and based upon that similarity, would be 
expected, by one skilled in the art, to exhibit the same or The term "C3 _15 cycloalkyl" as applied herein is meant to 
include cyclic hydrocarbon chains. Examples of these cyclic 
hydrocarbon chains include cyclopropane, cyclobutane, 25 
cyclopentane, cyclohexane, cycloheptane, cyclooctane, 
cyclononane, cyclodecane, cycloundecane, etc. 
similar activities and utilities as the claimed compounds. 
The following abbreviations have also been used: AFC, 
7-amino-4-trifluoromethylcoumarin; AAsp, aza-aspartic 
acid residue; AAsn, aza-asparagine; ALeu, aza-leucine; 
ALys, aza-lysine residue; AHph, aza-homophenylalanine 
residue; AOrn, aza-omithine; AMC, 7-amino-4-methylcou-
The term "C2 _12 dialky !amino," as used herein refers to two 
C1 _10 alkyl groups, as defined herein, that are attached to an 
amino substituent. 
The term "C1 _10 fluoroalkyl," as used herein, refers to a 
C1 _10 alkyl group, as defined herein, to which is attached at 
least one fluorine substituent. 
The term "C1_10 perfluoroalkyl," as used herein, refers to a 
cl-10 alkyl group in which all of the hydrogen atoms have 
been replaced with fluorine atoms. 
30 marin; Boe, tert-butoxycarbonyl; Brij, polyoxyethylenelau-
rylether; Bzl, benzyl; CHAPS, 3-[(3-cholamidopropyl)dim-
ethylarnmonio ]-1-propanesulfonate; Cbz, Ph-CH20CO-; 
DCC, 1,3-dicyclohexylcarbodiimide; DMAP, 4-dimethy-
laminopyridine; DMF, N,N-dimethylformamide; DMSO, 
The term biotinyl, as use herein, refers to biotin without the 
biotin carboxyl hydroxyl group. 
By the term "effective amount" of a compound as provided 
herein is meant a nontoxic but sufficient amount of the com-
pound to provide the desired utility. As will be pointed out 
below, the exact amount required will vary from subject to 
subject, depending on the species, age, and general condition 
35 dimethylsulfoxide; DTT, dithiothreitol; EDC, 1-(3-dimethy-
laminopropyl)-3-ethylcarbodiimide hydrochloride; EtOAc, 
ethyl acetate; HEPES, N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid HOBt, 1-hydroxybenzotriazole; HRMS, 
high resolution mass spectrometry; iBCF, isobutyl chlorofor-
40 mate; IBX, iodooxybenzoic acid; IC, inhibitory concentra-
tion; 2-Napth, 2-naphthyl; NMM, 4-methylmorpholine; Np2, 
2-naphthylalanyl; PhPr, Phenylpropyl; Pyr, pyridine, TFA, 
trifluoroacetic acid; THF, tetrahydrofuran; TLC, thin layer 
of the subject, the severity of the condition or disease that is 
being treated, the particular compound used, its mode of 45 
administration, and the like. Thus, it is not possible to specify 
an exact "effective amount." However, an appropriate effec-
tive amount may be determined by one of ordinary skill in the 
art using only routine experimentation. 
The term "pharmaceutically acceptable salt(s)", as used 50 
herein, unless otherwise indicated, includes salts of acidic or 
basic groups which may be present in the compounds of 
Formula I. The compounds of Formula I that are basic in 
nature are capable of forming a wide variety of salts with 
various inorganic and organic acids. The acids that may be 55 
used to prepare pharmaceutically acceptable acid addition 
salts of such basic compounds of Formula I are those that 
form non-toxic acid addition salts, i.e., salts containing phar-
macologically acceptable anions, such as the hydrochloride, 
hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phos- 60 
phate, acid phosphate, isonicotinate, acetate, lactate, salicy-
late, citrate, acid citrate, tartrate, TFA, pantothenate, bitar-
trate, ascorbate, succinate, maleate, gentisinate, fumarate, 
gluconate, glucaronate, saccharate, formate, benzoate, 
glutamate, methanesulfonate, ethanesulfonate, benzene- 65 
sulfonate, p-toluenesulfonate and pamoate [i.e., 1, 1 '-methyl-
ene-bis-(2-hydroxy-3-naphthoate )] salts. Those compounds 
chromatography. 
One embodiment of the present disclosure provides prope-
noyl hydrazides having the following structural Formula I: 
or 
wherein, 
R1 is selected from the group cons1stmg of M1 -AA1 , 
M1 -AA2 -AA1 , and M1 -AA3 -AA2 -AA1 ; 
Wis selected from the group consisting of halogen, cyano, 
and hydrogen; 
M 1 is selected from the group consisting of H, NH2 -
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, X2N-
US 7,482,379 B2 
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CO-, X-NH-CS-, X2N---CS-, X-NH-S02-, 
X2N-S02-, X---CO-, X---CS-, X-, Y-S02-, 
Y-0---CO-, Y---0-CS-, morpholine-CO-, and bioti-
nyl; 
X is selected from the group consisting of H, C1_10 alkyl, 5 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, pentafluorophenyl, phenyl monosubsti-
tuted with K, phenyl disubstituted with K, phenyl trisubsti-
tuted with K, naphthyl, naphthyl monosubstituted with K, 10 
naphthyl disubstituted with K, naphthyl trisubstituted with K, 
cl-10 fluoroalkyl with an attached phenyl group, cl-10 alkyl 
with an attached phenyl group, C1_10 alkyl with two attached 
phenyl groups, cl-10 alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with two attached phenyl 15 
groups substituted with K, C1_10 alkyl with an attached naph-
thyl group, C1_10 alkyl with an attached naphthyl group sub-
stituted with K, C1_10 alkyl with an attached phenoxy group, 
and C1_10 alkyl with an attached phenoxy group substituted 
with Kon the phenoxy group; 20 
Y is selected from the group consisting ofC1_10 alkyl, C3_15 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted with 
J, cl-10 fluoroalkyl substituted with J, 1 -admantyl, 9-fluore-
nyl, phenyl, phenyl monosubstituted with K, phenyl disubsti-
tuted with K, phenyl trisubstituted with K, naphthyl, naphthyl 25 
monosubstituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 fluoroalkyl with an 
attached phenyl group, C1_10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 
alkyl with an attached phenyl group substituted with K, C1_10 
30 
alkyl with two attached phenyl groups substituted with K, 
C1_10 alkyl with an attached naphthyl group, C1_10 alkyl with 
an attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phenoxy 35 
group; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02,amino, C1_10 alkoxy, C1_10 alkylamino, C2_12 
dialkylamino, C1_10 alkyl-0---CO-, C1_10 alkyl-0-CO- 40 NH-, and C1_10 alkyl-S-; 
16 
R2 is selected from the group consisting of C1_10 alkyl, 
cl-10 perfluoroalkyl, cl-10 alkyl substituted with Q, cl-10 
alkyl substituted with phenyl, C1_10 alkyl with an attached 
phenyl substituted with K, C1_10 alkyl substituted with naph-
thyl, C1_10 alkyl withanattachednaphthyl substituted withK, 
phenyl, phenyl substituted with K, naphthyl, naphthyl substi-
tuted with K, C1_10 alkyl substituted with CONH2, C1_10 alkyl 
substituted with CONHR5, C1_10 alkyl substituted with 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, 
CN, OH, C02H, CONH2, amino, C1_10 alkylamino, 
C2_12 dialkylamino, C1_10 acyl, and C1_10 alkoxy-CO-, 
and C1_10 alkyl-S-; 
AAv AA2,and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, or no 
chirality at the alpha-carbon selected from the group consist-
ing of alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutanine, aspartic acid, glutamic acid, lysine, arginine, his-
tidine, phenylglycineQ beta-alanine, norleucine, norvaline, 
alpha-aminobutanoic acid, epsilon-aminocaproic acid, citrul-
line, hydroxyproline, omithine, homoarginine, sarcosine, 
indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-C02H, alpha-aminohep-
tanoic acid, NH2---CH(CH2-l-naphthyl)-C02H, NH2-CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2CH2CH2-phenyl)-
C02H, NH2---CH(CH2-cyclohexyl)-C02H, NH2---CH 
(CH2-cyclopentyl)-C02H, NH2---CH(CH2-cyclobutyl)-
C02H, NH2---CH(CH2-cyclopropyl)-C02H, 
trifluoroleucine, 4-fluorophenylalanine, lysine substituted on 
the epsilon nitrogen with a biotinyl group, hexafluoroleucine, 
45 C02H, C1_10 alkyl substituted with S02NH2, C1_10 alkyl sub-
stituted with S03H, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 
2-furyl substituted with K, 3-furyl substituted with K, 2-thie-
nyl substituted with K, 3-thienyl substituted with K, 2-furyl 
substituted with G, 3-furyl substituted with G, 2-thienyl sub-
50 stituted with G, 3-thienyl substituted with G, C1_10 alkyl sub-
stituted with C02R5, CH2CH2SCH3, CH2-3-indolyl, C1_2 
alkyl with an attached 2-furyl, C1_2 alkyl with an attached 
3-furyl, cl-2 alkyl with an attached 2-thienyl, cl-2 alkyl with 
an attached 3-thienyl, C1_2 alkyl with an attached 2-furyl 
55 substituted with K, C1_2 alkyl with an attached 3-furyl substi-
tuted with K, C1_2 alkyl with an attached 2-thienyl substituted 
with K, C1_2 alkyl with an attached 3-thienyl substituted with 
K, C1_2 alkyl with an attached 2-furyl substituted with G, C1_2 
alkyl with an attached 3-furyl substituted with G, C1_2 alkyl 
60 with an attached 2-thienyl substituted with G, C1_2 alkyl with 
an attached 3-thienyl substituted with G, CH2-2-imidazyl, 
C1_10 alkyl substituted with G, C1_10 alkyl with an attached 
phenyl substituted with G, C1_10 alkyl with an attached naph-
thyl substituted with G, phenyl substituted with G, and naph-
65 thy! substituted with G; 
R5 is selected from the group consisting ofC1_10 alkyl and 
cl-10 alkyl substituted with phenyl; 
US 7,482,379 B2 
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Q is selected independently from the group consisting of 
C1 _10 alkoxy, C1_10 alkyl-S-, C1_10 alkoxy substituted with 
phenyl, and C1_10 alkyl-S- substituted with phenyl; 
G is selected from the group consisting of cyano, amidino 
(--C(=NH)NH2 ), guanidino (-NHC(=NH)NH2 ), isothi-
ureido (-S--C(=NH)NH2 ), amino, C1_6 alkylamino, C2 _12 
dialkylamino, and imidazyl; 
R3 is selected independently from the group consisting of 
18 
-continued 
0 0 
~I, I~ , and 
H, R6 , halogen, CN, CO-C6H5 , benzoyl substituted with K 10 
on the phenyl, C02H, C02R7 , CONHR8 , CONR8R9 , 
CO-AA4 -T, 
)lea )le 
~ # 
and 
R4 is selected from the group consisting of R6 , halogen, 
CN, CO--C6H5 , benzoyl substituted with K on the phenyl, 
C02 H, C02 R7 , CONHR8 , CONR8 R9 , CO-AA4 -T, 
15 
20 
R6 is selected independently from the group consisting of 
phenyl, phenyl monosubstituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K, naphthyl, naphthyl 
monosubstituted with K, naphthyl disubstituted with K, 
25 naphthyl trisubstituted with K, C1_10 alkenyl, C3 _15 cyclized 
alkyl, cl-10 alkyl with a phenyl group attached to the cl-10 
alkyl, C3 _15 cyclized alkyl with an attached phenyl group, 
C1_10 alkyl with an attached phenyl group monosubstituted 
with K, C1_10 alkyl with an attached phenyl group disubsti-30 tuted withK, C1 _10 alkyl with an attached phenyl grouptrisub-
stituted with K, C3 _15 cyclized alkyl with an attached phenyl 
group substituted with K, C1 _10 alkyl with a naphthyl group 
attached to the cl-10 alkyl, c3-15 cyclized alkyl with an 
35 attached naphthyl group, C1_10 alkyl with an attached naph-
thyl group monosubstituted with K, C1 _10 alkyl with an 
attached naphthyl group disubstituted with K, C1_10 alkyl 
with an attached naphthyl group trisubstituted with K, C3 _15 
cyclized alkyl with an attached naphthyl group substituted 
40 withK, C1 _10 alkyl withanattached2-furylgroup, C1 _10 alkyl 
with an attached 3-furyl group, C1 _10 alkyl with an attached 
2-pyridyl group, cl-10 alkyl with an attached 3-pyridyl group, 
cl-10 alkyl with an attached 4-pyridyl group, 2-furyl, 3-furyl, 
45 2-pyridyl, 3-pyridyl, and 4-pyridyl; 
50 
R7 is selected independently from the group consisting of 
phenyl, phenyl monosubstituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K, naphthyl, naphthyl 
monosubstituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1 _10 alkyl, C1 _10 alkenyl, 
c3-15 cyclized alkyl, cl-10 alkyl with a phenyl group attached 
to theC1 _10 alkyl, C3 _15 cyclizedalkyl with an attached phenyl 
group, C1_10 alkyl with an attached phenyl group substituted 
55 with K, C1_10 alkyl with an attached phenyl group disubsti-
tuted withK, C1 _10 alkyl with an attached phenyl grouptrisub-
stituted with K, C3 _15 cyclized alkyl with an attached phenyl 
group monosubstituted with K, C3 _15 cyclized alkyl with an 
attached phenyl group disubstituted with K, C3 _15 cyclized 
60 alkyl with an attached phenyl group trisubstituted with K, 
cl-10 alkyl with a naphthyl group attached to the cl-10 alkyl, 
c3-15 cyclized alkyl with an attached naphthyl group, cl-10 
alkyl with an attached naphthyl group monosubstituted with 
65 K, C1 _10 alkyl with an attached naphthyl group disubstituted 
with K, C 1 _10 alky 1 with an attached naphthy 1 group trisubsti-
tuted with K, C3 _15 cyclized alkyl with an attached naphthyl 
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group monosubstituted with K, C3_15 cyclized alkyl with an 
attached naphthyl group disubstituted with K, C3_15 cyclized 
alkyl with an attached naphthyl group trisubstituted with K, 
cl-10 alkyl withanattached2-furyl group, cl-10 alkyl with an 
attached 3-furyl group, cl-10 alkyl with an attached2-pyridyl 5 
group, C 1_ 10 alky 1 with an attached 3-pyridy 1 group, and C 1_ 10 
alkyl with an attached 4-pyridyl group; 
T is selected independently from the group consisting of 
OH, OR10, NHRw and NR10R11 ; 
20 
-continued 
and 
R8 and R9 are selected independently from the group con-
sisting ofH, C1_10 alkyl, C1_10 alkenyl, C3_20 cyclized alkyl, 
cl-10 alkyl with a phenyl group attached to the cl-10 alkyl, 
cl-10 alkyl with two phenyl groups attached to the cl-10 alkyl, 
C3_20 cyclized alkyl with an attached phenyl group, phenyl, 
phenyl substituted withK, C1_10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with an attached phenyl 
group disubstituted with K, C1_10 alkyl with an attached phe-
nyl group trisubstituted with K, C1_10 alkyl with two phenyl 
groups attached to the C1_10 alkyl and substituted with Kon 
the phenyl group, cl-10 alkyl with two phenyl groups attached 
to the C1_10 alkyl and disubstituted with K on the phenyl 
groups, c3-20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a morpholine [-N 
AA4 is a side chain blocked or unblocked amino acid with 10 
the L configuration, D configuration, or no chirality at the 
alpha-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 15 
glutamic acid, lysine, arginine, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-amninobutanoic 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi- 20 
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2---CH 
(CH2CHEt2)-C02H, alpha-aminoheptanoic acid, NH2---CH 
(CH2-l-naphthyl)-C02H, NH2---CH(CH2-2-naphthyl)-
C02H, NH2-CH(CH2CH2CH2-phenyl)-C02H, NH2---CH 25 
(CH2-cyclohexyl)-C02H, NH2---CH(CH2-cyclopentyl)-
C02H, NH2---CH(CH2-cyclobutyl)-C02H, NH2-CH(CH2-
cyclopropyl)-C02H, trifluoroleucine, 4-fluorophenylalanine, 
lysine substituted on the epsilon nitrogen with a biotinyl 
group, hexafluoroleucine, and 30 (CH2CH2)0] ring attached through nitrogen to the alkyl, 
cl-10 alkyl with a piperidine ring attached through nitrogen to 
the alkyl, C1_10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl, C1_20 alkyl with an OH group attached to 
Cbz-Val-AAsp-CH=CH-CH3, 
Cbz-Val-AAsp-CH=CH-Cl, 
35 
the alkyl, ---CH2CH2CH20CH3, C1_10 alkyl substituted by 
1-naphthyl, cl-10 alkyl substituted by 2-naphthyl, cl-10 alkyl 
with an attached cyclohexyl group, -NH---CH2CH2-( 4-hy-
droxyphenyl), -NH---CH2CH2-(3-indolyl), C1_10 alkyl with 
anattached2-furyl group, cl-10 alkyl withanattached3-furyl 
40 group, cl-10 alkyl with an attached 2-pyridyl group, cl-10 
alkyl with an attached 3-pyridyl group, C1_10 alkyl with an 
attached 4-pyridyl group, and C1_5 alkyl with an attached 
phenyl and a hydroxyl attached to the cl-5 alkyl; 
45 
R10 and R11 are selected independently from the group 
consisting of H, C1_10 alkyl, phenyl, nitrophenyl, and C1_10 
alkyl substituted with phenyl; 
50 Another embodiment of the present disclosure includes the 
55 
above compounds with formula I, wherein the double bond 
carbons have stereochemistry selected from the group con-
sisting of cis, trans, E, and Z. 
The following exemplary compounds are within the scope 
of the present disclosure: 
Cbz-Val-AAsp-CH=CH-CH=CH-CH3, 
Cbz-Val-AAsp-CH=CH-4-Cl - Ph, Cbz-Val-AAsp-CH=CH-COOEt, 
Cbz-Val-AAsp-CH=CH -CONH -n-Bu, Cbz-Val-AAsp-CH=CH -CONHCH2Ph, Cbz-Glu-Val-AAsp-CH=CH -COO Et, 
Cbz-Asp-Glu-Val-AAsp-CH=CH -COOEt(trans), Cbz-Asp-Glu-Val-AAsp-CH=CH -COOEt(cis), 
US 7,482,379 B2 
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Cbz-Asp-Glu-Val-AAsp-CH=CH -COOCH2Ph, Cbz-Asp-Glu-Val-AAsp-CH=CH -CONHCH2Ph, 
Cbz-Asp-Glu-Val-AAsp-CH=CH -CONHCH2-4-F- Ph, Cbz-Asp-Glu-Val-AAsp-CH =CH -CONHCH2CH2Ph, 
Cbz-Asp-Glu-Val-AAsp-CH=CH -CON(CH3)CH2Ph, Cbz-Asp-Glu-Val-AAsp-CH=CH -CON(CH3)CH2CH2Ph, 
Cbz-Asp-Glu-Val-AAsp-CH=CH -CON(CH2Ph)i, Cbz-Asp-Glu-Val-AAsp-CH=CH -CON(CH2-l-Napthyl)i, 
Cbz-Asp-Glu-Val-AAsp-CH=CH-COPh, Cbz-Val-Glu-Val-AAsp-CH=CH -COO Et, Cbz-Ile-Glu-Thr-AAsp-CH=CH -COO Et, 
Cbz-Ile-Glu-Thr-AAsp-CH =CH -COOCH2Ph, Cbz-Ile-Glu-Thr-AAsp-CH =CH -CONHPh, 
Cbz-Ile-Glu-Thr-AAsp-CH =CH -CONHCH2Ph, Cbz-Ile-Glu-Thr-AAsp-CH =CH -CONHCH2CH2Ph, 
Cbz-Ile-Glu-Thr-AAsp-CH=CH -CON(CH3)CH2Ph, Cbz-Ile-Glu-Thr-AAsp-CH=CH -CON(CH3)CH2CH2Ph, 
Cbz-Ile-Glu-Thr-AAsp-CH=CH -CON(CH2Ph)i, Cbz-Leu-Glu-Thr-AAsp-CH=CH -COO Et, 
Cbz-Leu-Glu-Thr-AAsp-CH= CH -COOCH2Ph, Cbz-Leu-Glu-Thr-AAsp-CH =CH -CONHCH2-4-F- Ph, 
Cbz-Leu-Glu-Thr-AAsp-CH= CH -CONHPh, Cbz-Leu-Glu-Thr-AAsp-CH =CH -CONHCH2Ph, 
Cbz-Leu-Glu-Thr-AAsp-CH=CH -CONHCH2CH2Ph, Cbz-Leu-Glu-Thr-AAsp-CH=CH -CON(CH3)CH2Ph, 
Cbz-Leu-Glu-Thr-AAsp-CH=CH -CON(CH3)CH2CH2Ph, Cbz-Leu-Glu-Thr-AAsp-CH=CH -CON(CH2Ph)i, 
Cbz-Leu-Glu-Thr-AAsp-CH=CH-CON(CH3)CH2-l-Napth, Cbz-Ala-Ala-AAsn-CH=CH -COOBzl, 
Cbz-Ala-Ala-AAsn-CH=CH -CONEti, Cbz-Ala-Ala-AAsn-CH=CH -CON(Bu)i, 
Cbz-Ala-Ala-AAsn-CH=CH -CONHPh, 
Cbz-Ala-Ala-AAsn-CH=CH -CONHBzl, Cbz-Ala-Ala-AAsn-CH=CH -CONHBzl-4-F, 
Cbz-Ala-Ala-AAsn-CH=CH -CONHCH2CH2Ph, Cbz-Ala-Ala-AAsn-CH=CH -CON(CH3)Ph, 
Cbz-Ala-Ala-AAsn-CH=CH -CON(CH3)Bzl, Cbz-Ala-Ala-AAsn-CH=CH-CON(CH3)-l-CH2-Napth, 
Cbz-Ala-Ala-AAsn-CH= CH -CON(CH3)CH2CH2Ph, Cbz-Ala-Ala-AAsn-CH=CH -CON(Bzl)Ph, 
Cbz-Ala-Ala-AAsn-CH=CH -CON(Bzl)i, 
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Cbz-Ala-Ala-AAsn-CH=CH -CO-MePhe- N(CH3)CH2CH2Ph, Cbz-Ala-Ala-AAsn-CH=CH -CO Ph, 
Cbz-Ala-Ala-AAsn-CH=CH -CH=CH -CH3, Cbz-Ala-Ala-AAsn-CH=CH-2-furyl, Cbz-Ala-Ala-AAsn-CH=CH-3-Py, 
0 
H 
PhPr-Leu-ALys-CH=CH-COOEt, PhPr-Leu-ALys-CH=CH -COOCH2Ph, PhPr-Leu-ALys-CH=CH -CONHCH2Ph, 
PhPr-Leu-ALys-CH =CH -CON(Me )CH2Ph, PhPr-Leu-ALys-CH =CH -CON(CH2Ph)i, 
PhPr-Leu-ALys-CH =CH -CON(Bzl)-p-CH2C6H4, PhPr-Leu-ALys-CH=CH-CON(Me)CHrl-naphthyl, 
PhPr-Leu-ALys-CH =CH -CON(Bzl)CHr 2-naphthyl, PhPr-Leu-ALys-CH=CH-CON(CH2-1-naphthyl)i, 
PhPr-Leu-ALys-CH=CH -CON(4H-quinoline), PhPr-Leu-AOm-CH=CH -COO Et, PhPr-Leu-AOm-CH=CH -CONHCH2Ph, 
PhPr-Leu-AArg-CH=CH -COO Et, PhPr-Leu-AOm-CH=CH -CON(CH2Ph)i, PhPr-Ala-AOm-CH=CH -COO Et, 
PhPr-Leu-AArg-CH= CH -CONHCH2Ph, and PhPr-Leu-AArg-CH =CH -CON(CH2Ph)i. 
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EXEMPLARY METHODS OF PREPARATION 
1. Preparation of the Substituted Propenoate Portion 
A variety of propenoates can be synthesized by following 
the schemes shown below. This substituted propenoate can 
then be coupled to the respective substituted hydrazide to 
yield a propenoyl hydrazide using general peptide coupling 
procedures. 
-iv 
-i 
0 ¢0Et OH 
0 
Reagents: (i) NMM, EDC, (ROH such as Bz!OH or 
PhCH2CH2 0H), DMF; (ii) KOH, EtOH, r.t.; (iii) NMM, 
iBCF, CH2Cl2 ; (iv) EtOH, r.t. 
2. Preparation of the Peptide Portion 
The peptide portion of the propenoyl hydrazide inhibitor 
can be prepared using standard peptide chemistry which is 
well described in publications such as The Peptides, Analysis, 
Synthesis, Biology, Vol. 1-9, published in 1979-1987 by Aca-
demic Press; Houben-Wey! Methoden der Organischen Che-
mie, Vol. 15, Parts 1 and 2, Synthese van Peptiden, published 
by Georg Thieme Verlag, Stuttgart in 1974; and Houben-
Weyl Methods of Organic Chemistry, Vol. E22, Parts a, b, c, 
and d, Synthesis ofPeptides and Peptidomimetics published 
by Georg Thieme Verlag, Stuttgart 2000-2003 (references 
incorporated herein by reference). 
The M1 group can be introduced using a number of differ-
ent reaction schemes. First, it could be introduced directly on 
an amino acid as shown in the following scheme (top), or the 
M1 group could be introduced by reaction with an amino acid 
ester, followed by removal of the ester group to give the same 
product (bottom). 
H-AA-OH Mi-AA-OH 
H-AA-OR' - Mi-AA-OR' - Mi-AA-OH 
The techniques for introduction of the M1 group are well 
documented in The Peptides, Houben-Weyel, and many other 
28 
textbooks on organic synthesis. For example reaction with 
cyanate orp-nitrophenyl cyanate would introduce a carbamyl 
group (M1=NH2CO-). Reaction with Me2NCOCI would 
introduce the Me2NCO- group. Reaction with p-nitrophe-
5 nyl thiocarbamate would introduce a thio carbamyl group 
(M1=NH2CS-). Reaction with NH2 S02Cl would introduce 
the NH2 S02- group. Reaction with Me2NS02 Cl would 
introduce the Me2NS02-group. Reaction with a substituted 
-ii 
-ii 
alkyl or aryl isocyanate would introduce the X-NH-CO-
group where Xis a substituted alkyl or aryl group. Reaction 
40 with a substituted alkyl or aryl isothiocyanate would intro-
duce the X-NH--CS- group where Xis a substituted alkyl 
or aryl group. Reaction with X-S02-Cl would introduce 
the X-S02 - group. Reaction with a substituted alkyl or 
aryl acid chloride would introduce an acyl group (M=X-
45 CO-). For example, reaction with Me0--CO-CH2CH2 -
CO--Cl would give the X--CO- group where X is a C2 
alkyl substituted with a C1 alkyl-OCO- group. Reaction 
with a substituted alkyl or aryl thioacid chloride would intro-
duce a thioacyl group (M=X--CS-). Reaction with a sub-
50 stituted alkyl or aryl sulfonyl chloride would introduce the 
X-S02-group. For example, reaction with dansyl chloride 
would give the X-S02- derivative where X was a naphthyl 
group mono substituted with a dimethylamino group. Reac-
tion with a substituted alkyl or aryl chloroformate would 
55 introduce the X---0-CO- group. Reaction with a substi-
tuted alkyl or aryl chlorothioformate would introduce the 
X---0-CS-. There are many alternate reaction schemes 
which could be used to introduce all of the above M1 groups 
to give either M1-AA-OH or M1 -AA-OR'. 
60 The M1 -AA-OH derivatives could then be used directly in 
the preparation of peptide hydrazides or could be converted 
into the dipeptides, tripeptides, and tetrapeptides M1 -AA-
AA-OH, M1 -AA-AA-AA-OH, or M1 -AA-AA-AA-AA-OH 
which could then be converted to peptide hydrazides. The 
65 substituted peptides M1 -AA-AA-OH, M1 -AA-AA-AA-OH, 
or M1 -AA-AA-AA-AA-OH could also be prepared directly 
from H-AA-AA-OH, H-AA-AA-AA-OH, or H-AA-AA-
US 7,482,379 B2 
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AA-AA-OH using the reactions described above for intro-
duction of the M1 group. Alternatively, the M1 group could be 
introduced by reaction with carboxyl blocked peptides to give 
M1 -AA-AA-OR', M1-AA-AA-AA-OR', or M1-AA-AA-AA-
AA-OR', followed by the removal of the blocking group R'. 
3. Peparation of Peptide Hydrazides 
Usually, peptide hydrazides are synthesized by reaction of 
an amino acid or peptide ester with hydrazine or by direct 
coupling of an amino acid or peptide acid with hydrazine as 
10 
shown in the following two figures. They can also be synthe-
sized directly by reaction of an amino acid or peptide ester 
with hydrazine. 
15 
30 
-continued 
0 
1. )l 
R1 H 
2. NaBJLi 
or 
The side chain of the aza-amino acid residue can be intro-
duced by reductive amination as shown specifically in the 
previous figure or by other methods known by those skilled in 
the art or by alkylation as shown in the following figure. 
1) BrCH2COOEt 
NMM,DMF 
2)NH3,NaCN 
MeOH,DMF 
BrCH2COOtBu 
NMM,DMF 
US 7,482,379 B2 
31 
The aza-amino acid side chain can also be introduced by 
coupling the peptide precursor to the desired hydrazide side 
chain as shown in the following figure. 
0 
R(')~~OMe 
R2 
2. cat. NaCN, NH3, 
MeOH 
The precursors for basic side chain propenoyl hydrazides 
were prepared as shown in the following figure. 
Tos-OH, EtOH, NaBH3CN, 
AcOH, THF 
lli,/~~ 
EtOH, NaBH3CN, 
AcOH, THF 
32 
0 
H II H 
/N~,.,N~/Boc 
R1 . N N 
~ H H 
R2 
ALys 
0 
H II H H 
/N~,.,N~N....__ 
R1 . N Boe 
~ H 
R2 
A Om 
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4. Preparation of the Propenoyl Hydrazide 
A. EDC/HOBt Coupling Method 
The propenoate portion of the propenoyl hydrazide is 
coupled to the substituted hydrazide by reacting the prope-
noate portion, the substituted hydrazide, EDC, and HOBt in 
DMF to form the propenoyl hydrazide (see the following 
figure). 
R1 
I 
R1...._ ,,NH 
N 
H 
HO~R3 
II I or 
0 ~ 
HOyy~ 
0 R3 
or 
EDC, HOBt DMF 
Methods for the protection and deprotection and replace-
ment of an amino protecting group with another moiety are 
well known. Deprotection of other side chain protecting 
groups were carried out by standard methods. 
B. The Mixed Anhydride Method 
Another coupling method is the mixed anhydride method. 
10 
34 
-continued 
0 fx 
R1'-..:ti/N~Y 
0 
6Y~COOEt 
7Y~COOBzl 
SY~CONHBzl 
Reagents: (i) BrCH2COOEt, NMM, DMF; NH3/MeOH, 15 0.1 eq NaCN, DMF. (ii) BrCH2 COO-tBu, NMM DMF. (iii) 3, 
EDC, HOBt, DMF or NMM, iBCF, DMF. (iv) TFA (can be 
used to deblock the t-Butyl Group in certain peptides where 
X=O-tBu). 
Examples of the preceding methods are exhibited below 
20 
and in the examples: 
5. Synthetic Procedures and Examples 
A. Material and Methods 
Mono and dipeptidyl methyl esters were purchased from 
25 Bachem Bioscience Inc., King of Prussia, Pa. Tripeptides 
were synthesized using standard coupling procedures such as 
the mixed anhydride method. The 1 H NMR spectra were 
obtained using a Varian Mercury 400 MHz spectrometer. 
Electrospray ionization (ESI), fast-atom-bombardment 
30 (FAB) and high-resolution mass spectrometry were per-
formed using Micromass Quattro LC and VG Analytical 
70-SE instruments. Elemental analysis was performed by 
Atlantic Microlab Inc., Norcross, Ga. 
In this method, the propenoate portion of the propenoyl 
hydrazide is coupled to the substituted hydrazide by reacting 
the acrylate portion ( carboxylic acid) with NMM in DMF and 
iBCF followed by the substituted hydrazide to form the pro-
penoyl hydrazide (see the following figure). Methods for the 35 
protection and deprotection of side chain protecting groups 
are well known. 
B. Preparation of Peptidyl Hydrazides (3). 
Anhydrous hydrazine (10 eq) was added to a solution of the 
peptidyl methyl ester (1 eq) in MeOH at room temperature, 
and the resulting mixture was then stirred for 16 hours. As 
with most hydrazides, excess hydrazine and solvent were 
removed by evaporation. The resulting residue was washed 
R1 
I 
R1...._ ,,NH 
N 
H 
HO~R3 
II I or 
0 ~ 
HOyy~ 
0 R3 
NMM, iBCF, THF 
R1 
I 
R1,1i,,.NYYR3 
0 ~ 
or 
The following figure shows how these methods are used to 
build the AAsp and AAsn derivatives. 
i or ii 
R1 ~ peptidyl 
4 
aX~ OEt; b X~NH2 
cX~ Ot-Bu; dX~ OH 
iii, iv 
40 with ethanol and ether to give the desired peptidyl hydrazide 
(3) as a white solid. MS and 1H NMR (CDC13 or DMSO-d6) 
were consistent with the proposed structures. 
PhPr-Val-Ala-NHNH2 , white solid, yield 75%. 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NHNH2 was purified 
45 by chromatography on a silica gel colunm using 1 :9 MeOH: 
CH2Cl2 as the eluent; white solid, yield 56%. 
Cbz-Leu-Glu(O-tBu)-Thr-NHNH2 , white solid, yield 
97%. 
N-Benzyloxycarbonylalanylalanyl Hydrazide (Cbz-Ala-
50 Ala-NHNH2 ) was synthesized from Cbz-Ala-Ala-OMe by 
hydrazinolysis; white solid (57% yield). 1H NMR (DMSO-
d6): 1.1-1.3 (d, CH3 ), 4.0-4.1 (m, lH, a-H), 4.1-4.3 (m, 2H, 
a-Hand NH), 5.05 (s, 2H, Cbz), 7.3-7.4 (m, SH, Ph), 7.5 (d, 
55 
lH, NH), 7.9 (d, lH, NH), 9.05 (s, lH, NH). 
Cbz-Leu-Leu-NHNH2 , white solid, yield 98%. 
Cbz-Val-NHNH2 , white solid, yield 92%. 
Cbz-Val-Glu(O-tBu)-Val-NHNH2 , white solid, yield 75%. 
Cbz-Glu(O-tBu)-Val-NHNH2 was purified by chromatog-
raphy on a silica gel colunm using 1 :9 MeOH:CH2Cl2 as the 
60 eluent; white solid, yield 47-53%. 
Cbz-Ile-Glu(O-tBu)-Thr-NHNH2 , white solid, yield 91 %. 
C. Preparation of PhPr-Leu-NHNH(CH2 ) 4-NH-Boc and 
PhPr-Leu-NHNH(CH2 ) 3-NH-Boc 
Boc-NH-(CH2 ) 2---CHO. To a solution of3-(t-butyloxy-
65 carbonylamino)propanol (1.419 g, 8.1 mmol) dissolved in 
DMSO (15 mL), IBX (2 eq, 4.5 g, 16.2 mmol) was added to 
form a slurry. The reaction was allowed to stir at rt for 5 hr. 
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The solid IBX dissolved slowly, but a white precipitate 
formed after approximately 1 hr of reaction time. Distilled 
water (80 mL) was added to the reaction mixture, and the 
resultant aqueous solution filtered and then extracted with 
diethyl ether (3x l 7S mL ). The organic layers were combined, 5 
dried over MgS04 , filtered, and evaporated. The crude oil was 
purified by silica gel chromatography using 10% CH30H in 
CH2Cl2 as the eluent. The solvent was evaporated to leave a 
clear, colorless oil with a very pleasant flowery or candy-like 
scent: yield 67%; one spot on TLC, Rf=0.70 (10% CH30H in 10 
CH2Cl2). 1H NMR (CDC13) o 9.80 (s, lH), 4.94 (s, lH), 
3.47-3.38 (m, 2H), 2.27-2.6S (t, 2H), 1.47 (s, 9H). MS (ESI+) 
m/z 174 (M+l). 
36 
(m, 2H), 2.40-2.28 (m, 2H), 2.08-1.90 (m, 2H), 1.8-1.64 (m, 
3H), 1.42 (s, 9H), 1.00-0.78 (m, 6H). MS (FAW) m/z 447 
(M+l). 
PhPr-Leu-NHNH(CH2)3-NH-Boc. This procedure is 
based on the method used by Gallina et al. to synthesize a 
series of Z-hydrazines [Calbretta et al, Eur. J. Med. Chem. 30, 
931 -941 (199S); incorporated herein by reference]. PhPr-
Leu-NH-N=CH(CH2)2-NH-Boc (1.928 g, 4.46 mmol) 
and NaBH3CN (Seq, 1.400 g, 22.3 mmol) were dissolved in 
anhydrous THF (23 mL ). Glacial acetic acid (104 eq, 27 .8S g, 
464 mmol, 26.S mL) was added dropwise to the solution, and 
the reaction mixture was allowed to stir at rt overnight. The 
solvents were evaporated and the crude oil dissolved in ethyl 
l-(t-Butyloxycarbonyl)-3,4-dihydropyrrole. To a solution 
of 4-(t-butyloxycarbonylamino )butanol (1.S40 g, 8.1 mmol) 
in DMSO (lS mL), IBX (2 eq, 4.S g, 16.2 mmol) was added 
at rt and reacted for S. 7 hr. The remainder of the workup was 
similar to that used for Boc-NH-(CH2)2---CHO. The crude 
oil was purified by silica gel chromatography in 10% CH30H 
in CH2Cl2 and concentrated, leaving the product as a clear, 
faintly yellow oil: yieldS8%; one spot on TLC, Rf=0.71 (10% 
CH30HinCH2Cl2). 1HNMR(CDC13) o S.47 (s, lH), S.40 (s, 
lH), 3.60-3.20 (m, 2H), 2.14-1.74 (m, 2H), l.4S (s, 9H). MS 
(ESI+) m/z 170 (M+l). 
15 acetate (20 mL). Distilled water (20 mL) was added to the 
solution, which was vigorously stirred while enough solid 
NaHC03 was added to tum the pH of the aqueous layer basic. 
The organic layer was isolated and washed with a saturated 
NaCl solution (2x1S mL), a saturated NaHC03 solution (10 
20 mL), and again with a saturated NaCl solution (10 mL). The 
organic layer was dried over MgS04 , filtered, and evaporated. 
The crude solid was purified by silica gel chromatography 
using 1/1 ethyl acetate/hexanes as the eluent. The solvent was 
evaporated, leaving a white, foamy solid that was used with-
PhPr-Leu-NHN=CH(CH2)2-NH-Boc. This procedure 
is based on the method used by Gray and Parker [Gray and 
Parker et al, Tetrahedron 31, 2940-2943, (197S); incorpo-
rated herein by reference] to prepare Boc-3-aminopropanal 
benzoylhydrazone. To a solution of Boc-NH-(CH2)2CHO 
(0.942 g, S.43 mmol) dissolved in absolute ethanol (11 mL) at 
25 out further purification: yield S9%; product spot on TLC, 
Rf=0.43 (10% CH30H in CH2Cl2). 1H NMR (CDC13) o 9.80 
(s, lH), 9.S4 (s, lH), 7.30-7.13 (m, SH), 6.94 (s, lH), 6.60 (s, 
lH), 4.60-4.47 (m, lH), 3.2S-3.06 (m, 2H), 3.04-2.93 (m, 
4H), 2.60-2.Sl (m, 2H), 2.87-1.72 (m, 3H), 1.70-1.60 (m, 
30 2H), 1.42 (s, 9H), 0.98-0.82 (m, 6H). MS (ESI+) m/z 43S 
(M+l). 
rt, PhPr-Leu-NHNH2 (1.498 g, S.43 mmol) was added to form PhPr-Leu-NHNH(CH2)4-NH-Boc. This procedure is 
based on the method used by Gallina et al. to synthesize a 
series of Z-hydrazines hydrazines [Calbretta et al, Eur. J. 
Med. Chem. 30, 931-941(199S); incorporated herein by ref-
erence]. PhPr-Leu-NHN=CH(CH2)3-NH-Boc (1.S43 g, 
3.46 mmol) and NaBH3CN (Seq, 1.086 g, 17.3 mmol) dis-
solved in anhydrous THF (24 mL) were reacted with glacial 
acetic acid (104 eq, 21.608 g, 360 mmol, 20.6 mL). The 
remainder of the workup was similar to that used for PhPr-
Leu-NHNH-(CH2)3-NH-Boc. The crude product was 
purified by silica gel chromatography using 1/1 ethyl acetate/ 
hexanes as the eluent. The solvent was evaporated to give a 
clear, colorless oil. Treatment with CH2Cl2, followed by 
diethyl ether and evaporation gave a white, foamy solid, 
which was used without further purification: yield49%; prod-
uct spot on TLC, Rf=0.67 (10% CH30H in CH2Cl2). 1H 
NMR(CDCl3) o 9.00 (s, lH), 8.7S (s, lH), 7.28-7.12 (m, SH), 
a slurry. The reaction mixture was allowed to stir at rt over-
night. The solvent was evaporated and the crude product 35 
dissolved in CH2Cl2 (SO mL ). The organic layer was washed 
with a 10% citric acid solution (3x40 mL), a saturated 
NaHC03 solution (3x2S mL), and a saturated NaCl solution 
(3x2S mL ). The organic layer was dried over MgSO 4 , filtered, 
and concentrated. The material was then purified by silica gel 40 
chromatography using 10% CH3 OH in CH2Cl2 as the eluent. 
The eluent was evaporated, giving a white, foamy solid that 
was used without further purification: yield 82%; product 
spot by TLC, Rf=O.S6 (10% CH30H in CH2Cl2). 1H NMR 
(CDC13) o 10.0S (s, lH), 8.90 (s, lH), 7.40-7.08 (m, SH), 45 
6.30-6.16 (t, lH), S.S2-S.36 (t, lH), 4.S2-4.40 (m, lH), 3.44-
3.28 (m, 2H), 3.00-2.86 (m, 2H), 2.S7-2.44 (m, 4H), 1.71-
1.44 (m, 3H), 1.40 (s, 9H), 0.98-0.82 (m, 6H). MS (ESI+) m/z 
433 (M+l). 
50 4.86 (s, lH), 4.80 (s, lH), 4.Sl-4.42 (m, lH), 3.24-3.04 (m, 
2H), 3.02-2.93 (m, 4H), 2.77-2.68 (m, 2H), 2.62-2.48 (m, 
2H), 2.01-1.90 (m, lH), 1.88-1.78 (m, 2H), 1.76-1.60 (m, 
4H), 1.42 (s, 9H), 0.97-0.82 (m, 6H). MS (ESI+) m/z 449 
(M+l). 
PhPr-Leu-NHN=CH(CH2)3-NH-Boc. This procedure 
is a modification of the method used by Gray and Parker 
[Gray and Parker et al, Tetrahedron 31, 2940-2943, (197S); 
incorporated herein by reference] to prepare Boc-3-amino-
propanal benzoy lhydrazone. The 1-( t-butyloxycarbony 1)-3, 
4-dihydropyrrole (0.80S g, 4.76 mmol) was reacted with 55 
PhPr-Leu-NHNH2 (1.320 g, 4.76 mmol) and p-toluene sul-
fonic acid monohydrate (0.3 eq, 0.272 g, 1.43 mmol) in 
absolute ethanol (12 mL) at rt. The remainder of the workup 
was similar to the procedure used to synthesize PhPr-Leu-
NH-N=CH(CH2)2-NH-Boc. The crude product was 60 
purified by silica gel chromatography using 10% CH30H in 
CH2Cl2 as the eluent. The eluent was evaporated to give a 
foamy white solid, which was used without further purifica-
tion: yield 73%; product spot by TLC, Rf=O.SS (10% CH30H 
in CH2Cl2). 1H NMR (CDC13) o 9.77 (s, lH), 8.80 (s, lH), 65 
7.43-7.13 (m, SH), 6.07-S.89 (t, lH), SAS-S.34 (t, lH), 4.48-
4.31 (m, lH), 3.20-3.09 (t, 2H), 3.00-2.87 (m, 2H), 2.S9-2.42 
D. Preparation of the Peptidyl Aza-Asn Precursor (Cbz-
Ala-Ala-NHNHCH2CONH2) 
Preparation of Cbz-Ala-Ala-NHNHCH2C00Et (4a). 
Ethyl bromoacetate (1.1 eq) was added dropwise to a stirred 
solutionofCbz-Ala-Ala-NHNH2 (1 eq) andNMM (1.1 eq) in 
DMF that was cooled to -10° C. The resulting solution was 
stirred for 30 min at -10° C., after which the mixture was 
allowed to react at room temperature for 36 hours. The DMF 
was evaporated, and the residue was purified on a silica gel 
column using 1:9 MeOH:CH2Cl2 as the eluting solvent sys-
tem to afford 4a as a white solid (yield=36% ). 1 H NMR 
(DMSO-d6): 1.18 (t, 9H, CH3), 3.S (d, 2H, NCH2C00Et), 
4.0-4.lS (m, 3H, a-Hand OCH2CH3), 4.2 (m, lH), a-H), 
US 7,482,379 B2 
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S.03 (m, 2H, Cbz), S.18 (m, lH, NH), 7.22-7.40 (m, SH, Ph), 
7.4-7.S (d, lH, NH), 7.9 (m, lH, NH), 9.3S (m, lH, NH). MS 
(FAB) m/z 39S [(M+ltJ. 
Preparation ofN1 -N-Benzyloxycarbonylalanylalanyl-N2-
carbamoylmethylhydrazine (Cbz-Ala-Ala- 5 
NHNHCH2CONH2, 4b). The ethyl ester (4a) was converted 
to the amide ( 4b) by the method described by [Hogberg et al. 
J. Org. Chem. 2033-2066 (1987); incorporated herein by 
reference]. The ethyl ester Cbz-Ala-Ala-NHNHCH2C00Et 
( 4a, 1 eq) was dissolved in a 9 M solution ofNH3 in methanol 10 
and a small amount ofDMF, and allowed to stiron an ice bath. 
To this solution was added NaCN (0.1 eq). The flask was 
closed with a rubber septum and allowed to stir at 0° C. for 
three days. The solvent was evaporated and the product was 
precipitated with 1 :9 MeOH:CH2Cl2 and methanol to yield a 15 
white solid (68% yield). 1H NMR (DMSO-d6): 1.18 (d, 6H, 
CH3 ), 3.2 (d, 2H, NCH2CONH2), 4.0-4.12 (m, lH, a-H), 4.2 
(m, lH, a-H), S.03 (m, 2H, Cbz), S.22 (m, lH, NH), 7.18 (d, 
lH, NH), 7.3-7.S (m, 6H, Ph and NH), 8.0 (m, lH, NH), 9.38 
(m, lH, NH). MS (FAB) m/z 366 [(M+ltJ. HRMS (FAB) 20 
Calcd. For C16H24N5 0 5 : 366.17774. Observed m/z 
366.1766S. 
D. Preparation of the t-Bu Protected Peptidyl Aza-Asp 
Precursors 
38 
1.3-1.S (m, 18H, tBu), 1.S-1.8 (m, 2H, Leu CH andG!u CH2), 
1.8-1.9S (m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu CH2), 3.4 (d, 
2H, NCH2), 3.9 (m, lH, a-H), 4.1 (m, lH, a-H and Thr 
CH-OH), 4.3 (m, lH, a-H), 4.9 (d, lH, NH), S.03 (m, 2H, 
Cbz), 7.3-7.4 (m, SH, phenyl), 7.S (d, lH, NH), 7.6 (d, lH, 
NH), 8.0S (d, lH, NH), 9.2 (d, lH, NH). 
Cbz-Ile-Glu(O-tBu)-Thr-NHNHCH2COO-tBu was puri-
fied by colunm chromatography on silica gel using 1 :9 
MeOH:CH2Cl2 as the eluent; white solid, yield 26%. MS 
(ESI) m/z 680 [(M+lt]. 1H NMR (DMSO-d6): 0.7-0.9 (t, 
6H, Ile CH3 ), 0.9-1.0 (d, 3H, Thr CH3 ), 1-1.2 (m, 2H, Ile 
CH2), 1.3-1.S (s, 18H, tBu), 1.6-1.8 (m, 2H, Ile CH and Glu 
CH2), 1.8-1.9 (m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu CH2), 
3.4 (d, 2H, NCH2), 3.9 (m, 2H, a-H), 4.1 (m, lH, a-H), 4.3S 
(m, lH, Thr CH-OH), 4.8 (d, lH, NH), S.03 (s, 2H, Cbz), 
S.OS (d, lH, NH), 7.3-7.4 (m, SH, phenyl), 7.7 (d, lH, NH), 
8.0S (d, lH, NH), 9.2 (s, lH, NH). 
Cbz-Val-Glu(O-tBu)-Val-NHNHCH2COO-tBu was puri-
fied by colunm chromatography on silica gel using 1 :9:S 
MeOH:CH2Cl2:EtOAc as the eluent, and then rechromato-
graphed using 1:9:S MeOH:CH2Cl2:EtOAc as the eluent; 
white solid, yield 18%. 1H NMR (DMSO-d6): 0.78-0.SS (dd, 
12H, Val), 1.40 (d, 18H, tBu), 1.71 (m, lH, Val), 1.83 (m, 2H, 
Glu), 1.91 (m, 1 h, Val), 2.17 (m, 2H, Glu), 3.86 (t, lH, a-H), 
Preparation of Peptidyl-AA2-NHNHCH2COO-tBu (4c). 
Neat t-butyl bromoacetate (1 eq) was added to a stirred solu-
tion of the peptide hydrazide (3) and NMM (1 eq) in DMF 
pre-cooled at -10° C. The resulting solution was stirred for 30 
min at -10° C., after which the mixture was allowed to react 
25 4.04 (t, lH, a-H), 4.32 (m, lH, a-H), S.Ol (s, 2H, Cbz), S.12 
(m, lH, NH), 7.33 (s, SH, Ph), 7.76 (d, lH, NH), 8.00 (d, lH, 
NH), 9.43 (d, lH, NH). 
E. Preparation ofMonoethyl Maleate (HOOCCH=CH-
COOEt) 
at room temperature for 20 hours. The DMF was removed by 30 
evaporation, and the resulting residue was washed with water, 
filtered, and dried in vacuo. Purification on a silica gel column 
using the appropriate solvent gave 4c (yields=48-6S%). MS 
and 1 H NMR (DMSO-d6 or CDCl3 ) were consistent with the 
proposed structure. 
PhPr-Val-Ala-NHNHCH2COO-tBu was purified by chro-
matography on silica gel column using 1 :7 MeOH:CH2Cl2 as 
the eluent; white solid, yield S6%. 
Monoethyl maleate was obtained as a colorless oil from the 
reaction of maleic anhydride with absolute ethanol at room 
temperature for 18 hours (yield=86%) [Batchelor et al, J. 
Chem. Soc. Perkin Trans. I 98S-99S (1998); incorporated 
herein by reference]. 1H NMR (DMSO-d6 ): 1.19 (t, 3H, 35 OCH2CH3 ), 4.11(q,2H, OCH2CH3 ), 6.33 (s, 2H, CH=CH). 
F. Preparation of Benzylnaphthyl-2-ylmethylamine (Bzl-
NHCH2-2-Napth)-Reductive Amination Procedure. 
Benzylamine (1 eq) was dissolved in absolute ethanol. A 
solution of 2-naphthaldehyde (1 eq) in absolute ethanol was 
added dropwise via an addition funnel to the benzylamine 
solution while stirring. The mixture was heated at reflux for 2 
hours. Sodium borohydride (2.1 eq) was added to the mixture. 
The mixture was heated at reflux for 2 hours. The solvent was 
Cbz-Val-NHNHCH2COO-tBu was purified by column 
chromatography on silica gel using 1 :20:4.2 MeOH:CH2Cl2: 40 
EtOAc as the eluent; white solid, yield 64%. 1H NMR 
(DMSO-d6): 0.90 (t, 6H, Val), 1.40 (s, 9H, tBu), 1.86 (m, lH, 
Val), 3.37 (d, 2H, NHCH2COOH), 3.72 (t, lH, a-H), 4.99 (s, 
2H, Cbz), S.13 (d, lH, NH), 7.30 (s, SH, Ph), 9.38 (d, lH, 
NH). 45 removed under reduced pressure. The residue was dissolved 
in dichloromethane. The solution was washed with aqueous 
base (NaOH, IM) and dried (MgS04). The solvent was 
removed under reduced pressure to give a clear, colorless oil 
(90% yield). 1H NMR (CDCl3 ): 2.37 (s, lH, CH2NHCH2), 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NHNHCH2COO-tBu 
was purified by column chromatography on silica gel using 
2: 1 S:S MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield 
6S%. MS (ESI) nm/z 736.6 [(M+lt]. 1H NMR (DMSO-d6): 
0.90 (d, 6H, Val), 1.49 (s, 27H, tBu), 1.SS-2.20 (m, 3H, Val 50 
and Glu), 2.21 (m, 2H, Glu), 2.40-2.70 (m, 2H, Asp CH2), 
3.30 and 3.38 (m, 3H, NHCH2 and NHCH2), 4.0S-4.30 (m, 
3H, a-H), S.OS (m, 2H, Cbz), 7.20-7.40 (m, SH, Ph), 7.60-
7.9S (m, 3H, NH), 9.2 (m, lH, NH). 
Cbz-Glu(O-tBu)-Val-NHNHCH2COO-tBu was purified 55 
by column chromatography on silica gel using 2: 1 S:S MeOH: 
CH2Cl2:Et0Ac as the eluent; white solid, yield 78%. MS 
(ESI) m/z S6S.3 [(M+ltJ, 1H NMR (CDCl3 ): 0.9S (t, 6H, 
Val), 1.49 (s, 18H, tBu), 1.SS-2.20 (m, 3H, Val and Glu), 2.21 
(m, 2H, Glu), 3.4S-3.70 (m, 3H, NHCH2 and NHCH2), 4.2S- 60 
4.30 (m, 2H, a-H), S.OS (m, 2H, Cbz), S.SS (d, lH, NH), 7.0S 
(d, lH, NH), 7.20-7.40 (m, SH, Ph), 8.00 (m, lH, NH). 
Cbz-Leu-Glu(O-tBu )-Thr-NHNHCH2COO-tBu was puri-
fied by colunm chromatography on silica gel using 1:9 
MeOH:CH2Cl2 as the eluent; white solid, yield 34%. MS 65 
(ESI) m/z 680 [(M+lt]. 1H NMR (DMSO-d6): 0.7-0.9 (t, 
6H, Leu CH3 ), 1.0 ( d, 3H, Thr CH3 ), 1-1.3 (m, 2H, Leu CH2), 
3.84 (s, 2H, NHCH2PH), 3.97 (s, 2H, Napth-CH2NH), 7.23-
7.SO (m, SH, Ph, Napth), 7.76-7.81 (m, 4H, Napth). 
Bis-furan-2-ylmethylamine (NH(CH2-2-furyl)2). The 
amine was prepared following the reductive amination pro-
cedure (89% yield). 1H NMR (CDCl3 ): 3.84 (s, 4H, 
CH2NHCH2), 6.29-6.33 (2 dd, 4H, fury!), 7.37-7.38 (dd, 2H, 
fury!). 
Benzyl-( 4-methoxybenzyl)amine (Bz!NH(Bzl-4-0Me )). 
The amine was prepared prepared following the reductive 
aminationprocedure (98%yield). 1HNMR (CDCl3 ): 2.16 (s, 
lH, CH2NHCH2), 3.74 (s, 3H, CH3 0), 3.78-3.86 (m, 4H, 
CH2NHCH2), 6.83-6.97 (m, 2H, MeO-Ph), 7.24-7.33 (m, 7H, 
Ph). 
Benzyl-(4-fluorobenzyl)amine (Bz!NH(Bzl-4-F). The 
amine was prepared following the reductive amination pro-
cedure (89% yield). 1H NMR (CDCl3 ): 2.0S (s, lH, 
CH2NHCH2), 3.77-3.79 (d, 4H, CH2NHCH2), 6.96-7.02 (m, 
4H, F-Ph), 7.19-7.23 (m, SH, Ph). 
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Benzylnaphthyl-1-ylmethylamine (Bz!NHCH2-l-Napth). 
The amine was prepared prepared following the reductive 
amination procedure (97% yield). 1 H NMR (CDCl3): 2.03 (s, 
lH, CH2NHCH2), 3.91 (s, 2H, NHCH2Ph), 4.24 (s, 2H, 
Napth-CH2NH), 7.22-7.Sl (m, !OH, Ph, Napth), 7.71-7.8S 5 
(m, 2H, Napth). 
7.02-7.14 (m, lH, CH=CHCON), 7.14-7.31 (m, 2H, Ph), 
7.32 (t, 2H, Ph), 7.66 (d, 2H, Ph), 10.47 (s, lH, NH). 
trans-3-Benzylcarbamoylacrylic Acid 
(HOOCCH=CH--CONHBzl). This compound was synthe-
sized using the above procedure with benzylamine as the 
starting material. 1H-NMR (DMSO-d6): 4.37 (d, 2H, 
G. Preparation oftrans-3-Benzyloxycarbonylacrylic Acid 
or Monobenzyl Fumarate (HOOCCH=CH--COOBzl). 
N--CH2-Ph), 6.S2-6.S6 (d, lH, J=lS.2 Hz, CH=CHCON), 
6.94-6.98 (d, lH, J=lS.6 Hz, CH=CHCON), 7.14-7.31 (m, 
SH, Ph), 8.97 (t, lH, NH). 
trans-3-( 4-Fluorobenzylcarbamoyl)acrylic Acid 
(HOOCCH=CH--CONH-Bzl-4-F). This compound was 
synthesized using the above procedure with 4-fluoro benzy-
lamine as the starting material. 1H-NMR (DMSO-d6): 4.34-
4.3S (d, 2H, N-CH2-Ph), 6.S2-6.SS (d, lH, J=lS.2 Hz, 
15 CH=CHCON), 6.93-6.94 (d, lH, J=lS.6 Hz, 
Equimolar amounts of fumaric acid and benzyl alcohol 
were dissolved in anhydrous DMF. NMM (1 eq) was added at 10 
0° C. followed by EDC after IS minutes. The reaction was 
stirred over night at room temperature. DMF was evaporated 
and the crude residue was redissolved in EtOAc. The product 
was extracted with saturated aqueous NaHC03. The aqueous 
layer was then acidified with IN HCI to pH 2. The product 
was extracted with EtOAc, and the organic layer was washed 
with water and dried (MgS04). The solvent was evaporated 
and the crude residue was subjected to column chromatogra-
phy (MeOH/CH2Cl2) to give a white powder (Sl % yield). 
1H-NMR (DMSO-d6): S.21 (s, 2H, CH=CH-
COOCH2Ph), 6.73 (s, 2H, CH=CH--COOCH2Ph), 7.29-
7.43 (m, SH, Ph). MS (ESI) rn/z 207 [(M+lt]. 
CH=CHCON), 7.14-7.16 (t, 2H, Ph), 7.27-7.31 (t, 2H, Ph), 
8.99 (t, lH, NH), 
trans-3-Phenethy lcarbamoylacry lie Acid 
(HOOCCH=CH--CONHCH2CH2Ph). This compound was 
20 synthesized using the above procedure with phenethylamine 
as the starting material. 1 H-NMR (DMSO-d6): 3.S4 (t, 2H, 
N--CH2--CH2-Ph), 3.61 (t, 2H, N--CH2--CH2-Ph) 6.43-
6.47 (d, lH, J=lS.2 Hz, CH=CHCON), 6.98-7.02 (d, lH, H. General Procedure for Coupling Monoethyl Fumarate 
to Amines-Mixed Anhydride Coupling. J=lS.6 Hz, CH=CHCON), 7.14-7.31 (m, SH, Ph). 
Coupling of the amine precursors to the fumarates was 25 
accomplished using the mixed anhydride coupling method. 
trans-N-Methy lpheny lcarbamoylacrylic Acid 
(HOOCCH=CH--CON(CH3)Ph). This compound was syn-
thesized using the above procedure with N-methyl aniline as 
the starting material. 1H-NMR (DMSO-d6): 3.14 (s, 3H, 
N--CH3), 6.S0-6.S4 (d, lH, J=lS.2 Hz, CH=CHCON), 
To a solution of the fumarate (1 eq) in CH2Cl2 at-20° C. was 
addedN-methylmorpholine (NMM, 1 eq) followed by isobu-
ty I chloroformate (iBCF, 1 eq). After the reaction mixture was 
allowed to stir for 30 min, the amine (1 eq) was added to the 
mixture. Hydrochloride salts of the amine were pretreated 
withNMM (1 eq) at-20° C. in CH2Cl2 prior to addition.After 
30 mim the reaction was continued to stir for 4 hours at room 
temperature. The DMF was evaporated and the residue was 
washed and purified using the same procedure as described 
above forthe EDC/HOBt coupling method. MS and 1 H NMR 
(DMSO-d6 or CDCl3) were consistent with the proposed 
structures. Hydrolysis of the ester by NaOH (1.2 eq) gave the 
desired amides (yields=40-98% ). 
trans-3-Dibutylcarbamoylacrylic Acid 
(HOOCCH=CH--CON(nBu)2). This compound was syn-
thesized using the above procedure with dibutylamine as the 
starting material. 1H-NMR (CDCl3): 0.9S (m, 6H, 2xnBu-
CH3), 1.30-1.37 (m, 4H, 2xCH2CH2CH2CH3), l.S3-l.S9 (m, 
4H, 2xCH2CH2CH2CH3), 3.33 (t, 2H, N-CH2), 3.39 (t, 2H, 
N-CH2), 6.79-6.83 (d, lH, J=lS.6 Hz, CH=CHCON), 
7.33-7.36 (d, lH, J=lS.2 Hz, CH=CHCON). 
trans-3-Diethy lcarbamoy lacry lie Acid 
(HOOCCH=CH--CONEt2). This compound was synthe-
sized using the above procedure with diethylamine as the 
starting material. 1H-NMR (CDCl3): 1.17-1.21 (t, 3H, 
N-CH2CH3), 1.22-1.24 (t, 3H, N--CH2CH3), 3.40-3.47 (m, 
4H, 2xN-CH2), 6.78-6.82 (d, lH, J=14.8 Hz, 
30 6.60-6.64 (d, lH, J=lS.2 Hz, CH=CHCON), 7.32 (t, 2H, 
Ph), 7.40 (d, lH, Ph), 7.47 (d, lH, Ph). 
trans-3-Benzylmethylcarbamoylacrylic Acid 
(HOOCCH=CH--CON(CH3)Bzl). This compound was 
synthesized using the above procedure with N-methyl ben-
35 zylamine as the starting material. 1 H-NMR (D MSO-d6): 3. 03 
(s, 3H, N-CH3), 4.62-4.67 (d, 2H, N-CH2-Ph), 6.83-6.87 
(d, lH, J=16 Hz, CH=CHCON), 7.lS-7.17 (d, lH, J=8 Hz, 
CH=CHCON), 7.2S-7.SO(m, SH, Ph). 
trans-3-(Methy 1-1-naphthy lmethy lcarbamoyl )a cry lie 
40 Acid (HOOCCH=CH--CON(CH3)CH2-l-Napth). This 
compound was synthesized using the above procedure with 
N-methyl-1-naphthyl methylamine hydrochloride as the 
starting material. 1H-NMR (DMSO-d6): 3.01 (s, 3H, CH3), 
S.Ol (s, 2H, CH2), 6.6l-6.6S (d, lH, J=lS.2 Hz, 
45 CH=CHCON), 7.17-7.21 (d, lH,CH=CHCON), 7.37-7.60 
(m, 4H, naphthyl), 7.8S-8.01 (m, 3H, naphthyl). 
trans-3-(Methylphenethylcarbamoyl)acrylic Acid 
(HOOCCH=CH--CON(CH3)CH2CH2Ph). This compound 
was synthesized using the above procedure with N-methyl 
50 phenethylamine as the starting material. 1H-NMR (DMSO-
d6): 2.82 (s, 3H, N-CH3), 3.S4 (t, 2H, N-CH2-CH2-Ph), 
3.61 (t, 2H, N-CH2--CH2-Ph), 6.43-6.47 (d, lH, J=lS.2 
Hz, CH=CHCON), 6.98-6.7.02 (d, lH, J=lS.6 Hz, 
CH=CHCON), 7.31-7.3S (d, lH, J=14.8 Hz, 55 
CH=CHCON), 7.14-7.31 (m, SH, Ph). 
trans-3-Pheny lbenzylcarbamoy la cry lie Acid 
CH=CHCON). 
trans-3-(1-Piperidylcarbonyl)acrylic Acid 
(HOOCCH=CH--CO-Pip). This compound was synthe-
sized using the above procedure with piperidine as the start-
ing material. 1H-NMR(DMSO-d6): 1.46-1.60 (m, 6H, 3xpip-
eridine CH2), 3.4S-3.49 (m, 4H, CH2-N--CH2), 6.41-6.44 
(d, lH, J=lS.2 Hz, CH=CHCON), 7.33-7.37 (d, lH, J=lS.2 
Hz, CH=CHCON). 
trans-3-Pheny lcarbamoylacrylic Acid (H OOCCH=CH-
CONHPh ). This compound was synthesized using the above 
procedure with aniline as the starting material. 1 H-NMR 
(DMSO-d6): 6.61-6.6S (d, lH, J=lS.2 Hz, CH=CHCON), 
(HOOCCH=CH--CON(Bzl)Ph). This compound was syn-
thesized using the above procedure with phenyl benzylamine 
as the starting material. 1H-NMR (DMSO-d6): 4.97 (s, 2H, 
N--CH2-Ph), 6.61-6.62 (d, lH, CH=CHCON), 7.lS-7.43 
60 (m, 1 lH, CH=CHCON and 2xPh). 
trans-3-Dibenzylcarbamoylacrylic Acid 
(HOOCCH=CH--CON(Bzl)2). This compound was syn-
thesized using the above procedure with dibenzy !amine as the 
starting material. 1H-NMR (DMSO-d6): 4.S7 (s, 2H, 
65 N--CH2-Ph), 4.6S (s, 2H, N--CH2-Ph), 6.S9-6.63 (d, lH, 
J=lS.2 Hz, CH=CHCON), 7.lS-7.17 (d, lH, J=8 Hz, 
CH=CHCON), 7.2S-7.SO (m, !OH, 2xPh). 
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trans-3-(Benzyl-4-methoxybenzylcarbamoyl)acrylic Acid 
(HOOCCH=CH--CON(Bzl-4-0Me)Bzl). This compound 
was synthesized using the above procedure with 4-methoxy-
benzyl benzylamine as the starting material. 1H-NMR 
(DMSO-d6): 3.73 (s, 3H, OCH3 ), 4.50-4.54 (d, 2H, N--CH2- 5 
Ph), 4.56-4.61(d,2H, N--CH2-Ph), 6.59-6.63 (d, lH, J=15.2 
Hz, CH=CHCON), 6.86-6.92 (2xd, 2H, Ph), 7.07-7.09 (d, 
lH, J=8 Hz, CH=CHCON), 7.14-7.39 (m, 7H, 2xPh). 
trans-3-Benzyl-( 4-fluorobenzyl)carbamoylacrylic Acid 
(HOOCCH=CH--CON(Bzl-4-F)Bzl). This compound was 10 
synthesized using the above procedure with 4-fluorobenzyl 
benzylamine as the starting material. 1 H-NMR (DMSO-d6): 
4.50-4.54 (d, 2H, N--CH2-Ph), 4.56-4.61 (d, 2H, N--CH2-
Ph), 6.59-6.63 (d, lH, J=15.2 Hz, CH=CHCON), 6.99-7.44 
(m, 1 lH, CH=CHCON and CH=CH--CON and 2xPh). 15 
trans-3-(Bis-(2-furylmethyl)carbamoyl)acrylic Acid 
(HOOCCH=CH--CON(CH2-2-furyl)2. This compound 
was synthesized using the above procedure with bis-2-furan-
methyl amine as the starting material. 1 H-NMR (DMSO-d6): 
2.73 (d, lH, J=3.6 Hz, fury!), 3.13 (t, lH, fury!), 3.49 (d, lH, 20 
N-CH2), 4.03 (d, lH, N-CH2), 4.35-4.49 (dd, 2H, 
N-CH2), 5.17 (d, lH, fury!), 6.30-6.40 (m, 3H, fury!), 6.63-
6.64 (d, lH, J=15.2 Hz, CH=CHCON), 7.60 (s, lH, 
CH=CHCON). 
42 
trans-3-(1,3-Dihydroisoindol-2-ylcarbonyl)acrylic Acid 
(HOOCCH=CH--CO-isoindoline). This compound was 
synthesized using the above procedure with isoindoline as the 
starting material. 1H-NMR (DMSO-d6 ): 4.73 (s, 2H, NCH2), 
4.99 (s, 2H, NCH2), 6.63-6.67 (d, lH, J=15.2 Hz, 
CH=CHCON), 7.33 (m, SH, isoindoline and 
CH=CHCON). 
trans-3-( 4-Phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl) 
acrylic Acid (HOOCCH=CH--CO-( 4-Ph-Py )). This com-
pound was synthesized using the above procedure with 
4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride as the 
starting material. 1 H-NMR (DMSO-d6): 2.57 (s, 2H, pyridyl-
CH2), 3.73-3.76 (t, 2H, pyridyl-CH2), 4.17-4.26 (d, 2H, 
pyridyl-CH2), 6.14-6.17 (d, lH, pyridyl CH=), 7.23-7.27 (t, 
lH, Ph), 7.31-7.35 (t, 2H, Ph), 7.39-7.48 (m, 3H, 
CH=CHCON and Ph). 
trans-3-(Methy 1-(1-methy lphenethy lcarbamoy l)phenyl-
ethy lcarbamoy l)acry lic Acid (HOOCCH=CH-Phe(Me)-N 
(Me)(CH2)2Ph). This compound was synthesized using the 
above procedure with Phe(Me )-N(Me )(CH2)2Ph as the start-
ing material. 1H-NMR (DMSO-d6): 2.73-2.98 (m, !OH, Phe-
CH2 and CH2Ph and 2xMe), 3.40-3.51 (m, 2H, N-CH2), 
5.20 (m, lH, a-H), 6.63-5.78 (2xt, lH, CH=CHCON), 6.80-
6.99 (m, lH, CH=CHCON), 7.10-7.33 (m, !OH, 2xPh). 
trans-3-(Benzyl-2-naphthylmethylcarbamoyl)acrylic 25 Exemplary Methods of Use Acid (HOOCCH=CH--CON(Bzl)-2-CH2-Napth). This 
compound was synthesized using the above procedure with 
benzyl-2-naphthylmethylamine as the starting material. 
1H-NMR (DMSO-d6): 4.82 (d, 2H, N--CH2), 5.01 (d, 2H, 
N-CH2), 6.61-6.65 (d, lH, J=15.2 Hz, CH=CHCON), 30 
7.17-7.21 (d, lH, CH=CHCON), 7.37-7.60 (m, 9H, naph-
thyl and Ph), 7.85-8.01 (m, 3H, naphthyl). 
trans-3-(Benzyl-1-naphthylmethylcarbamoyl)acrylic 
Peptide propenoyl hydrazides are irreversible inhibitors for 
cysteine proteases. Peptide propenoyl hydrazides containing 
aza-amino acid residues with anionic side chains in the Pl site 
are excellent inhibitors of caspases. Legumain is inhibited by 
peptide propenoyl hydrazides with a Pl aza-asparagine resi-
due. Clostripain and gingipain are inhibited by peptide pro-
penoyl hydrazides with Pl basic side chains. These structures 
may be used in vivo to treat diseases such as cancer and 
neurodegenerative diseases, which result from the uncon-
trolled proteolysis by cathepsin B, calpain, caspases, and 
related cysteine proteases. These inhibitors may be used in 
vitro to prevent proteolysis, which occurs in the process of 
production, isolation, purification, storage, or transport of 
Acid (HOOCCH=CH--CON(Bzl)-1-CH2-Napth). This 
compound was synthesized using the above procedure with 35 
benzyl-1-naphthylmethylamine as the starting material. 
1H-NMR (DMSO-d6): 4.82 (d, 2H, N--CH2), 5.01 (d, 2H, 
N-CH2), 6.61-6.65 (d, lH, J=15.2Hz, CH=CHCON), 
7.17-7.21 (d, lH, CH=CHCON), 7.37-7.60 (m, 9H, naph-
thyl and Ph), 7.85-8.01 (m, 3H, naphthyl). 40 peptides and proteins. These inhibitors may be useful as therapeutic agents for treatment of neurodegeneration, viral 
infections, muscular dystrophy, myocardial tissue damage, 
tumor metastasis, and bone resorption. 
trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)acrylic 
Acid (HOOCCH=CH-CO-tetrahydroquinoline ). This 
compound was synthesized using the above procedure with 
1,2,3,4-tetrahydroquinoline as the starting material. 
1H-NMR (DMSO-d6): 1.99-2.02 (m, 2H, N--CH2--CH2- 45 
CH2), 2.73-2.76 (t, lH, N--CH2--CH2--CH2), 3.86-3.98 (t, 
lH, N--CH2--CH2--CH2), 6.78-6.82 (dd, lH, J=14.8 Hz, 
CH=CHCON), 7.18-7.22 (m, 4H, quinoline), 7.44-7.48 (d, 
lH, J=14.8 Hz, CH=CHCON). 
trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)acrylic 50 
Acid (HOOCCH=CH-CO-tetrahydroisoquinoline ). This 
compound was synthesized using the above procedure with 
1,2,3,4-tetrahydroisoquinoline as the starting material. 
1H-NMR (DMSO-d6): 1.99-2.02 (m, 2H, N--CH2--CH2-
CH2), 2.73-2.76 (t, lH, N--CH2--CH2--CH2), 3.86-3.98 (t, 55 
lH, N--CH2--CH2--CH2), 6.78-6.82 (dd, lH, J=14.8 Hz, 
CH=CHCON), 7.18-7.22 (m, 4H, quinoline), 7.44-7.48 (d, 
lH, J=14.8 Hz, CH=CHCON). 
trans-3-(2,3-Dihydroindol-1-ylcarbonyl)acrylic Acid 
(HOOC--CH=CH-CO-indoline). This compound was 60 
synthesized using the above procedure with indoline as the 
starting material. 1H-NMR (DMSO-d6): 3.55 (t, 2H, 
N-CH2--CH2), 4.27 (t, lH, N-CH2-CH2), 6.64-6.67 
(dd, lH, J=15.2HzCH=CHCON,), 7.03 (t, lH,indoline-H), 
7.17 (t, lH, indoline-H), 7.24-7.26 (d, lH, J=7.2 Hz, indoline- 65 
H), 7.28-7.32 (d, lH, J=15.2 Hz, CH=CHCON), 8.11-8.13 
(d, lH, J=8 Hz, indoline-H). 
Enzyme Assays. 
Caspase-1. The preparation of the autolytically stable 
caspase-1 variant used in these studies has been described 
previously. Briefly, the variant contains a mutation (D381E), 
.which renders it resistant to autolytic inactivation, but has no 
detectable affect on enzyme activity as compared to the natu-
rally occurring enzyme. The enzyme variant was expressed in 
E. coli, purified first by immobilized metal chromatography 
via the N-terminal N-His tag, treated with excess oxidized 
glutathione to stabilize the reactive thiolate, and then re-
purified by size-exclusion chromatography. 
Inhibition data was measured using the progress curve 
assay method. Serial dilutions of each compound were pre-
pared using an initial 8-fold dilution of a DMSO stock into 
HGE (100 mM HEPES, 20% glycerol v/v, 0.5 mM EDTA), 
followed by seven serial two-fold dilutions into HGE and 
12.5% DMSO, thus maintaining constant DMSO through the 
dilution series. Ten µL of diluted stocks or of vehicle (HGE 
and 12.5% DMSO) were placed in triplicate onto a 96-well 
microtiter plate, allowing several compounds to be tested on 
each plate. The plate was covered to minimize evaporation, 
and the plate was pre-warmed to 30° C. for 20 minutes. 
Enzyme was diluted into 10.0 mL of assay buffer (HGE, 5 
mM DTT, plus 15 µMAc-YVAD-AMC, 2 nM approximate 
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k2 values are 15.73-fold higher than the apparent rate for 
caspase-8 because of the 100 mM [SJ and KM=6.79 FM. The 
k2 values are 2.32-fold higher than the apparent rate for 
caspase-9 because of the 150 mM [SJ and KM=114 µM. The 
final enzyme concentration), and this activated reaction mix-
ture was added to the plate at 90 µL/well. Progress of substrate 
hydrolysis was monitored for 900 s in a LabSystems 
(Needham, Mass.) Fluoroskan Ascent fluorescent plate-
reader using 385 and 460 nm excitation and emission filters, 
respectively, and a photomultiplier gain setting of 10. Tripli-
cate curves were averaged and fit by nonlinear regression to 
the equation for irreversible inactivation shown below. 
5 k2 values are 8.43-fold higher than the apparent rate for 
caspase-10 because of the 150 mM [SJ and KM=20.2 µM. 
The concentration of the caspase-3 stock solution was 2 
nM in the assay buffer. Assay buffer is a 1: 1 mixture of 
caspase buffer (40 mM Pipes, 200 mM NaCl, 0.2% (w/v) 
V;(l - e-kofa') 
F(t) = Fo + --k-
0
-fa--
10 CHAPS, sucrose 20% (w/v)) and 20 mM DTT solution in 
H2 0 at pH 7.2. The concentration of the substrate stock 
solution was 2 mM in DMSO. The enzyme was pre-activated 
for 10 min at 3 7° C. in the assay buffer. The standard 100 µL 
reaction was started by adding 40 µL of assay buffer, 5 µL of 
where F 0 was routinely fixed to zero, since fluorescence val-
ues were always adjusted to an origin ofO. The second order 
rate constant k
0
n (M- 1s- 1) was obtained from the slopes by 
linear regression, and errors represent the standard deviation 
of the regression slope. 
15 various amounts of inhibitor (stock solution concentrations 
variedfrom5xl0-3 Mto 4.84xl0-7 MinDMSO), and5 µLof 
substrate in DMSO (100 µM final concentration) at 37° C. 50 
µL of2 nM enzyme stock solution (final concentration: 1 nM) 
was added to the mixture after 1 min and reading started 
Enzyme Assays 
Caspase-2, -3, -6, -7, -8, -9 and-10. Caspases-2, -3, -6, -7, 
20 immediately for 20 min at 3 7° C. Inhibition experiments were 
repeated in duplicate and standard deviations determined. 
-8, -9 and -10 were expressed in E. coli and purified in Guy 
Salvesen's laboratory at the Burnham Institute, La Jolla, 
Calif., according to the methods known in the art. Inhibition 25 
rates were determined by the progress curve method known in 
the art. This method is suitable for measuring irreversible 
inhibition rates with fast inhibitors, where the inhibitor, the 
substrate and the enzyme are incubated together and the rate 
of substrate hydrolysis is measured continuously. The rate of 30 
substrate hydrolysis in the presence of the inhibitor was moni-
tored for 20 minutes. The progress curve of inhibition, where 
the product formation approaches an asymptote is described 
in the equation 
Caspase-6 kinetic assays were performed using the same 
conditions and the same substrate (Ac-DEVD-AMC, 2 mM 
stock solution in DMSO). The enzyme stock solution was 10 
nM (final concentration in the well: 5 nM) in the assay buffer. 
The inhibitor stock solution concentrations varied from 
5x10-3 M to 2.42xl0-6 Min DMSO. 
Caspase-7 kinetic assays were performed using the same 
conditions and the same substrate (Ac-DEVD-AMC, 2 mM 
stock solution in DMSO). The enzyme stock solution was 10 
nM (final concentration in the well: 5 nM) in the assay buffer. 
The inhibitor stock solution concentrations varied from 
5xl0-3 M to 2.5xl0-6 Min DMSO. 
ln([P 00}-[Pj)~Zn[P 00}-A[I}t 35 
Caspase-8 kinetic assays were performed using the same 
conditions and the same substrate (Ac-DEVD-AMC, 2 mM 
stock solution in D MSO). The enzyme stock solution was 100 
nM (final concentration in the well: 50 nM) in the assay 
buffer. The inhibitor stock solution concentrations varied 
from 5xl0-3 M to 2.42xl0-6 Min DMSO. 
where [P] and [P =] are the product concentrations at t and t=oo 
respectively, A is the apparent rate constant in the presence of 
the substrate. The apparent rate constants were determined 
from the slopes of plots of In ([P =]-[Pl) versus time (t) in 
seconds as previously described, where A=slope/[I]. 
For competitive and irreversible inhibition, the apparent 
rate constant is converted to the second order rate constant k2 
40 
by taking into consideration the effect of the substrate con-
centration on the apparent rate constant. The second order 45 
rate constant is described as in the equation: 
Caspase-2 kinetic assays were performed using Z-VD-
VAD-AFC as the substrate (2 mM stock solution in DMSO) 
and with the same conditions as caspase-3. The concentration 
of the caspase-2 stock solution was 86.7 nM in the assay 
buffer (final concentration in the well: 43.3 nM). The inhibi-
tor stock solution concentrations varied from 5x10-3 M to 
1 xl0-4 Min DMSO. 
Caspase-9 kinetic assays were performed usingAc-LEHD-
AFC as the substrate (3 mM stock solution in DMSO) and 
50 with the following conditions. The concentration of the 
caspase-9 stock solution was 150 mM in the assay buffer 
(final concentration in the well: 75 nM). Assay buffer is a 1 :1 
mixture of buffer (200 mM Hepes, 100 mM NaCl, 0.02% 
(w/v) CHAPS, sucrose 20% (w/v)) and 20 mM DTT solution 
Assays using the fluorogenic substrates Ac-DEVD-AMC 
O'-ex=360 nm, "-em=465 nm), Z-VDVAD-AFC C"-ex=430 nm, 
"-em=535 nm), and Ac-LEHD-AFC were carried out on a 
Tecan Spectra Fluor microplate reader at 37° C. The KM 
values for Ac-DEVD-AMC with caspase-3 (KM=9.7 µM), 
caspase-6 (KM=236.35 µM), caspase-7 (KM=23.0 M), 
caspase-8 (KM=6.79 µM), and caspase-10 (KM=20.2 ,µM) 
were determined in the laboratory of Guy Salvesen. The KM 
value for Ac-LEHD-AFC with caspase-9(KM=l14 µM) was 
also determined in the laboratory of Guy Salvesen. The KM 
value for Z-VDVAD-AFC with caspase-2 was found to be 
80.5 µM. The k2 values are 2.24-foldhigherthan the apparent 60 
rate for caspase-2 because of the 100 mM [SJ and KM=80.5 
IM. The k2 values are 11.31-fold higher than the apparent rate 
for caspase-3 because of the 100 mM [SJ and KM=9.7 µM. 
The k2 values are 1.42-fold higher than the apparent rate for 
caspase-6 because of the 100 mM [SJ and KMM=236.35 µM. 65 
The k2 values are 5.35-fold higher than the apparent rate for 
caspase-7 because of the 100 mM [SJ and KM=23.0 µM. The 
55 in H20 at pH 7.0). The assay buffer was supplemented with 
0.7 M sodium citrate. The enzyme was pre-activated for 10 
min at 3 7° C. in the assay buffer. The inhibitor stock solution 
concentrations varied from 5x10- 1 M to 2.5x10-5 M in 
DMSO. 
Caspase-10 kinetic assays were performed using the same 
substrate as caspase-3 (Ac-DEVD-AMC, 3 mM stock solu-
tion in DMSO) and with the following conditions. The con-
centration of the caspase-10 stock solution was 50 nM in the 
assay buffer (final concentration in the well: 25 nM). Assay 
buffer is a 1:1 mixture ofbuffer (200 mM Hepes, 0.2% (w/v) 
CHAPS, PEG 20% (w/v)) and 20 mM DTT solution in H20 
at pH 7.0). The enzyme was pre-activated for 10 minat 25° C. 
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in the assay buffer. The inhibitor stock solution concentra-
tions varied from 5xl 0-3 M to 2.5xl 0-5 Min DMSO. 
S. mansoni Legumain. Assays with legumain were per-
formed as follows. A fluorometric assay for legumain has 
been described previously. Legumain, purified from pig kid-
ney tissue, was assayed at 30° C. in buffer (39.5 mM citric 
acid, 121mMNa2 HP04 atpH5.8containing1mMEDTA,1 
mM TCEP, and 0.01 % CHAPS) with Cbz-Ala-Ala-Asn-
AMC as the substrate (10 µM final concentration). The assays 
were carried out in a Perkin Elmer LS 3B fluorescence spec-
trometer O'-ex =360 nm, "-em =460 nm) under the control of an 
IBM-compatible computer running the FLUSYS software. 
The rate of substrate hydrolysis in the absence of inhibitor 
was recorded, after which the inhibitor was added in a negli-
gible volume and the new rate was monitored. Rate constants 
for irreversible inactivation were found by nonlinear regres-
sion analysis of the pseudo first-order curves using the FLU-
SYS software, giving k065 . The second-order rate constant k2 
was calculated as k06)[I], at [SJ <KM" The test substrates were 
used at [S]<KM, so no corrections for competition with the 
inhibitors were required. A minimum of three different con-
centrations of inhibitor was used to determine second-order 
rate constants with legumain (range used 100 µM-100 nM). 
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The incubation method was also used for papain. The inhi-
bition incubation buffer for papain was 50 mM Hepes buffer 
at pH 7 .5, containing 2.5 mM DTT and 2.5 mM EDTA. The 
assay used the substrate Z-Phe-Arg-pNA (53.7 µM) in the 
5 same buffer. The approximate concentration of papain added 
to the incubation buffer was 0.29 mg/mL. The release of 
p-nitroanilide was monitored at 405 nm with a Molecular 
Devices Thermomax microplate reader. 
Clostripain. Clostripain was purchased from Sigma 
10 Chemical Co. (St. Louis, Mo.) as a solid which was dissolved 
in an activation solution of 8 mM DTT at a concentration of 
5.962 µMand stored at -20° C. prior to use. The inhibition of 
clostripain began with the addition of25 µL of stock inhibitor 
solution (concentration varies by inhibitor) in DMSO to a 
15 solution of 250 µL of 20 mM Tris/HCI, 10 mM CaCl2 , 
0.005% Brij 35, 2 mM DTT buffer at pH 7.6 (clostripain 
buffer) and 5 µL of the stock enzyme solution. Aliquots (25 
µL) of this incubation mixture were taken at various time 
points and added to a solution containing 100 µL of the 
20 clostripain buffer and 5 µL of Z-Phe-Arg-AMC substrate 
solution (0.139 mM) in DMSO. The enzymatic activity was 
monitored by following the change in fluorescence at 465 nm. 
All data obtained was processed by pseudo-first order kinet-
ics, 
Gingipain K. Gingipain K stock solution consisted of a 
buffer containing 20 mM Bis-Tris, 150 mM NaCl, 5 mM 
CaCl2 , 0.02% NaN3 , at pH 8.0 at a concentration of 9 µM, 
which was stored at -20° C. prior to use. Before using the 
enzyme, an-aliquot (1 µL) of the stock enzyme was diluted to 
Studies with the propenoyl hydrazides using the schisto- 25 
some legumain SmAF, (Schistosoma mansoni asparaginyl 
endopeptidase) were also performed. The enzymatically pure 
enzyme (zymogen form) was expressed in Pichia without 
interference from other proteases [Caffrey et al, FEBS lett, 
466, 244-248 (2000); incorporated herein by reference]. The 
actual active site enzyme concentration is unknown. The lyo-
philized enzyme (50-100 mg) was reconstituted in 1.5 mL 0.5 
30 a concentration of 4.61nMin1.951 mLofa solutionof0.2 M 
Tris/HCI, 0.1 M NaCl, 5 mM CaCl2 , 2 mM DTT at pH 8.0 
(gingipain K buffer) and kept at 0° C. This solution was used 
only for one day, as freezing the enzyme at this concentration 
destroyed all activity. The inhibition of gingipain K began 
M sodium acetate, pH 4.5 containing 4 mM DTT, and left to 
stand at 3 7° C. for 3-4 hours to allow for auto-activation of the 
zymogen. In a black 96-well microtiter plate, 50 µL of acti-
vated enzyme was added to an equal volume of 0.1 M citrate-
phosphate buffer pH 6.8 containing 4 mM DTT. Inhibitor 
stock solutions (20 mM) were prepared in DMSO. Serial 
dilutions (using water) of inhibitor were added (as 1 µL ali-
quots) to yield concentrations of between 2 and 0.00002 µM 
inhibitor. The inhibitors were preincubated with the protease 
at room temperature for 20 minutes before the assay (IC50s 
were the same when incubated for only 5 minutes). After 
incubating various inhibitor concentrations with enzyme, 100 
35 with the addition of 25 µL of stock inhibitor solution (con-
centration varies by inhibitor) in DMSO to 244 µL of the 
diluted enzyme solution (4.61 nM) in gingipain K buffer 
warmed to rt. Aliquots (20 µL) of this were taken at various 
time points and added to a solution containing 100 µL of the 
40 gingipainK buffer and 5 µL ofSuc-Ala-Phe-Lys-AMC. TFA 
as the substrate (0.910 mM stock) in DMSO. The enzymatic 
activity was monitored by following the change in fluores-
cence at 465 nm. The data for gingipain K was processed by 
µL of the same buffer containing 20 µM substrate (Cbz-Ala- 45 
Ala-Asn-AMC) was added to the wells and the reaction moni-
tored at room temperature with linear kinetics up to 20 min-
utes. Inhibitors are tested in duplicate. A plot of the RFU/min 
versus the inhibitor concentration [µM] permitted calculation 
pseudo-first order kinetics. 
Calpain I. Irreversible kinetic assays were performed by 
the incubation method with calpain I from porcine erythro-
cytes. Enzymatic activities of calpain I were measured at 23 ° 
C. in 50 mM Hepes buffer (pH 7.5) containing 10 mM cys-
teine and 5 mM CaCl2 , using Suc-Leu-Tyr-AMC as the sub-
of an IC50 value and estimation of the k06)[I]. 
Papain and Cathepsin B. The incubation method was used 
to measure the irreversible inhibition of papain and cathepsin 
50 strate. To 30 µL of an enzyme stock solution (1 mg/mL) of 
cal pain I was added 300 µL of incubation buffer and 30 µL of 
a stock inhibitor solution in DMSO. At various time intervals 
50 µL aliquots were withdrawn from the incubation mixture B. With cathepsin B, 30 µL of a stock inhibitor solution was 
added to 300 µL of 0.1 M potassium phosphate buffer con-
taining 1.25 mM EDTA, 0.01 % Brij 35 at pH 6.0, followed by 55 
the addition of30 µL of a freshly prepared cathepsin B solu-
tion (approximate concentration 6.98xl0-3 µg/µL) in the 
same potassium phosphate buffer containing 1 mM DTT 
(freshly prepared). Aliquots (50 µL) from the inhibition mix-
ture were withdrawn at various time intervals and added to 60 
200 µL of a 0.1 M potassium phosphate buffer containing 
1.25 mM EDTA, 0.01 % Brij 35 at pH 6.0, and the substrate 
Cbz-Arg-Arg-AMC (499 µM). The release of 7-amino-4-
methylcoumarin was monitored C"-ex =360 nm, "-em =465 nm) 
using a Tecan Spectra Fluor microplate reader. Pseudo first- 65 
order inactivation rate constants were obtained from plots of 
In v /v 0 versus time. 
and added to 200 µL enzyme buffer containing Suc-Leu-Tyr-
AMC (1.6 mM). Substrate hydrolysis was monitored using a 
Tecan Spectra Fluor microplate reader C"-eF360 nm, "-em =465 
nm). Pseudo first-order rate constants (k06J were obtained 
from plots of Inv /v 0 versus time. 
Trypsin. Trypsin was purchased from Sigma Chemical Co. 
(St. Louis, Mo.) as a solid which was dissolved in a solution 
of 1 mM HCI at a concentration of 1 µM, kept at 0° C., and 
used immediately. The trypsin assay was conducted with 224 
µL of a solution of 0.1 M Hepes, 0.01 M CaCl2 , at pH 7.5 
(trypsin buffer), 9 µL of Z-Phe-Arg-AMC substrate solution 
(1 mM, 2 mM, and 4 mM stocks) in DMSO, 4.2 µL of 
inhibitorsolution(l.25 mM, 2.5 mM, 5 mM, 7.5 mM, and 10 
mM for PhPr-Leu-ALys-CH=CH-C02Et, and 2.5 mM, 5 
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mM, and 7.5 mM for PhPr-Leu-AOm-CH=CH---C02 Et) in 2. Structure-Activity Relationships 
DMSO, and4.2 µL of the trypsin stock solution (1 µM) at23° Table 1 shows the inhibitory constants (k2 ) for the inhibi-C. The enzymatic activity was monitored by following the tion of caspases-2, -3, -6, -7, -8, -9 and -10 by propenoyl 
change in fluorescence at 465 nm. The enzymatic assay was 
followed for 10 min with the 2.5 mM stock inhibitor solution hydrazides. The inhibition constants k2 are second-order rate 
and 1 mM stock substrate solution. The data was processed as constants and the inhibitors with the higher numbers are more 
a competitive reversible inhibitor by a Dixon plot. potent. 
TABLE 1 
Inhibition of Cas2ases by Aza-Pe2tide Michael Acce2tors 
k M-1s-1 
Caspase- Caspase- Caspase- Caspase- Caspase- Caspase- Caspase-
INHIBITOR 2"·d 3" 6" 7" 8" 9b 1oc 
Cbz-Val-AAsp-CH=CH---{:H3 ND NI NI ND NI ND ND 
Cbz-Val-AAsp-CH=CH---{:H=CH---{:H 3 NI NI NI 56 ± NI NI NI 
4 
Cbz-Val-AAsp-CH=CH---{:H2 CH2 Ph ND NI NI ND NI ND ND 
Cbz-Val-AAsp-CH=CH---{:l NI NI NI NI NI 15 ± NI 
1 
Cbz-Val-AAsp-CH=CH-4-Cl-Ph NI NI NI NI NI 19 ± NI 
1 
Cbz-Val-AAsp-CH=CH---{:OOEt NI 8,000 NI 2,680 ± NI 5,240 ± 389 ± 
60 380 87 
Cbz-Val-AAsp-CH=CH---{:ONH-nBu NI 184 ± NI 55 ± NI 32 ± NI 
9 5 13 
Cbz-Val-AAsp-CH=CH---{:0NHCH2Ph NI 185 NI 60 ± NI 20 ± NI 
1 2 
Cbz-Glu-Val-AAsp-CH=CH---{:OOEt 90 ± 38,600 ± 3,540 ± 52,400 ± 244,000 ± 32,900 ± 8,940 ± 
10 4,200 4,200 10,600 30,000 10,250 5,250 
Cbz-Asp-Glu-Val-AAsp- 26,200 ± 1,060,000 ± 11,000 ± 139,000 ± 181,000 ± ND 13,500 ± 
CH=CH---{:00Et 6,000 92,500 515 4,500 13,700 2,300 
(cis) 
Cbz-Asp-Glu-Val-AAsp- 2,640 ± 2,130,000 ± 35,575 ± 239,000 ± 272,960 ± ND 49,900 ± 
CH=CH---{:00Et 10 99,130 0 55,600 18,370 7,000 
(trans) 
Cbz-Asp-Glu-Val-AAsp- ND 1,700,000 ± 8,470 114,000 ± 121,000 ± ND 28,300 ± 
CH=CH---{:00CH2Ph 106,000 15,900 13,700 7,700 
Cbz-Asp-Glu-Val-AAsp- 130 ± 1,750,000 ± 3,210 ± 249,000 ± 78,235 ± 2,010 ± 19,400 ± 
CH=CH---{:0NHCH2Ph 20 18,500 105 52,500 8,000 150 400 
Cbz-Asp-Glu-Val-AAsp- 130 ± 2,100,000 ± 4,400 ± 329,000 ± 85,100 ± 900 ± 37,700 ± 
CH=CH---{:ONHCHr 20 26,400 361 53,300 9,700 70 2,550 
4-F-Ph 
Cbz-Asp-Glu-Val-AAsp- 120 ± 1,950,000 ± 3,470 ± 267,000 ± 129,000 ± 655 ± 31,400 ± 
CH=CH---{:0NHCH2CH2Ph 10 53,000 52 15,000 27,400 50 3,600 
Cbz-Asp-Glu-Val-AAsp- 660 ± 2,640,000 ± 9,500 ± 275,000 ± 90,300 ± 820 ± 29,400 ± 
CH=CH---{:0N(CH3)CH2 Ph 240 397,000 210 11,300 18,250 215 830 
Cbz-Asp-Glu-Val-AAsp- 320 ± 1,180,000 ± 4,000 ± 172,000 ± 31,900 ± 425 ± 9,570 ± 
CH=CH---{:0N(CH3)CH2 CH2 Ph 25 264,000 413 72,000 2,800 10 5,240 
Cbz-Asp-Glu-Val-AAsp- 110 ± 3,000,00 ± 5,100 ± 359,000 ± 8,600 ± 450 ± 6,300 ± 
CH=CH---{:0N(CH2Ph)o 25 80,000 0 8,400 1,600 30 50 
Cbz-Asp-Glu-Val-AAsp- 410 ± 5,620,000 ± 29,700 ± 875,000 ± 9,460 ± 150 ± 32,500 ± 
CH=CH---{:ON(CHr 60 1,120,000 540 106,000 880 10 5,250 
1-Napth)o 
Cbz-Asp-Glu-Val-AAsp- 390 ± 2,300,000 ± 5,700 ± 137,000 ± 118,000 ± 340 ± 8,330 ± 
CH=CH---{:ON- 90 26,500 0 25,000 14,800 120 1,400 
tetrahydroquinoline 
Cbz-Asp-Glu-Val-AAsp- 165 ± 122,000 1,800 ± 10,800 ± 9,720 ± ND 930 ± 
CH=CH---{:OPh 85 13 2,000 500 80 
Cbz-Val-Glu-Val-AAsp- 115 ± 41,200 ± 83,600 ± 3,650 ± 175,800 ± 340 ± 6,600 ± 
CH=CH---{:00Et 20 8,600 8,400 1,330 6,800 120 690 
Cbz-Ile-Glu-Thr-AAsp- 300 ± 6,740 ± 88,700 ± 530 ± 56,500 ± ND 6,900 ± 
CH=CH---{:00Et 160 1,650 33,700 10 3,800 250 
Cbz-Ile-Glu-Thr-AAsp- 110 ± 2,300 ± 23,350 ± 660 ± 148,400 ND 15,200 ± 
CH=CH---{:00CH2Ph 40 77 1,650 210 2,500 
Cbz-Ile-Glu-Thr-AAsp- 365 ± 7,030 ± 99,200 ± 920 ± 245,000 ± 940 ± 9,210 ± 
CH=CH---{:ONHPh 20 720 10,800 60 22,800 275 377 
Cbz-Ile-Glu-Thr-AAsp- 15 ± 2,250 ± 16,800 ± 100 ± 61,300 ± 440 ± 503 ± 
CH=CH---{:0NHCH2Ph 3 560 1,030 20 2,300 160 209 
Cbz-Ile-Glu-Thr-AAsp- 30 ± 4,750 ± 18,700 ± 440 ± 71,000 ± 615 ± 8,290 ± 
CH=CH---{:0NHCH2CH2Ph 0 565 1,250 95 13,700 160 1,560 
Cbz-Ile-Glu-Thr-AAsp- 95 ± 6,000 ± 45,900 ± 390 ± 59,700 ± 845 ± 8,500 ± 
CH=CH---{:0N(CH3)CH2 Ph 8 100 5,000 90 4,500 190 300 
Cbz-Ile-Glu-Thr-AAsp- 38 ± 5,480 ± ND 1,020 ± 60,500 ± 760 ± 8,770 ± 
CH=CH---{:0N(CH3)CH2 CH2 Ph 1 26 440 8,000 335 1,780 
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TABLE I-continued 
Inhibition of Cas2ases by Aza-Pe2tide Michael Acce2tors 
INHIBITOR 
Cbz-Ile-Glu-Thr-AAsp-
CH=CH---{::0N(CH2Ph)o 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::00Et 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::00CH2Ph 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::ONHPh 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::0NHCH2Ph 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::ONHCHr 
4-F-Ph 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::0NHCH2CH2Ph 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::0N(CH3)CH2 Ph 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::0N(CH3)CH2 CH2 Ph 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::0N(CH2Ph)o 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::ON-
tetrahydroquinoline 
Cbz-Leu-Glu-Thr-AAsp-
CH=CH---{::0N(CH3)CHr 
1-Napth 
NI= no inhibition, 
ND = not determined, 
Cbz ~ PhCHr-OCO-; 
Caspase-
2",d 
76 ± 
1 
NI 
480 ± 
170 
290 ± 
150 
66 ± 
25 
70 ± 
1 
110 ± 
40 
140 ± 
25 
50 ± 
10 
110 ± 
10 
92 ± 
51 
290 ± 
110 
k 
Caspase- Caspase-
3" 6" 
9,570 ± 83,900 ± 
1,230 29,000 
5,560 ± 18,700 ± 
290 1,040 
4,600 ± 47,600 ± 
330 2,500 
4,700 ± 11,400 ± 
308 2,060 
1,120 1,550 ± 
50 
4,490 ± 3,100 ± 
410 465 
5,400 ± 2,150 ± 
51 52 
6,000 ± 10,800 ± 
100 410 
2,620 ± 2,550 ± 
26 413 
8,630 ± 14,100 ± 
1,330 1,440 
12,100 ± 13,000 ± 
720 1,850 
11,200 ± 21,700 ± 
1,130 206 
M-1s-1 
Caspase- Caspase- Caspase- Caspase-
7" 8" 9b 1oc 
1,140 ± 39,500 ± 1,930 ± 7,930 ± 
210 0 35 2,510 
NI 237,000 ± 37 ± NI 
52,700 0 
1,570 ± 98,400 ± ND 18,900 ± 
135 9,130 1,580 
730 ± 176,000 ± 1,190 ± 6,050 ± 
200 2,280 230 1,380 
340 ± 70,170 ± 1,400 ± 14,400 ± 
15 13,700 260 1,900 
410 ± 171,000 ± 1,695 ± 9,380 ± 
60 36,500 30 1,560 
440 ± 121,000 ± 1,760 ± 17,900 ± 
60 2,300 190 2,300 
520 ± 169,000 4,320 ± 8,430 ± 
60 930 710 
290 ± 65,300 ± 960 ± 6,190 ± 
170 5,700 30 820 
760 ± 129,000 ± 1,105 ± 8,080 ± 
100 13,700 460 1,660 
540 ± 216,000 ± 1,660 ± 9,000 ± 
30 4,600 710 500 
1,100 ± 179,000 ± 5,030 ± 13,600 ± 
35 38,800 555 970 
"Assay buffer was 20 mM Pipes, 100 mM NaCl, 0,1 % (w/v) CHAPS, sucrose 10% (w/v) and 10 mM DTT, at pH 7,2, with Ac-DEVD-AMC 
as the substrate; 
bAssay buffer was 100 mM Hepes, 50 mM NaCl, 0,01% (w/v) CHAPS, sucrose 10% (w/v)) and 10 mM DTT, at pH 7,0, withAc-LEHD-AFC 
as the substrate, The assay buffer was supplemented with 0,7 M sodium citrate; 
c100 mM Hepes, 0,1 % (w/v) CHAPS, PEG 10% (w/v)) and 10 mM DTT, at pH 7,0, with Ac-DEVD-AMC as the substrate; 
dCbz-VDVAD-AFC was used as the substrate, 
The compounds were tested for their inhibitory potency 
towards S. mansoni legumain. The IC50 values are reported in 
Table 2. An IC50 value represents the inhibitory concentra-
tion, which achieved 50% inhibition of the enzyme. There-
The propenoyl hydrazides with a Pl aza-Asp residue 40 
inhibit caspases-2, -3, -6, -7, -8, -9 and -10 with some k2 
values in the order of 106 M- 1s-1 (Table 1). The DEVD and 
LETD sequences are optimal sequences for caspase-3 and 
caspase-8, respectively. The DEVD inhibitors Cbz-Asp-Glu-
Val-AAsp-CH=CH--CON(CH3)CH2Ph and Cbz-Asp-Glu-
Val-AAsp-CH=CH--COOEt are potent inihibitors of 
caspase-3 (k2 values in the range ofl,700,000 M- 1s- 1-2,640, 
000 M- 1s- 1 ), while the LETD derivatives Cbz-Leu-Glu-Thr-
45 fore a lower IC50 value is a characteristic of a more potent 
inhibitor. 
AAsp-CH=CH-COOEt, Cbz-Leu-Glu-Thr-AAsp- 50 
CH=CH-COOBzl, and Cbz-Leu-Glu-Thr-AAsp-
CH=CH-CON(CH3)Bzl are potent inhibitors of 
caspases-6 and -8 with k2 values up to 47,600 M- 1s- 1 and 
237,000 M- 1s- 1 , respectively. The disubstituted amide ana-
log Cbz-Asp-Glu-Val-AAsp-CH=CH--CON(Bzl)2 is the 55 
most potent compound forcaspase-3 with a k2 value of3,000, 
000 M- 1 s- 1 . It is also the most selective compound among the 
caspases-3, -6, and -8, where it inhibits caspase-3 588 fold 
more potently than caspase-6 and 348 fold more potently than 
caspase-8. Esters seem to work better with caspases-6 and-8. 60 
The ethyl ester analogs Cbz-Asp-Glu-Val-AAsp-CH=CH-
COOEt and Cbz-Leu-Glu-Thr-AAsp-CH=CH--COOEt are 
very potent inhibitors of caspase-8 with k2 values of 273,000 
M- 1s- 1 and 237,000 M- 1s- 1 , respectively. We propose that 
the ethyl ester group is especially favored in the caspase-8 65 
active site, since the prime site has been observed to be 
relatively small. 
TABLE2 
S. mansoni Legumain Inhibition with Pe2tidyl Pro2enoyl Hydrazides. 
0 
0 ~ 0 ~NH2 
V )l ~~,-N~R 0 N . N H ~ H 0 = 0 
R~ IC50 (nM) 1',b/[I] (M-1s-1) 
---{::00Et 31 ± 25 17,420 
---{::00Bzl 38 
---{::0NEt2 NI 
---{::0N(nBu)2 550 
---{::0-Pip 1,000 
---{::QNHPh 700 
---{::QNHBzl 1,000 
---{::QBzl-4-F 800 
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TABLE 2-continued 
S. mansoni Legumain Inhibition with Peptidyl Propenoyl Hydrazides. 
inhibitor and the active site is optimal with the carbonyl next 
to the double bond and without the H-bond donating NH of a 
monosubstituted amide. The benzoyl acrylate Cbz-Ala-Ala-
AAsn-CH=CH--COPh fulfills both of the aforementioned 
requirements, but does not inhibit legumain. We found that 
the aromatic fumarate substituents are preferred by the 
enzyme over the alkyl derivatives (NEt2, N(nBu)2, Pip). The 
extended aromaticity of the N-methyl-1-methyl naphthyl 
derivative compared to the N-methyl benzyl amide produced 
0 
0 Jy 0 ~NH2 
V )l ~0_,N~R 0 N . N H ~ H 0 = 0 10 an even lower IC50 (35 nM). The dibenzyl amide shows the 
R~ 
---{:0NHCH2CH2Ph 
---{:0N(CH3)Ph 
---{:0N(CH3)Bzl 
---{:0N(CH3)CHrl-Napth 
---{:0N(CH3)CH2CH2Ph 
---{:ON(Bzl)Ph 
---{:0N(Bzl)2 
---{:ON(Bzl-4-0Me)Bzl 
---{:ON(Bzl-4-F)Bzl 
---{:0N(CHr2-furyl)2 
---{:ON(Bzl)-2-CHrNapth 
---{:ON(Bzl)-1-CHrNapth 
---{:0-tetrahydroquinoline 
---{:0-tetrahydroisoquinoline 
---{:0-indoline 
---{:0-isoindoline 
---{:0-(4-Ph-pyridine) 
---{:0-MePhe-N(CH3 )CH2CH2Ph 
---{:0Ph 
---{:H=CH---{:H3 
-2-furyl 
-3-Py 
NI~ No Inhibition 
600 
60 
55 
35 
600 
70 
45 
90 
60 
900 
70 
62 
70 
200 
70 
300 
750 
750 
NI 
NI 
>2,000 
>2,000 
1',b/[I] (M-1s-1) 
16,930 
5,800 
6,100 
6,180 
15 
20 
25 
lowest IC50 of the aromatic disubstituted amides (IC50=45 
nM). The substitution of one of the benzyl rings with an 
electron donating methoxy or an electron withdrawing fluo-
rine only reduces the potency. Both quinoline and indoline 
exhibited good potency (IC50=70 nM), but poorer in compari-
son to the dibenzyl amide. The aromatic ring is much less 
flexible in the indoline and quinoline bicyclic system. The 
altered orientation of the aromatic ring significantly lowers 
their potency. Both the 4-plhenyltetrahydropyridine and the 
amino acid derivative Cbz-Ala-Ala-AAsn-CH=CH-CO-
MePhe-N(CH3)CH2CH2Ph did not improve the effectiveness 
of the warhead. The esters are generally more potent than the 
amide analogs. 
The peptidyl propenoyl hydrazides with an aza-Lys, aza-
Arg, or aza-Om residue at Pl are potent inhibitors of gingi-
pain K, gingipain R, and clostripain (Table 3). The aza-Lys 
derivative inhibits gingipain K very potently with a k2 value of 
3,280,000 M- 1s- 1 . The aza-Om derivative is also a very 
potent inhibitor of gingipain K, but it is much more selective 
The fumarate benzyl and ethyl esters Cbz-Ala-Ala-AAsn-
CH=CH-COOEt, Cbz-Ala-Ala-AAsn-CH=CH-
COOBzl, and Biotinyl-Ala-Ala-AAsn-CH=CH--COOEt 
30 toward gingipain K, since the k2 value with clostripain is only 
788 M- 1s- 1 . Both compounds were also tested for activity 
toward gingipain R. Both compounds, PhPr-Leu-ALys-
CH=CH-COOEt and PhPr-Leu-AOm-CH=CH-
COOEt, inhibit gingipain R weakly with k2 values of 289 35 M- 1s- 1 and 32 M- 1s-1, respectively. However the AArg 
derivatives with very effective inhibitors of gingipain R, but 
didn't inhibit ginipain K effectively 
TABLE3 
Inhibition of Clostripain and Gingipain Kand R by Peptidyl Propenoyl Hydrazides. 
Gingipain Gingipain 
Inhibitor Clostripain K R 
PhPr-Leu-ALys-CH=CH---{:OOEt 40,750 3,280,000 289 
PhPr-Leu-ALys-CH=CH---{:00CH2Ph 20,500 2,510,00 632 
PhPr-Leu-ALys-CH=CH---{:0NHCH2Ph 1,050 236,000 20 
PhPr-Leu-ALys-CH=CH---{:0N(Me)CH2Ph 6,000 1,360,000 79 
PhPr-Leu-ALys-CH=CH---{:0N(CH2Phh 20,000 2,130,000 65 
PhPr-Leu-ALys-CH=CH---{:0N(Bzl)-p-CH2C6H4 F 13,800 801,000 75 
PhPr-Leu-ALys-CH=CH---{:ON(Me )CHr 1-naphthyl 639 975,000 576 
PhPr-Leu-ALys-CH=CH---{:0N(Bzl)CHr2-naphthyl 17,500 811,000 98 
PhPr-Leu-ALys-CH=CH---{:0N(CHrl-naphthyl2 2,250 1,890,000 214 
PhPr-Leu-ALys-CH=CH---{:ON( 4H-quinoline) 326 252,000 73 
PhPr-Leu-AOrn-CH=CH---{:OOEt 788 927,000 32 
PhPr-Leu-AOrn-CH=CH---{:0NHCH2Ph NI 24,700 71 
PhPr-Leu-AOrn-CH=CH---{:0N(CH2Ph)2 541 61,600 541 
PhPr-Ala-AOrn-CH=CH---{:OOEt NI 632,000 18 
PhPr-Leu-AArg-CH=CH---{:OOEt 69,600 1,580 
PhPr-Leu-AArg-CH=CH---{:0NHCH2Ph 287,000 555,000 
PhPr-Leu-AArg-CH=CH---{:0N(CH2Phh 474,000 804,000 
(PhPr ~ 3-phenylpropanoyl) 
(IC50=10 nM, not shown in table 2) are some of the most 
potent inhibitors. The monosubstituted amides and the acry-
late derivatives show little to no inhibition, which leads us 
to-conclude that the hydrogen bonding network between the 
Propenoyl hydrazides designed with clan CD specific 
65 sequences are quite specific and in general do not inhibit clan 
CA proteases such as papain, cathepsin B, and cal pain (Tables 
4, 5, and 6). There was usually no reactivity toward papain, 
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cathepsin B and calpain after an incubation period of up to 1 
h. The inhibitors show little to no cross reactivity with the 
other members of clan CD proteases. 
TABLE4 
Cross Reactivity of Caspase Inhibitors 
with Clan CA and Other Clan CD Enzymes 
Inhibitor 
Cbz-Asp-Glu-
Val-AAsp-trans-
CH=CH---{::00Et 
Cbz-Asp-Glu-
Val-AAsp-trans-
CH=CH---{::00Bzl 
Cbz-Asp-Glu-
Val-AAsp-trans-
CH=CH---{::ONHBzl 
Cbz-Leu-Glu-
Thr-AAsp-trans-
CH=CH---{::00Et 
NI~ No inhibition, 
ND ~ not determined. 
Cathep- Pa- Cal- Legu- Clos-
sin B pain pain main tripain 
NI NI NI NI NI 
NI ND ND ND NI 
NI ND ND ND NI 
<10 NI <10 NI NI 
TABLES 
Gingi 
painK 
NI 
NI 
NI 
NI 
Inhibition of Clan CD, Clan CA Cysteine Proteases and Trypsin 
54 
Inhibition Mechanism 
The active site of cysteine proteases contains a cysteine and 
a histidine residue. The proposed mechanism involves the 
attack of the active site cysteine residue on the double bond to 
form a covalent adduct. An example of a caspase inhibitor is 
shown in the following figure. The enzyme recognizes the Pl 
AAsp residue and inhibition occurs. Additional interactions 
would occur between the extended substrate binding site of 
10 the cysteine protease and the inhibitor, which would increase 
the binding affinity and specificity of the inhibitors. 
15 (?' -~-Cys-Enz 
H~ H-His+ /N'- # 
peptidyl N 3 ~ 
20 lC02~ 
c-y '\-3 
25 
by Gingipain and Clostripain Specific Propenoyl Hydrazides. 0 R3 -----~k=0~,,-~/[~l]~(~M~--1 s~--1)~----- 30 peptidyl/~'-N¥~ 
Caspases- Cal- Pa-
Inhibitor 3, -6, -8 pain I pain 
Cathep-
sin B 
Tryp-
sin 
) s, 
H02C Cys-Enz 
PhPr-Leu-ALys- NI NI NI 9 17 35 
CH=CH---{::00Et 
PhPr-Leu-AOrn- NI NI 
CH=CH---{::00Et 
NI 
TABLE6 
NI 
The peptide and amino acid propenoyl hydrazide deriva-
tives, as shown above, bind to the enzymes using many of the 
interactions that are found in complexes of a particular 
enzyme with its substrates and/or inhibitors. Additional inter-
Inhibition ofVarious Clan CD and Clan CA Cysteine 
Proteaes by Legwnain Specific Propenoyl Hydrazides. 
Caspases- Cal pain 
Inhibitor 3, -6, -8 I 
Cbz-Ala-Ala-AAsn-CH=CH---{::OOEt NI NI 
Cbz-Ala-Ala-AAsn-CH=CH---{::0N(CH3 )Bzl NI NI 
Cbz-Ala-Ala-AAsn-CH=CH---{::ON(Bzl)o NI NI 
Cbz-Ala-Ala-AAsn-CH=CH---{::0-indoline NI NI 
Cbz-Ala-Ala-AAsn-CH=CH---{::0N(CH3 )-2-Napth NI NI 
Cbz-Ala-Ala-AAsn-CH=CH---{::0NHCH2CH2 Ph NI NI 
NI~ No Inhibition after 20 minutes of incubation. 
The peptidyl propenoyl hydrazides are generally poor with 
clan CA cysteine proteases, such as papain, cal pain, or cathe-
psin B. However, a select few do show limited inhibition with 
papain, calpain, and cathepsin B. For example the caspase 
specific inhibitor Cbz-Leu-Glu-Thr-AAsp-trans-CH=CH-
COOEt inhibits calpain and cathepsin B with a k2 of <10 
M- 1 s- 1 , the legumain specific inhibitor Cbz-Ala-Ala-AAsn-
CH=CH-CONHCH2CH2Ph inhibits papain (12 M- 1s- 1). 
The gingipain specific inhibitor PhPr-Leu-ALys-CH=CH-
COOEt inhibits cathepsin B (9 M- 1s- 1) and the serine pro-
tease trypsin (17 M- 1 s- 1). 
Cathepsin Gingipain 
Papain B K 
NI 
NI NI 
NI 2 
NI NI 
NI NI 
12 NI NI 
actions with the. enzyme can be obtained by tailoring the R3 
or R4 groups of the inhibitor to imitate the amino acid resi-
60 dues, which are preferred by an individual protease at the S 1' 
and S2' subsites. For example, peptidyl propenoyl hydrazides 
with R3 phenylalkyl groups would interact effectively with 
caspase-1, which is shown to prefer such structures in alpha-
ketoamide peptide inhibitors. Likewise, the M1 group can 
65 interact with the S subsites of the target cysteine protease. 
Once a good inhibitor structure for a particular enzyme is 
found, it is then possible to change other characteristics such 
US 7,482,379 B2 
55 
as solubility or hydrophobicity by adding substituents to the 
M1 or Rv R2, R3, and R4 groups. 
56 
Cbz-Asp-Glu-Val-AAsp-CH=CH-CO-Phe-OBzl 
caspase-3 
for 
The following structures are inhibitors for the listed 
enzymes. The inhibitor sequences were obtained from pep-
tide substrate and/or inhibitor seqences in the protease litera- 5 
Cbz-Asp-Glu-Val-AAsp-CH=CH-CO-Pyr for caspase-3 
Cbz-Ala-Ala-AAsn-CH=CH--COO(CH2)2-2-Napth for 
legumain 
PhCH2CH2CO-Val-Ala-AAsp-CH=CH-(CH2)2Ph-3-F 
for caspase-1 
PhCH2CH2CO-Val-Ala-AAsp-CH=CH--COO(CH2)2-2-
Napth for caspase-1 
ture. 
Cl-C6H4 CH20CO-Phe-AGly-CH=CH--COOH 
pa pain 
C6H5CH2NHCO-Gly-Phe-AGly-CH=CH--COOH 
cathepsin B 
Morpholine-C0-2-Napth-AHph-CH=CH--COOEt 
cathepsin S 
for 
for 
for 
2-Napth-S02-Ile-ATrp-CH=CH-COOH for cathepsin B 
l-Napth-S02-Val-ATrp-CH=CH--COOH for cathepsin B 
andL 
Pro-Phe-AArg-CH=CH-COOH for cathepsin Band L 
Cbz-Phe-Leu-Leu-AMet(02)-CH=CH-COOH for 
cathepsin K 
Ph-CH2-S02-AAsp-CH=CH--COOCH2Ph for caspase-1 
Ph-CH2CHFCO-Val-Ala-AAsp-CH=CH--COOCH2Ph for 
caspase-1 
4-Cl-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
4-N02-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
4-CH30-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
3-F-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-COOCH2Ph 
for caspase-1 
3,4-dichloro-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
Napth-CH20CO-Val-Ala-AAsp-CH=CH--COOCH2Ph 
for caspase-1 
4-CF 3-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
4-CH3-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
PhCH2NHCO-Val-Ala-AAsp-CH=CH--COOCH2Ph for 
caspase-1 
4-HO-PhCH2CH2CO-Val-Ala-AAsp-CH=CH-
COOCH2Ph for caspase-1 
4-Cl-Ph-CH20CO-Leu-Glu-Thr-AAsp-CH=CH-CON 
(Bzl)2 for caspase-3 
4-Cl-Ph-CH20CO-Ile-Glu-Thr-AAsp-CH=CH-CON 
(Bzl)2 for caspase-3 
4-Cl-Ph-CH20CO-Asp-Glu-Val-AAsp-CH=CH--CON 
(Bzl)2 for caspase-3 
Biotinyl-Asp-Glu-Val-AAsp-CH=CH-COOEt for 
10 Cbz-Leu-Glu-Thr-AAsp-CH=CH--COO(CH2)2C6H4 -p-
N02 for caspase-6 
Cbz-Ala-Ala-AAsn-CH=CH--COO(CH2)2C6H4 -p-CN for 
legumain 
PhCH2CH2CO-Val-Ala-AAsp-CH=CH--COO(CH2)2 
C6H4 -m-0Ph for caspase-1 
2,4-dinitrophenyl-Ahx-Gly-Phe-AAla-CH=CH--COOH 
for cathepsin L 
15 
Cbz-Leu-ALys-CH=CH-CON(Bzl)2 for gingipain 
Cbz-Leu-AOrn-CH=CH-CON(Bzl)2 for gingipain 
20 Cbz-Leu-ALys-CH=CH-CON(Bzl)2 for clostripain 
Cbz-Leu-AOrn-CH=CH-CON(Bzl)2 for clostripain 
Cbz-Leu-ALys-CH=CH-CO-Phe-OBzl for gingipain 
Cbz-ALys-CH=CH--COOEt for gingipain 
Cbz-AOrm-CH=CH--CON(Bzl)2 for clostripain 
25 Cbz-Lys(Biotinyl)-Val-Ala-AAsp-CH=CH-COOEt for 
30 
35 
caspase-1 
Cbz-Leu-ALys-CH=CCl--CON(Bzl)2 for clostripain 
Cbz-Leu-AOm-CH=CCl--CON(Bzl)2 for clostripain 
Cbz-Asp-Glu-Val-AAsp-CH=CF-CO-N(Bzl)2 
caspase-3 
for 
Cbz-Ala-Ala-AAsn-CH=CF--CO-N(Bzl)2 for legumain 
Cbz-Glu-Ala-Gly-AArg-CH=CH--CO-N(Bzl)2 for sepa-
rase 
2. In Vitro Uses. 
To use the above inhibitors in vitro, they are dissolved in an 
organic solvent such as dimethylsulfoxide or ethanol, and are 
added to an aqueous solution containing serine and/or cys-
teine proteases. The final concentration of the organic solvent 
40 
should be less than 25%. The inhibitors may also be added as 
solids or in suspension. The cysteine protease inhibitors of 
this disclosure would be useful in a variety of experimental 
procedures where proteolysis is a significant problem. Inclu-
sion of these inhibitors in radioimmunoassay experiments 
45 
would result in higher sensitivity. The use of these inhibitors 
in plasma fractionation procedures would result in higher 
yields of valuable plasma proteins and would make purifica-
tion of the proteins easier. The inhibitors disclosed here could 
be used in cloning experiments utilizing bacterial cultures, 
caspase-3 
C5 H9 -0CO-Asp-Glu-Val-AAsp-CH=CH--COOEt 
caspase-3 
for 50 yeast, and human cells to produce a purified cloned product in higher yield. 
3-F-Ph-CH20CO-Ala-Ala-AAsn-CH=CH--COOEt for 
legumain 
4-PhO-PhCH20CO-Ala-Ala-AAsn-CH=CH--COOEt for 
legumain 
Biotinyl-Ala-Ala-AAsn-CH=CH--CON(Bzl)2 for legu-
mam 
3-F-Ph-CH20CO-Leu-Glu-Thr-AAsp-CH=CH--COOEt 
for caspase-6 
PhCH2CH2CO-Val-Ala-AAsp-CH=CH--COO(CH2)2Ph-
4-Cl for caspase-1 
Cbz-Leu-Glu-Thr-AAsp-CH=CH--COO( CH2)2Ph-4-CH3 
for caspase-8 
Cbz-Leu-Glu-Thr-AAsp-CH=CH--COOCH2C6H11 for 
caspase-8 
Cbz-Asp-Glu-Val-AAsp-CH=CH--COO(CH2)2C6H4 -p-
OCH3 for caspase-3 
The novel compounds of this disclosure are effective in the 
prevention of unnecessary proteolysis caused by cysteine 
proteases in the process of purification, transport and storage 
55 
of peptides and proteins as shown in Table 1-3 by effective 
inhibition of many cysteine proteases. 
Diagnostic Reagents 
Propenoyl hydrazides of the present disclosure can be used 
for the identification of proteases, for example novel cysteine 
60 proteases. One embodiment provides a method for screening 
a sample for the presence of a protease, particularly a cysteine 
protease, by contacting the sample with a propenoyl 
hydrazide, for example a propenoyl hydrazide of Formula I, 
and detecting the presence of the the propenoyl hydrazide-
65 protease conjugate. Detection of the conjugate may be 
accomplished using known techniques. For example, prope-
noyl hydrazides of the present disclosure can be modified 
US 7,482,379 B2 
57 58 
with a detectable label including but not limited to a radio-
isotope, fluorescent marker, biotin, antibody, enzyme conju-
gate such as horseradish peroxidase, or the like. The aza-
peptide conjugates can be fixed to a support, for example 
using known chemical fixatives, and a sample can then by 
added to the propenoyl hydrazide. Such support can be 
microarrays or the like. The fixed propenoyl hydrazide can 
then irreversible or reversibly bind a protease, for example a 
cysteine protease, in the sample. The support can be washed 
to remove excess sample. The propenoyl hydrazide-protease 
conjugate can then be eluted from the support and the pro-
tease can be detected or identified using conventional tech-
niques. The support can be any durable substance including 
but not limited to metal, plastic, glass, quartz or the like. The 
propenoyl hydrazides can be linked to the support with a 
linker, for example a cleavable linker to facilliate the removal 
of propenoyl hydrazide-protease conjugates. 
caspase activation develops in models of global ischemia and 
may accompany the ischemic component of head injury. The 
effect of irreversible inhibitors (Z-VAD-FMK, Z-DEVD-
FMK, and YVAD-CMK) on ischemia-induced tissue shows 
that caspase-1 and caspase-3 are involved in the mechanism 
of cell death in ischemic and excitotoxic brain injury. 
Caspases are recognized as novel therapeutic targets for cen-
tral nervous diseases in which cell death occurs mainly by the 
mechanism of apoptosis. Thus effective caspase propenoyl 
10 hydrazide inhibitors (Table 1) can be used for the treatment of 
many diseases involving apoptosis. 
Legumain is involved in Schistosomiasis (blood flukes) 
and in immune disorders. Thus, legumain inhibitors can be 
3. In Vivo Uses. 
15 used to treat Schistosomiasis and many immunological prob-
lems: Gingipain is involved in periodontal disease and thus 
gingipain inhibitors can be use to treat periodontal disease. 
Clostripain inhibitors should be useful as antibacterial agents. 
Separase inhibitors can be used to treat diseases, which Effective inhibitors of the proteolytic function of caspases 
(Table 1) can be used to treat a variety of diseases. Excessive 
cell death can result from acquired or genetic conditions, 
which increase the accumulation of signals that induce apo-
ptosis or that diminish the threshold at which such events 
induce apoptosis. Excessive apoptosis has been associated 25 
with a variety of disease states including neurodegenerative 
disorders, ischemic injuries, acquired immunodeficiency 
syndrome (AIDS), and osteoporosis. Apoptosis is involved in 
amyotrophic lateral sclerosis (ALS), Huntington's disease, 
Alzheimer's disease, Parkinson's disease, and spinal muscu- 30 
lar atrophy. In multiple sclerosis (MS), the death of the oli-
godendrocytes is an important example of the glial degenera-
tion through apoptosis. 
20 involve cell mitosis. 
4. Drug Delivery. 
This disclosure also provides a pharmaceutical composi-
tion, which comprises a compound according to Formula I 
and a pharmaceutically accepted carrier, diluent or excipient. 
Accordingly, the compounds of Formula I may be used in the 
manufacture of a medicament. For therapeutic use, the pep-
tide propenoyl hydrazides may be administered orally, topi-
Huntington, the first protein identified as a caspase sub-
strate that is specifically involved in a neurodegenerative 35 
disease, is a substrate for proteolytic cleavage by caspase-3. 
Thus, propenoyl hydrazides would be useful for the treatment 
cally, or parenterally. The term parenteral, as used, includes 
subcutaneous injection, intravenous, intramuscular, intraste-
mal injection, or infusion techniques. The dosage depends 
primarily on the specific formulation and on the object of the 
therapy or prophylaxis. The amount of the individual doses as 
well as the administration is best determined by individually 
assessing each case. 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use, for example, 
as tablets, troches, lozenges, aqueous or oily suspensions, 
dispersible powders or granules, emulsions, hard or soft cap-
sules, syrups, or elixirs. Dosage levels of the order of0.2 mg 
to 140 mg per kilogram of body weight per day are useful in 
the treatment of the above-indicated conditions (10 mg to 7 
gms per patient per day). The amount ofactive ingredient that 
of Huntington's disease and other neurodegenerative diseases 
such as dentatorubropallidoluysian atrophy (DRPLA), 
spinocerebellar atrophy type 3 (SCA-3), and spinal bulbar 40 
muscular atrophy (SBMA). 
Effector caspases cleave Alzheimer's gene products, pres-
enilins 1 and 2 proteins. Recently, it has been shown that 
caspase-6 is involved in human neuronal cell apoptosis, amy-
loidogenesis, and Alzheimer's disease. Amyloid ~ peptide 
(A~), which builds up in the brains of people with Alzhe-
imer's disease, causes cultured neurons to die by apoptosis. 
Thus effective caspase-6 propenoyl hydrazide inhibitors 
(Table 1) can be used for the treatment of Alzheimer's dis-
ease. 
In models related to Parkinson disease, peptide caspase 
inhibitors protect against l-methyl-4-phenylpyridinium 
(MPP+)-induced apoptosis of cultured cerebellar granular 
neurons and increase the rate of survival. Also, in mice over-
expressing Bcl-2, dopaminergic l-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) caspase activity is blocked, tox-
icity is decreased, and substantial nigra neurons survive. 
Thus, effective caspase propenoyl hydrazide inhibitors (Table 
1) can be used for the treatment of Parkinson's disease. 
45 may be combined with carrier materials to produce a single 
dosage form will vary depending upon the host treated and the 
particular mode of administration. 
For injection, the therapeutic amount of the peptide prope-
50 noyl hydrazides or their pharmaceutically acceptable salts 
will normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
muscular, or subcutaneous injection. Accordingly, pharma-
ceutical compositions for parenteral administration will con-
55 tain from about 10 mg to 7 gms of the compounds per dose. In 
addition to the active ingredient, these pharmaceutical com-
positions will usually contain a buffer, e.g. a phosphate buffer, 
which keeps the pH in the range from 3.5 to 7 and sodium 
chloride, mannitol, or sorbitol for adjusting the isotonic pres-
Neuronal apoptosis is also seen after acute injuries such as 60 sure. 
stroke, trauma, and ischemia. Apoptosis has been observed in A composition for topical application can be formulated as 
striatal and cortical neurons in animal models of stroke. an aqueous solution, lotion, jelly or an oily solution or sus-
Transgenic mice, expressing a caspase-1 inhibitor, are pro- pension. A composition in the form of an aqueous solution is 
tected from ischemic damage after middle cerebral artery obtained by dissolving the compounds of this disclosure in 
occlusion. During ischemia, activated caspases dismantle the 65 aqueous buffer solution of pH 4 to 6.5 and, if desired, adding 
cell by cleaving multiple substrates such as the enzymes a polymeric binder. An oily formulation for topical applica-
essential for cell repair and cytoskeletal proteins. Therefore, tion is obtained by suspending the compounds of this disclo-
US 7,482,379 B2 
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sure in an oil, optionally with the addition of a swelling agent 
such as aluminium stearate and/or a surfactant. 
EXAMPLES 
The following detailed examples are given to illustrate the 
disclosure and are not intended to limit it in any manner. 
60 
Val), 3.98 (t, lH, a-H), 4.21 (q, 2H, OCH2CH3 ), S.11(s,2H, 
Cbz), S.21 (d, lH, NH), 6.86 (d, lH, db), 7.33 (s, 6H, Ph and 
db), 8.49 (s, lH, NH-N). 
Example2A 
Cbz-Val-AAsp(O-tBu)-CH=CHCH3 was obtained by the 
EDC/HOBt coupling method, and purified by column chro-
matography on silica gel with O.S:49.S:SO MeOH:CH2Cl2: 
Example 1 
General Procedure for the Preparation of Propenoyl 
Hydrazides. 
10 EtOAc as the eluent; white solid, yield S3%. MS (ESI) m/z 
448.4 [(M+ltJ. 1H NMR (DMSO-d6): 0.8S-0.89 (dd, 6H, 
Val), 1.39 (s, 9H, tBu), 1.94 (m, lH, Val), 3.83 (t, lH, a-H), 
S.02 (q, 2H, Cbz), 6.41 (m, lH, db), 6.72 (m, lH, db), 7.32 (s, 
Mixed Anhydride Coupling Method. Coupling of some of 15 
the bulky peptides, such as Cbz-Asp(O-tBu)-Glu(O-tBu)-
Val-NHNHCH2COO-tBu and Cbz-Leu-Glu(O-tBu)-Thr-
NHNHCH2COO-tBu, with the monoethyl fumarate, was 
accomplished using the mixed anhydride coupling method. 
To a solution of the monoethyl fumarate (Seq) in DMF at 0° 20 
C. was addedN-methylmorpholine (NMM, Seq) followed by 
isobutyl chloroformate (iBCF, Seq). After the reaction mix-
ture was allowed to stir for 30 min, the substituted hydrazide 
(1 eq) dissolved in DMF, was added to the mixture. After 10 
25 
min the ice bath was removed and the reaction mixture was 
stirred for 16 hours at room temperature. The DMF was 
evaporated and the residue was washed and purified using the 
same procedure as described above for the EDC/HOBt cou-
pling method. MS and 1H NMR (DMSO-d6, CDC13 or 30 
acetone-d6) were consistent with the proposed structures. 
Example IA 
35 Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-CH=CH-COOEt 
was obtained using the mixed anhydride method and was 
purified using column chromatography on silica gel using 
1:9:10 MeOH:CH2Cl2:EtOAc as the eluent, white solid, yield 
49%. 1 H NMR (DMSO-d6): 0.90 (m, 6H, Val), 1.20 (t, 3H, 40 OCH2CH3 ), 1.41(m,18H, tBu), 1.60-2.00 (m, 3H, Val, Glu), 
2.21 (m, 2H, Glu), (m, 4H, NCH2COOH, and OCH2CH3 ), 
4.20-4.40 (m, 2H, a-H), S.OS (m, 2H, Cbz), 7.10 (-CO-
CH=CH-COOEt), 7.20-7.40 (m, SH, Ph), 8.00 (m, 2H, 
NH). ESI (M+l) Calcd. forC34H51N4 0 11 : 691.3S. Observed 45 
m/z 691.30. 
Example 2 
SH, Ph), 7.S8 (d, lH, NH). 
Example2B 
Cbz-Val-AAsp(O-tBu )-CH=CH--CH=CH--CH3 was 
obtained by the EDC/HOBt coupling method, and purified by 
column chromatography on silica gel with O.S:49.S:SO 
MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield 8%. 
MS (ESI) m/z 474.3 [(M+ltJ. 1H NMR (DMSO-d6): 0.83-
0.89 (dd, 6H, Val), 1.39 (s, 9H, tBu), l.7S (d, 3H, CH3 ), 1.92 
(m, lH, Val), 3.83 (t, lH, a-H), S.02 (q, 2H, Cbz), 6.14 (m, 
2H, db), 6.40 (m, lH, db), 7.09 (m, lH, db), 7.33 (s, SH, Ph), 
7.S8 (d, lH, NH), 10.77 (s, lH, NH-N). 
Example2C 
Cbz-Val-AAsp(O-tBu)-CH=CHCH2CH2Ph was 
obtained by the EDC/HOBt coupling method, and purified by 
column chromatography on silica gel with O.S:49.S:SO 
MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield S3%. 
MS (ESI) m/z S38.3 [(M+ltJ. 
Example2D 
Cbz-Val-AAsp(O-tBu)-cis-CH=CH--Cl was obtained 
by the EDC/HOBt coupling method, and purified by column 
chromatography on silica gel with O.S:49.S:SO MeOH: 
CH2Cl2:Et0Ac as the eluent; white solid, yield 2S%. MS 
(ESI)m/z468.4 [(M+lt]. 1HNMR(DMSO-d6): 0.89 (d, 6H, 
Val), 1.43 (s, 9H, tBu), l.9S (m, lH, Val), 3.84 (t, lH, a-H), 
S.04 (s, 2H, Cbz), 6.S9 (s, lH, db), 6.81 (d, lH, db), 7.3S (s, 
SH, Ph), 7.S6 (d, lH, NH), 10.81 (s, lH, NH-N). 
Example2E 
Cbz-Val-AAsp(O-tBu)-CH=CH-Ph-4-Cl was obtained 
The EDC/HOBt Coupling Method. Cbz-Val-AAsp(O-
tBu)-CH=CH-COOEt. To a stirred solution of Cbz-Val-
NHNHCH2COOtBu (0.34 mmol, 1 eq), HOBt (0.37 mmol, 
50 by the EDC/HOBt coupling method, and purified by column 
chromatography on silica gel with O.S:49.S:SO MeOH: 
CH2Cl2:Et0Ac as the eluent; white solid, yield 62%. MS 
(ESI) m/z S44.3 [(M+ltJ. 1H NMR (DMSO-d6): 0.86-0.93 
(dd, 6H, Val), 1.41 (s, 9H, tBu), 1.98 (m, lH, Val), 3.80 (t, lH, 
55 a-H), S.03 (q, 2H, Cbz), 7.30 (s, SH, Ph), 7.40 (d, lH, db), 
7.S2 (d, lH, db), 7.76 (m, 4H, Ph-Cl), 10.9S (s, 1 H, NH-N). 
1.1 eq), andmonoethyl fumarate (0.37 mmol, 1.1 eq) inDMF 
was added EDC (0.37 mmol, 1.1 eq) and the mixture was 
allowed to react for 16 h at room temperature (2 eq of EDC/ 
HOBt were used with the tetrapeptides). The DMF was 
removed under vacuum and the residue was treated with 10 
mL EtOAc. The organic layer was then washed with2x10 mL 
2% citric acid, lxlS mL saturated NaHC03 , and 2x10 mL 60 
brine. The organic layer was dried over Na2S04 , filtered and 
concentrated. Column chromatography on silica gel with 
1 :4 9: SO MeO H: CH2Cl2: EtOAc as the eluent gave the product 
as a white solid with 63% yield. MS and 1H NMR (DMSO-
d6) were consistent with the proposed structure. MS (ESI) 65 
m/z S06.3 [(M+lt]. 1H NMR (CDC13 ): 0.97-1.02 (dd, 6H, 
Val), 1.28 (t, 3H, OCH2CH3 ), 1.46 (s, 9H, tBu), 2.18 (m, lH, 
Example 2F 
Cbz-Val-AAsp(O-tBu)-CH=CH--CONH-nBu was 
obtained by the EDC/HOBt coupling method, and purified by 
column chromatography on silica gel with 1:9:10 MeOH: 
CH2Cl2:Et0Ac as the eluent; white solid, yield S3%. MS 
(ESI) m/z S33.2 [(M+ltJ. 1H NMR (DMSO-d6): 0.83-0.87 
(m, 9H, Val and NHCH2CH2CH2CH3 ), 1.27 (m, 2H, 
NHCH2CH2CH2CH3 ), 1.41 ( s, 11 H, tBu and 
NHCH2CH2CH2CH3 ), 1.96 (m, lH, Val), 3.12 (dd, 2H, 
US 7,482,379 B2 
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NHCH2CH2CH2CH3), 3.90 (t, lH, a-H), S.03 (q, 2H, Cbz), 
6.91 (d, lH, db), 7.08 (d, lH, db), 7.28-7.34 (m, SH, Ph), 7.47 
(d, lH, NH), 8.37 (t, lH, NHCH2CH2CH2CH3), 10.93 (s, lH, 
NH-N). 
Example2G 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp( 0-tBu )-trans-
CH=CH-COO Et was obtained using the EDC/HOBt cou-
pling method from monoethyl fumarate, purified by column 
chromatography on silica gel with S0:4S:S CH2Cl2:Et0Ac: 
MeOH as the eluent; white solid, yield 68%. 1 H NMR 
(CDC13): 1.00 (d, 6H, Val CH3), 1.29 (t, 3H, OEt), l.4S (s, 
27H, t-Bu), 1.90(m, lH, Val CH), 2.lO(dofm, 2H, GluCH2), 
2.40 ( d of m, 2H, Glu CH2), 2.80 ( d of m, 2H, Asp CH2), 3.20 
(s, 2H, AAsp CH2), 4.19 (q, 3H, OEt and a-H), 4.30 (b, lH, 
a-H), 4.4S (b, lH, a-H), S.12 (q, 2H, Cbz), 6.0S (d, lH, NH), 
6.81 and 7.20 (d of d, 2H, CH=CH), 7.33 (m, 6H, Ph and 
NH), 7.90 (d, lH, NH), 9.00 (s, lH, NH). 
Example2H 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp(O-tBu )-cis-
CH=CH-COOEt was obtained using the EDC/HOBt cou-
pling method from monoethyl maleate, purified by column 
chromatography on silica gel with 1:19:20 MeOH:CH2Cl2: 
EtOAc as the eluent; white solid, yield S3%. MS (ESI) m/z 
862.S [(M+lt]. 1HNMR(DMSO-d6 ): 0.8S (d, 6H, Val), 1.18 
(t, 3H, OCH2CH3), 1.33-1.39 (m, 27H, tBu), 1.74 (m, lH, 
Glu), 1.86 (m, lH, Glu), l.9S (m, lH, Val), 2.18 (m, 2H, Glu), 
2.4S (dd, lH,Asp), 2.61 (dd, lH,Asp), 4.09 (t, lH, a-H), 4.16 
(q, 2H OCH2CH3), 4.33 (m, 2H, a-H), S.Ol (q, 2H, Cbz), 6.61 
62 
Example2K 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-
CH=CH-CONHCH2CH2Ph was obtained by the EDC/ 
5 HOBt coupling method, and purified by colunm chromatog-
raphy on silica gel with 1 :9:S MeOH:CH2Cl2:EtOAc as the 
eluent, and then rechromatographed using 1:1 EtOAc: 
CH2Cl2 as the eluent; white solid, yield 29%. MS (ESI) m/z 
937.S [(M+lt]. 1H NMR (DMSO-d6 ): 0.8S (t, 6H, Val), 
10 1.3S-l.41 (m, 27H, tBu), 1.72 (m, lH, Glu), 1.86 (m, lH, 
Glu), 2.00 (m, lH, Val), 2.17 (m, 2H, Glu), 2.43 (dd, lH,Asp), 
2.61-2.64 (dd, lH,Asp), 2.73 (t, 2H, NHCH2CH2Ph), 3.3S (q, 
2H, NHCH2CH2Ph), 4.17 (t, lH, a-H), 4.29-4.3S (m, 2H, 
a-H), S.02 (q, 2H, Cbz), 6.89 (d, lH, db), 7.07 (d, lH, db), 
15 7.17-7.31 (m, lOH, Ph), 7.S9 (d, lH, NH) (d, lH, NH), 8.Sl (t, 
lH, NHCH2CH2Ph), l0.9S (s, lH, NH-N). 
20 
Example2L 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-
CH=CH-CON(CH3) CH2Ph was obtained by the EDC/ 
HOBt coupling method, and purified by colunm chromatog-
raphy on silica gel with 1 :9:S MeOH:CH2Cl2:EtOAc as the 
eluent, and then rechromatographed using 1:1 EtOAc:hex-
25 anes as the eluent; white solid, yield 34%. MS (ESI) m/z 
937.S [(M+lt]. 1H NMR (DMSO-d6 ): 0.86 (t, 6H, Val), 
1.34-1.41 (m, 27H, tBu), l.6S (m, lH, Glu), 1.88 (m, lH, 
Glu), 1.97 (m, lH, Val), 2.17 (m, 2H, Glu), 2.43 (dd, lH,Asp), 
2.S9 (dd, lH,Asp), 2.88-2.98 (d, 3H, N(CH3)CH2Ph), 4.16 (t, 
30 lH, a-H), 4.29-4.34 (dm, 2H, a-H), 4.S4 (q, lH, N(CH3) 
CH2Ph), 4.67 (s, lH, N(CH3)CH2Ph), S.02 (q, 2H, Cbz), 7.14 
(d, lH, db), 7.20 (d, lH, db), 7.28-7.37 (m, lOH, Ph), 7.S6 (d, 
lH, NH), 7.94 (t, lH, NH), 10.97 (s, lH, NH-N). 
(d, lH, db), 7.2S (d, lH, db), 7.33 (s, SH, Ph), 7.62 (d, lH, 35 
NH), 7 .93 (t, 2H, NH), 11.0S (s, lH, NH-N). 
Example2M 
Example 21 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp(O-tBu )-
CH=CH-COOCH2Ph was obtained by the EDC/HOBt 
coupling method, and purified by colunm chromatography on 
silica gel with 1:499:SOO MeOH:CH2Cl2:EtOAc as the elu-
ent; white solid, yield49%. MS (ESI)m/z 924.S [(M+ltJ. 1H 
NMR (DMSO-d6 ): 0.80 (t, 6H, Val), 1.3S-l.41(m,27H, tBu), 
l.7S (m, lH, Glu), 1.84 (m, lH, Glu), 1.94 (m, lH, Val), 2.17 
(m, 2H, Glu), 2.4S (dd, lH,Asp), 2.60 (dd, lH,Asp), 4.13 (t, 
lH, a-H), 4.28-4.3S (dm, 2H, a-H), S.02 (q, 2H, Cbz), S.19 
(s, 2H, Bzl), 6.70 (d, lH, db), 7.2S-7.37 (m, llH, Ph and db), 
7.S7 (d, lH, NH), 7.92 (d, lH, NH), 7.98 (d, lH, NH), 11.02 
(s, lH, NH-N). 
Example 21 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp(O-tBu )-
CH=CH-CONHCH2Ph was obtained by the EDC/HOBt 
coupling method, and purified by colunm chromatography on 
silica gel with 1:9:10 MeOH:CH2Cl2:EtOAc as the eluent; 
white solid, yield 49%. MS (ESI) m/z 923.S [(M+ltJ. 1H 
NMR (DMSO-d6 ): 0.8S (t, 6H, Val), 1.3S-l.41(m,27H, tBu), 
1.72 (m, lH, Glu), 1.84 (m, lH, Glu), 1.96 (m, lH, Val), 2.17 
(m, 2H, Glu), 2.44 (dd, lH,Asp), 2.60 (dd, lH,Asp), 4.17 (t, 
lH, a-H), 4.28 (m, 2H, a-H), 4.36 (d, 2H, NHCH2Ph), S.02 
(q, 2H, Cbz), 6.9S (d, lH, db), 7.12 (d, llH, db), 7.22-7.31 
(m, lOH, Ph), 7.S7 (d, lH, NH), 7.94 (d, lH, NH), 8.92 (t, lH, 
NHCH2Ph), 10.96 (s, lH, NH-N). 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-
CH=CH-CON(CH3)CH2CH2Ph was obtained by the 
EDC/HOBt coupling method, and purified by colunm chro-
40 matography on silica gel with 1:19:20 MeOH:CH2Cl2: 
EtOAc as the eluent, and then rechromatographed using 1: 1 
Et0Ac:CH2Cl2 as the eluent; white solid, yield 4S%. MS 
(ESI)m/z9Sl.S [(M+ltJ. 1HNMR(acetone-d6): 0.86 (t, 6H, 
Val), 1.41-1.48 (m, 27H, tBu), l.7S (m, lH, Glu), 1.89 (m, 
45 lH, Glu), 2.01 (m, lH, Val), 2.21 (m, 2H, Glu), 2.46 (dd, lH, 
Asp), 2.62 (dd, lH, Asp), 2.80 (t, 2H, N(CH3)CH2CH2Ph), 
2.8S-2.98 (d, 3H, N(CH3)CH2CH2Ph), 3.73 (m, 2H, N(CH3) 
CH2CH2Ph), 4.18 (t, lH, a-H), 4.32 (dm, 2H, a-H), S.00 (q, 
2H, Cbz), 6.88 (t, lH, NH), 7.17-7.34 (m, 12H, Cbz-Ph, 
50 N(CH3)CH2CH2Ph, and CH=CH), 7.S9 (d, lH, NH), 7.8S 
(d, lH, NH), 7.97 (d, lH, NH), 9.89 (d, lH, NH-N). 
Example2N 
55 Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-
CH=CH-CON(CH2Ph)2 was obtained by the EDC/HOBt 
coupling method, and purified by colunm chromatography on 
silica gel with 2:1 EtOAc:hexane as the eluent, and then 
rechromatographed using 1:1 EtOAc:hexanes as the eluent; 
60 white solid, yield 62%. MS (ESI) m/z 1013.4 [(M+ltJ. 1H 
NMR (DMSO-d6 ): 0.87 (t, 6H, Val), 1.3S-l .39 (m, 27H, tBu), 
1.73 (m, lH, Glu), 1.87 (m, lH, Glu), 2.02 (m, lH, Val), 2.23 
(m, 2H, Glu), 2.48 (dd, lH,Asp), 2.6S (dd, lH,Asp), 4.19 (t, 
lH, a-H), 4.33 (m, 2H, a-H), 4.SS (d, 2H, N(CH2Ph)2), 4.63 
65 (s, 2H, N(CH2Ph)2), S.00 (q, 2H, Cbz), 7.14 (d, lH, db), 
7 .21-7 .34 (m, 16H, db, Cbz-Ph, andN(CH2Ph)2), 7 .60 ( d, lH, 
NH), 7.91-7.98 (dd, 2H, NH), 11.00 (s, 1 H, NH-N). 
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Example20 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp(O-tBu )-
CH=CH-CONHCH2-4-F-Ph was obtained by the EDC/ 
HOBt coupling method, and purified by colunm chromatog- 5 
raphy on silica gel with 1: 19:20 MeOH:CH2Cl2:EtOAc as the 
eluent; white solid, yield67%. MS (ESI)m/z941.4 [(M+lt]. 
1H NMR (DMSO-d6): 0.86 (t, 6H, Val), 1.34-1.41 (m, 27H, 
tBu), l.7S (m, lH, Glu), 1.88 (m, lH, Glu), 2.01 (m, lH, Val), 
2.20 (m, 2H, Glu), 2.48 (dd, lH, Asp), 2.6S (dd, lH, Asp), 10 
4.18 (t, lH, a-H), 4.34 (m, 4H, a-HandNHCH2Ph-4-F), S.01 
64 
4H, Cbz andCH2Ph), S.40 (d, lH, NH), 6.SS and 7.20 (dofd, 
2H, CH=CH), 7.20-7.40 (m, !OH, Ph), 7.SO (d, lH, NH), 
8.00 (d, lH, NH), 9.40 (s, lH, NH). 
Example2T 
Cbz-Ile-Glu(O-tBu)-Thr-AAsp(O-tBu)-CH=CH-
CONHPh was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 67%. 1H NMR (acetone-d6 ): 0.89 and 0.99 (m, 
6H, Ile CH3 ), 1.24 (m, SH, Thr CH3 and Ile CH2), l.4S (s, 
18H, t-Bu), 1.60 (m, lH, Ile CH), l.9S and 2.lS (d ofm, 2H, 
(q, 2H, Cbz), 6.93 (d, lH, db), 7.12 (d, 2H, NHCH2Ph-4-F), 
7.2S-7.32 (m, SH, Cbz-Ph, NHCH2Ph-4-F, and db), 7.S9 (d, 
lH, NH), 7.90-7.99 (dd, 2H, NH), 8.94 (t, lH, NHCH2Ph-4-
F), 10.98 (s, lH, NH-N). 
Example 2P 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp(O-tBu )-
CH=CH-CO-tetrahydroquinoline was obtained by the 
EDC/HOBt coupling method, and purified by colunm chro-
matography on silica gel with 1 :2 CH2Cl2:Et0Ac as the elu-
ent; yellow solid, yield S4%. MS (ESI) m/z 949.4 [(M+lt]. 
15 Glu CH2), 2.39 (m, 2H, Glu CH2), 2.86 (s, 2H, AAsp CH2), 
4.16 (m, lH, a-H), 4.3S (m, lH, a-H), 4.4S (m, 2H, a-Hand 
Thr CH), S.10 (q, 2H, Cbz), 6.70 (d, lH, NH), 6.80 and 7.20 
(d of d, 2H, CH=CH), 7.08 (m, 2H, Ph), 7.3S (m, 6H, Ph), 
7.S2 (m, lH, NH), 7.78 (t, 2H, Ph), 7.90 (b, lH, NH), 9.60 (s, 
20 lH, NH), 9.70 (s, lH, NH). 
1H NMR (DMSO-d6): 0.89 (t, 6H, Val), 1.3S-1.42 (m, 27H, 
tBu), l.7S (m, lH, Glu), 1.87 (m, 3H, Glu and 25 
NCH2CH2CH2), 2.02 (m, lH, Val), 2.20 (m, 2H, Glu), 2.48 
(dd, lH, Asp), 2.6S (dd, lH, Asp), 2.70 (t, 2H, 
NCH2CH2CH2), 3.73 (t, 2H, NCH2CH2CH2), 4.19 (t, lH, 
a-H), 4.33 (m, 2H, a-H), S.Ol (q, 2H, Cbz), 6.9S (m, lH, db), 
7.04 (d, lH, db), 7.14-7.33 (m, 9H, Cbz-Ph, and quinoline), 30 
7.60 (d, lH, NH), 7.96 (dd, 2H, NH), 11.02 (s, lH, NH-N). 
Example2Q 
Example2U 
Cbz-Ile-Glu(O-tBu)-Thr-AAsp(O-tBu)-CH=CH-
CONHCH2Ph was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 30%. 1 H NMR (CDC13 ): 0.92 and 0.9S (m, 6H, Ile 
CH3 ), 1.19 (m, SH, IleCH2 and ThrCH3 ), l .4S (s, 18H, t-Bu), 
1.80 (m, lH, Ile CH), 1.90 (m, 2H, Glu CH2), 2.30 and 2.40 ( d 
ofm, 2H, Glu CH2), 3.20 (s, 2H, AAsp CH2), 4.12 (m, lH, 
a-H), 4.38 (m, 3H, a-H, Thr CH and CH2Ph), 4.S2 (m, lH, 
CH2Ph), S.10 (s, 2H, Cbz), S.S3 (d, lH, NH), 6.SS (d, lH, 
35 CH=CH), 7.1S-7.40(m, llH,CH=CHandPh), 7.70(s, lH, 
NH), 8.0S (b, lH, NH), 8.3S (b, lH, NH), 9.4S (s, lH, NH). 
Cbz-Asp(O-tBu )-Glu(O-tBu )-Val-AAsp(O-tBu )-
CH=CH-COPh was obtained by the EDC/HOBt coupling 
method, and purified by colunm chromatography on silica gel 
with 1:499:SOO MeOH:CH2Cl2:EtOAc as the eluent; white 
solid, yield 40%. MS (ESI) m/z 894.4 [(M+ltJ. 1H NMR 
(DMSO-d6): 0.82 (t, 6H, Val), 1.34-1.42 (m, 27H, tBu), 1.70 40 
(m, lH, Glu), 1.SS (m, lH, Glu), 1.96 (m, lH, Val), 2.lS (m, 
2H, Glu), 2.44 (dd, lH,Asp ), 2.SS-2.60 (dd, lH,Asp ), 4.14 (t, 
lH, a-H), 4.26-4.33 (dm, 2H, a-H), S.02 (q, 2H, Cbz), 7.23 
Example2V 
(d, lH, db), 7.31 (s, SH, Cbz), 7.Sl (m, 3H, Ph), 7.66 (t, lH, 
NH), 7.80 (d, lH, db), 7.99 (d, 2H, Ph), 11.02 (s, lH, 45 
NH-N). 
Cbz-Ile-Glu(O-tBu)-Thr-AAsp(O-tBu)-CH=CH-
CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 77%. 1 H NMR (CDC13 ): 0.92 and 0.98 (m, 6H, Ile 
CH3 ), 1.19 (m, SH, IleCH2 and ThrCH3 ), l .4S (s, 18H, t-Bu), 
1.80 (m, lH, Ile CH), l.9S and 2.10 (d ofm, 2H, Glu CH2), 
2.3S and 2.SO (d ofm, 2H, Glu CH2), 2.80 (m, 2H, CH2Ph), 
3.20 (s, 2H, AAsp CH2), 3.S2 (m, 2H, NCH2), 4.lS (m, 2H, 
Example2R 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-CH=CH- 50 a-H), 4.2S (m, lH, a-H), 4.40 (m, lH, Thr CH), S.11 (s, 2H, 
Cbz), SAS (d, lH, NH), 6.SS (d, lH, CH=CH), 7.lS-7.40 (m, 
12H, CH=CH, Ph and NH), 7.70 (b, lH, NH), 8.0S (b, lH, 
NH), 9.40 (s, lH, NH). 
COO Et was synthesized using the mixed anhydride coupling 
method and purified by colunm chromatography using 4: 1 
(1:9 MeOH:CH2Cl2):EtOAc as an eluent, and then rechro-
matographed using 4:1 (1:19 MeOH:CH2Cl2):EtOAc as the 
eluent; white solid, yield 36%. MS (ESI) m/z 806 [(M+ltJ. 55 Example2W 
Example 2S 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-CH=CH-
COOCH2Ph was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 37%. 1 H NMR (CDC13 ): 0.91 and 0.94 (m, 6H, Ile 
CH3 ), 1.20 (m, H, Ile CH2 and Thr CH3 ), l.4S (s, 19H, t-Bu 
and Ile CH), 2.0S and 2.20 (d ofm, 2H, Glu CH2), 2.3S and 
2.SO (dofm, 2H, GluCH2), 3.21(s,2H,AAsp CH2), 4.12 (m, 
2H, a-H), 4.30 (m, lH, a-H), 4.44 (m, lH, ThrCH), S.10 (m, 
Cbz-Ile-Glu(O-tBu)-Thr-AAsp(O-tBu)-CH=CH-CON 
(CH3 )CH2Ph was obtained using the EDC/HOBt coupling 
60 method, purified by colunm chromatography on silica gel 
with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 77%. 1H NMR (acetone-d6 ): 0.90 and 0.99 (m, 
6H,IleCH3 ), 1.21 (m,3H, ThrCH3 ), l.4S (s, 18H, t-Bu), 1.60 
(m, 3H, Ile CH and CH2), 1.96 (m, 2H, Glu CH2), 2.38 (m, 
65 2H, Glu CH2), 2.84 (s, 2H,AAsp CH2), 2.9S and3.08 (d, 3H, 
NCH3 ), 4.lS-4.30 (m, 3H, a-H), 4.42 (m, lH, Thr CH), 4.6S 
(s, 2H, CH2Ph), S.08 (q, 2H, Cbz), 6.63 (d, lH, NH), 7.20-
US 7,482,379 B2 
65 
7.40 (m, 13H, CH=CH, Ph and NH), 7.52 (d, lH, NH), 7.84 
(d, lH, NH), 9.75 (s, lH, NH). 
66 
Example2BB 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CONHPh was obtained using the EDC/HOBt coupling Example2X 
5 method, purified by colunm chromatography on silica gel 
with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 80%. 1H NMR (acetone-d6 ): 0.93 (d, 6H, Leu 
CH3), 1.22 (m, 3H, ThrCH3), 1.44 (s, 18H, t-Bu), 1.67 (t, 2H, 
Leu CH2), 1.78 (m, lH, Leu CH), 1.95 and 2.15 (d ofm, 2H, 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-CH=CH--CON 
(CH3)CH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 71 %. 1H NMR (CDCl3): 0.90 (m, 3H, Ile CH3), 
0.96 (m, 3H, Ile CH3), 1.20 (m, 3H, Thr CH3), 1.45 (s, 18H, 
t-Bu), 1.80-1.90 (m, 3H, Ile CH and CH2), 2.10 (m, 2H, Glu 
CH2), 2.40 (m, 2H, Glu CH2), 2.85 (m, 2H, CH2Ph), 2.97 ( d, 
3H, NCH3), 3.30 (m, 2H, AAsp CH2), 3.54 (m, 2H, NCH2), 15 
4.20 (m, 2H, a-H), 4.41 (m, 2H, a-Hand Thr CH), 5.11 (q, 
2H, Cbz), 5.60 (d, lH, NH), 7.10-7.40 (m, 13H, CH=CH, Ph 
and NH), 7.85 (b, lH, NH), 9.50 (d, lH, NH). 
10 Glu CH2), 2.38 (m, 2H, Glu CH2), 2.87 (s, 2H, AAsp CH2), 
4.30-4.35 (m, 3H, a-H), 4.42 (m, lH, Thr CH), 5.09 (q, 2H, 
Cbz), 6.75 (d, lH, NH), 6.80and 7.20 (dofd, 2H, CH=CH), 
7.08 (m, 2H, Ph), 7.35 (m, 6H, Ph), 7.52 (m, lH, NH), 7.78 (t, 
2H, Ph), 7.88 (b, lH, NH), 9.63 (s, lH, NH), 9.72 (s, lH, NH). 
Example2CC 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CONHCH2Ph was obtained using the EDC/HOBt coupling 
Example2Y 20 method, purified by colunm chromatography on silica gel 
with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 38%. 1H NMR (CDCl3): 0.94 (d, 6H, Leu CH3), 
1.20 (m, 3H, Thr CH3), 1.45 (s, 18H, t-Bu), 1.64 (m, 3H, Leu 
CH and CH2), 2.00 (m, 2H, Glu CH2), 2.34 and 2.42 ( d of m, 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-CH=CH--CON 
(CH2Ph)2 was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 46%. 1H NMR (acetone-d6 ): 0.89 and 0.99 (m, 
6H, Ile CH3), 1.21(m,3H, ThrCH3), 1.45 (s, 18H, t-Bu), 1.60 
(m, 3H, Ile CH and CH2), 1.95 and 2.10 (d of m, 2H, Glu 
CH2), 2.39 (m, 2H, Glu CH2), 2.84 (s, 2H, AAsp, CH2), 4.15 30 
(t, lH, a-H), 4.35 (m, lH, a-H), 4.45 (m, 2H, a-Hand Thr 
CH), 4.67 (m, 4H, CH2Ph), 5.09 (q, 2H, Cbz), 5.60 (d, lH, 
NH), 7 .20-7.40 (m, 17H, CH=CH and Ph), 7 .55 ( d, lH, NH), 
7.85 (d, lH, NH), 9.75 (s, lH, NH). 
25 2H, Glu CH2), 3.20 (s, 2H, AAsp CH2), 4.10 (m, lH, a-H), 
4.21 (m, 2H, a-H), 4.40-4.50 (m, 3H, Thr CH and CH2Ph), 
5.05 (q, 2H, Cbz), 5.42 (d, lH, NH), 6.85 (d, lH, CH=CH), 
7.15-7.40 (m, llH, CH=CHand, Ph), 7.55 (b, lH, NH), 7.70 
(b, lH, NH), 8.20 (b, lH, NH), 9.40 (s, lH, NH). 
Example2DD 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
Example2Z 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
COOEt was synthesized using the mixed anhydride coupling 
method and purified by colunm chromatography using 4: 1 
35 piing method, purified by colunm chromatography on silica 
gel with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 55%. 1H NMR (CDCl3): 0.94 (d, 6H, Leu CH3), 
1.20 (m, 3H, Thr CH3), 1.45 (s, 18H, t-Bu), 1.65 (m, 3H, Leu 
CH and CH2), 2.05 (m, 2H, Glu CH2), 2.40 (m, 2H, Glu CH2), 
40 2.78 (m, 2H, CH2Ph), 3.20 (s, 2H, AAsp CH2), 3.50 (m, 2H, 
NCH2), 4.24 (m, 3H, a-H), 4.41 (m, lH, ThrCH), 5.05 (s, 2H, 
Cbz), 5.62 (d, lH, NH), 6.80 and 7.10 (dofd, 2H, CH=CH), 
7.15-7.40 (m, 12H, Ph and NH), 8.00 (b, lH, NH), 9.45 (s, 
(1: 19 MeOH:CH2Cl2):EtOAc as the eluent; white solid, yield 
35%. MS (ESI) m/z 806 [(M+lt]. 1H NMR (DMSO-d6): 
0.85 (t, 6H, Leu CH3), 1.1 (d, 3H, Thr CH3), 1.2-1.3 (t, 3H, 
OCH2CH3), 1.3-1.5 (d, 20H, tBu and Leu CH2), 1.6 (m, lH, 45 
CH Leu), 1.7 (m, lH, GluCH2), 1.9 (m, lH, GluCH2), 2.2 (m, 
2H, Glu CH2), 3.9-4.1 (m, 4H, NCH2COOH and a-H), 4.1-
4.2 (m, 3H, OCH2CH3 and CH-OH), 4.3 (m, 2H, a-H), 5.0 
(s, 2H, Cbz), 6.6 (d, lH, CH=CH), 7.20-7.40 (m, 6H, Ph and 
CH=CH), 7.50 (d, lH, NH), 7.75 (d, lH, NH), 8.0 (d, lH, 50 
NH). 
Example2AA 
lH, NH). 
Example2EE 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CON(CH3)CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 77%. 1H NMR (acetone-d6 ): 0.94 (d, 6H, Leu 
CH3), 1.20 (m, 3H, Thr CH3), 1.45 (s, 18H, t-Bu), 1.65 (m, 
2H, Leu CH2), 1.80 (m, lH, Leu CH), 1.95-2.10 (d ofm, 2H, 
55 Glu CH2), 2.38 (d of m, 2H, Glu CH2), 2.85 (s, 2H, AAsp 
CH2), 2.95 and 3.08 (d, 3H,NCH3), 4.30 (m, 3H, a-H), 4.42 
(m, lH, ThrCH), 4.65 (s, 2H, CH2Ph), 5.08 (q, 2H, Cbz), 6.75 
(d, lH, NH), 7.20-7.40 (m, 12H, CH=CH and Ph), 7.44 (d, 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
COOCH2Ph was obtained by the EDC/HOBt coupling 
method, and purified by colunm chromatography on silica gel 
with 1:499:500 MeOH:CH2Cl2:EtOAc as the eluent; white 
solid, yield 52%. MS (ESI) m/z 868.4 [(M+lt]. 1H NMR 60 
(DMSO-d6): 0.83 (t, 6H, Leu), 1.02 ( d, 3H, Thr), 1.36-1.40 (t, 
20H, tBuandLeu), 1.60(m, lH, Glu), 1.72 (m, lH, Glu), 1.88 
(m, lH, Leu), 2.21 (m, 2H, Glu), 3.92 (m, lH, a-H), 4.03 (m, 
lH, a-H), 4.17 (m, lH, a-H), 4.34 (m, lH, Thr), 4.99 (s, 2H, 
Cbz), 5.19 (s, 2H, Bzl), 6.67-6.71 (d, lH, db), 7.32-7.38 (m, 65 
lOH, Ph), 7.40 (d, lH, db), 7.76 (d, lH, NH), 8.04 (d, lH, 
NH), 10.80 (s, lH, NH-N). 
lH, NH), 7.90 (d, lH, NH), 9.75 (s, lH, NH). 
Example 2FF 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CON(CH3)CH2CH2Ph was obtained using the EDC/HOBt 
coupling method, purified by column chromatography on 
silica gel with 50:45:5 CH2Cl2:EtOAc:MeOH as the eluent; 
white solid, yield 76%. 1H NMR (CDCl3): 0.94 (m, 6H, Leu 
US 7,482,379 B2 
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CH3), 1.21 (m, 3H, Thr CH3), l.4S (s, 18H, t-Bu), I.SS (m, 
2H, Leu CH2), 1.70 (m, lH, Leu CH), 2.13 (m, 2H, Glu CH2), 
2.43 (m, 2H, Glu CH2), 2.81 (m, 2H, CH2Ph), 2.88 and 2.92 
(d, 3H, NCH3), 3.S6 (m, 4H, NCH2 andAAsp CH2), 4.30 (m, 
2H, a-H), 4.43 (m, 2H, a-Hand Thr CH), S.10 (q, 2H, Cbz), 5 
S.SS (m, lH, NH), 7.10-7.40 (m, 12H, CH=CH and Ph), 7.4S 
(d, lH, NH), 7.9S (b, lH, NH), 9.42 (d, lH, NH). 
7.10 (d, lH, NH), 7.20-7.40 (m, lOH, CH=CH and Ph), 7.S2 
(m, 2H,napth), 7.79 (d, lH, NH), 7.90(m, 2H,napth), 9.4S (d, 
lH, NH). 
Example2KK 
Cbz-Val-Glu(O-tBu)-Val-AAsp(O-tBu)-CH=CH-
COOEt was obtained by the EDC/HOBt coupling method, 
and purified by column chromatography on silica gel with Example2GG 
10 1 :9:S MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield 
71%. MS (ESI) m/z 790.3 [(M+ltJ. 1H NMR (DMSO-d6): 
0.81-0.87 (dd, 12H, Val), 1.22 (t, 3H, OCH2CH3), 1.24-1.41 
(d, 18H, tBu), 1.72 (m, lH, Glu), 1.83 (m, lH, Glu), 1.96 (m, 
lH, Val), 2.19 (m, 2H, Glu), 3.86 (t, lH, a-H), 4.17 (m, 3H, 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CON(CH2Ph)2 was obtained using the EDC/HOBt coupling 
method, purified by column chromatography on silica gel 
with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield SS%. 1H NMR (acetone-d6 ): 0.93 (d, 6H, Leu 
CH3), 1.21 (m, 3H, Thr CH3), l.4S (s, 18H, t-Bu), 1.67 (m, 
2H, Leu CH2), 1.80 (m, lH, Leu CH), l.9S and 2.10 (d ofm, 
2H, Glu CH2), 2.39 (m, 2H, Glu CH2), 2.88 (s, 2H, AAsp 
CH2), 4.2S-4.3S (m, 3H, a-H), 4.43 (m, lH, Thr CH), 4.66 
(m, 4H, CH2Ph), S.09 (q, 2H, Cbz), 6.7S (d, lH, NH), 7.20- 20 
7.40 (m, 17H, CH=CH and Ph), 7 .SS ( d, lH, NH), 7 .90 (b, 
lH, NH), 9.7S (s, lH, NH). 
15 a-Hand OCH2CH3), 4.32 (m, lH, a-H), S.Ol (s, 2H, Cbz), 
6.64 (d, lH, db), 7.20 (d, lH, db), 7.30-7.33 (m, SH, Ph), 7.97 
(t, 2H, NH), 11.02 (s, lH, NH-N). 
Example3A 
N2 -(N-Benzy loxycarbonylalanylalanyl )-N1-carbamoy1-
methyl-N 1 -trans-(3-ethylesterpropenoyl)hydrazine (Cbz-
Ala-Ala-AAsn-CH=CH--COOEt) was synthesized using 
the EDC/HOBt coupling method, purified by chromatogra-Example2HH 
25 phy on a silica gel colunm using 1:13 MeOH:CH2Cl2 as the 
eluent, and then recrystallized from EtOAc/hexane; white 
solid, yield 33%. 1H NMR (DMSO-d6 ): 1.lS-1.3 (m, 9H, 
CH3), 3.3 (m, 2H, NCH2CO), 4.0S (m, lH, a-H), 4.1-4.2 (q, 
2H, OCH2CH3), 4.3 (m, lH, a-H), S.O (m, 2H, Cbz), 6.SS-
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CONHCH2-4-F-Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield 46%. 1H NMR (acetone-d6 ): 0.92 (d, 6H, Leu 
CH3), 1.21(d,3H, ThrCH3), l.4S (s, 18H, t-Bu), 1.66 (t, 2H, 
Leu CH2), 1.76 (m, lH, Leu CH), l.9S and 2.10 (d ofm, 2H, 
Glu CH2), 2.36 (m, 2H, Glu CH2), 3.20 (s, 2H, AAsp CH2), 
4.29 (m, 3H, a-H), 4.40 (m, lH, Thr CH), 4.SO (d, 2H, 
CH2Ph), S.10 (q, 2H, Cbz), 6.76 (d, lH, NH), 6.91 (d, lH, 35 
CH=CH), 7 .07 ( d. 2H, CH=CH and Ph), 7 .2S-7.40 (m, SH, 
Ph), 7.SO (b, lH, NH), 7.9S (b, lH, NH), 8.23 (b, lH, NH), 
9.70 (s, lH, NH). 
30 6.6S (d, lH, CH=CH), 7.1-7.2 (m, 2H, NH and CH=CH), 
7.2-7.4 (m, SH, Ph), 7.S (s, lH, NH), 8.lS (d, lH, NH). HRMS 
(FAB) Calcd. for C22H30N5 0 8 : 492.20944. Observed m/z 
492.20S6S. Anal. Calcd. for C22H29N5 0 8 : C, S3.76; H, S.9S; 
N, l4.2S. Found: C, S3.S2; H, S.87; N, 14.11. 
Example3B 
N2 -(N-Benzy loxycarbonylalanylalany 1)-N1 -trans-(3-
benzyloxycarbony lpropenoy 1)-N1 -carbamoy lmethylhydra-
Example2II 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-CO-
tetrahydroquinoline was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; white 
solid, yield SS%. 1 H NMR (CDC13): 0.94 (m, 6H, Leu CH3), 
1.21(m,3H, ThrCH3), l.4S (s, 18H, t-Bu), 1.60 (m, 2H, Leu 
CH2), 1.70 (m, lH, Leu CH), 1.90 (m, 2H, quinoline CH2), 
2.10 (m, 2H, Glu CH2), 2.4S (m, 2H, Glu CH2), 2.67 (t, 2H, 
quinoline CH2), 3.40 (m, 2H, AAsp CH2), 3.90 (m, 2H, 
NCH2), 4.30 (m, 2H, a-H), 4.4S (m, 2H, a-Hand Thr CH), 
S.10 (q, 2H, Cbz), S.SS (b, lH, NH), 6.90 (b, lH, NH), 
7.10-7.40 (m, lOH, CH=CH and Ph), 7.SO (d, lH, Ph), 7.9S 
(d, lH, NH), 9.40 (d, lH, NH). 
Example 2JJ 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-CH=CH-
CON ( CH3)CH2-l -N apth was obtained using the EDC/H 0 Bt 
coupling method, purified by colunm chromatography on 
silica gel with S0:4S:S CH2Cl2:EtOAc:MeOH as the eluent; 
white solid, yield 66%. lH NMR (CDC13): 0.9S (m, 6H, Leu 
CH3), 1.22 (m, 3H, Thr CH3), l.4S (s, 18H, t-Bu), I.SS (m, 
2H, LeuCH2), 1.70 (m, lH, Leu CH), 2.lS (m, 2H, GluCH2), 
2.4S (m, 2H, Glu CH2), 2.92 and2.99 (d, 3H, NCH3), 3.30 (m, 
2H,AAsp CH2), 4.31(m,2H, a-H), 4.47 (m, 2H, a-Hand Thr 
CH), S.09 (m, 4H, CH2-napth and Cbz), S.SO (b, lH, NH), 
40 zine (Cbz-Ala-Ala-AAsn-CH=CH-COOBzl). This com-
pound was obtained using the HOBt/EDC coupling method 
and purified by colunm chromatography on silica gel using 
10% MeOH/CH2Cl2 as the eluent and then recrystallized 
from EtOAc/hexane to give a white powder (20% yield). 
45 1H-NMR ((CD3)2CO): 1.37 (m, 6H, 2xAla-CH3), 2.88 (s, 
2H, NCH2CO), 4.21-4.24 (m, lH, a-H), 4.SO (m, lH, a-H), 
S.10 (m, 2H, Cbz), S.24 (s, 2H, O-CH2-Ph), 6.SS-6.33 (m, 
2H, NH and CH=CH), 6.74-6.88 (d, lH, CH=CH), 7.31-
7.44 (m, 1 lH, 2xPh and NH), 7.76 (s, lH, NH), 8.16 (d, lH, 
50 NH), 9.89 (s, lH, NH). MS (ESI) m/z SS4 [(M+ltJ. HRMS 
(ESI) calculated for C27H32N5 0 8 : SS4.22l9. Observed m/z 
SS4.22S088. Anal. Calcd. for C27H31N50 8 .0.2H20: C, 
SS.20; H, S.68; N, 12.S7. Found: C, SS.16; H, S.60; N, 12.47. 
55 Example3C 
N2 -(N-Benzy loxycarbonylalanylalany 1)-N1-carbamoy1-
methyl-N 1 -trans-(3-diethylcarbamoy lpropenoyl )hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-CONEt2). This compound 
60 was obtained using the HOBt/EDC coupling method and 
purified by colunm chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent and then recrystallized from 
EtOAc/hexane to give a white powder (11 % yield). 1 H-NMR 
(DMSO-d6): 1.02-1.0S (t, 3H, NCH2CH3), 1.08-1.11 (t, 3H, 
65 NCH2CH3), 1.17-1.19 ( d, 2H, Ala-CH3), 1.24-1.26 ( d, 2H, 
Ala-CH3), 3.20-3.32 (d, 6H, NCH2CO and 2xN-CH2), 
4.02-4.07 (m, lH, a-H), 4.27-4.31 (m, lH, a-H), 4.99 (m, 2H, 
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Cbz), 7.00-7.04 (d, lH, CH=CHCON), 7.18 (s, lH, NH), 
7.33 (m, 6H, PhandCH=CHCON), 7.39 (d, lH, NH), 8.20 
(d, lH, NH), 10.68 (s, lH, NH). MS (ESI) m/z 519 [(M+ltJ. 
HRMS (ESI) calculated for C24H35N60 7 : 519.2608. 
Observed m/z 519.2657. Anal. Calcd. for 5 
C24H34N60 7 .0.7H20: C, 54.27; H, 6.72; N, 15.82. Found: C, 
54.25; H, 6.69; N, 15.87. 
Example3D 
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Example3G 
N2 -(N-Benzy loxycarbonylalanylalany I )-N1-carbamoy1-
methyl-N 1 -trans-(3-benzylcarbamoy lpropenoyl )hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-CONHBzl). This com-
pound was obtained using the HOBt/EDC coupling method 
with minimal washing during the workup and purified by 
recrystallization from ice cold EtOAc without column chro-
matography (18% yield). 1H-NMR (DMSO-d6): 1.17-1.26 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1-carbamoy1-
methyl-N 1 -trans-(3-dibuty lcarbamoy lpropenoy !)hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-CON(nBu)2). This com-
pound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography on silica gel using 
10% MeOH/CH2Cl2 as the eluent and then recrystallized 
from EtOAc/hexane to give a white powder (15% yield). 
10 (m, 6H, 2xA!a-CH3), 3.30-3.32 (d, 2H, NCH2CO), 4.02-4.07 
(m, lH, a-H), 4.27-4.32 (m, lH, a-H), 4.35-4.36 (d, 2H, 
CH2Ph), 4.99 (m, 2H, Cbz), 6.89-6.92 (d, lH, J=14.2 Hz, 
CH=CHCON), 7.06-7.10 (d, lH, J=14.8 Hz, 
CH=CHCON), 7.16-7.41 (m, 1 lH, 2xPh and NH), 7.42 (d, 
1 H-NMR (DMSO-d6): 0.95 (m, 6H, 2xnBu-CH3), 1.11-1.27 
(m, 6H, 2xA!a-CH3), 1.30-1.37 (m, 4H, 
15 lH, NH), 8.16 (d, lH; NH), 8.94 (t, lH, NH), 10.72 (s, lH, 
NH). MS (ESI) m/z 553 [(M+ltJ. HRMS (ESI) calculated 
for C27H33N60 7 : 553.2397. Observed m/z 553.2411. Anal. 
Calcd. forC27H32N60 7 .0.3H20: C, 58.12; H, 5.89; N, 15.06. 
2xCH2CH2CH2CH3), 1.53 -1.59 (m, 4H, 20 
2xCH2CH2CH2CH3), 3.20-3.32 (d, 6H, NCH2CO and 
2xN-CH2), 4.00-4.01 (m, lH, a-H), 4.25-4.30 (m, lH, 
a-H), 4.99 (m, 2H, Cbz), 7.00-7.04 (d, lH, CH=CHCON), 
7.21 (s, lH, NH), 7.33 (m, 6H, Ph and CH=CHCON), 7.42 
(d, lH, NH), 8.20 (d, lH, NH), 10.73 (s, lH, NH). MS (FAB) 25 
m/z 575 [(M+ltJ. HRMS (FAB) calculated for 
C28H43N60 7 :575.32052. Observed m/z 575.31932. Anal. 
Calcd. forC28H42N60 7 0.8H20: C, 57.16; H, 7.35; N, 14.28. 
Found: C, 57.18; H, 7.35; N, 14.28. 
Found: C, 58.07; H, 5.81; N, 15.03. 
Example3H 
Example 3E 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N1 -carbamoy l-
methyl-N1-trans-(3-(1-piperidy loxo )propenoyl )hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-CO-Pip ). This compound 
was obtained using the HOBt/EDC coupling method and 35 
purified by columin chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent and recrystallized from hexane/ 
EtOAc to give a white powder (10% yield). 1H-NMR ((CD3) 
CO): 1.28 (m, 2H, piperidine-CH2), 1.37 (d, 3H, Ala-CH3), 
1.41(d,3H,Ala-CH3),1.52-1.67(m,4H,2xpiperidine-CH2), 40 
2.80 (s, 2H, NCH2CO), 3.55 (m, 4H, CH2-N--CH2), 4.24 
(m, lH, a-H), 4.50 (m, lH, a-H), 5.10 (m, 2H, Cbz), 7.11-
7.15 (d, lH, J=14.8 Hz, CH=CHCON), 7.30-7.44 (m, 7H, 
CH=CHCON and Ph and NH), 7.77 (s, lH, NH), 9.82 (s, lH, 
NH). MS (ESI) m/z 531 [(M+ltJ. HRMS (ESI) calculated 45 
forC25H35N60 7 : 531.2532. Observedm/z 531.256723.Anal. 
Calcd. forC25H34N60 7 .0.7H20: C, 55.32; H, 6.50; N, 15.48. 
Found: C, 55.26; H, 6.43; N, 15.28. 
N2 -(N-Benzy loxycarbonylalanylalany I )-N 1-carbamoy1-
methyl-N 1 -trans-(3-( 4-fluorobenzyl)carbamoylpropenoyl) 
hydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CONH-Bzl-4-
F). This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography 
using 10% MeOH/CH2Cl2 as the eluent to give a pink powder 
(8% yield). 1H-NMR (DMSO-d6): 1.17-1.26 (m, 6H, 2xA!a-
30 CH3), 3.30-3.32 (d, 2H, NCH2CO), 4.02-4.07 (m, lH, a-H), 
4.27-4.35 (m, 3H, a-H and CH2PhF), 4.99 (m, 2H, Cbz), 
6.88-6.92 (d, lH, J=16 Hz, CH=CHCON), 7.06-7.32 (m, 
llH, CH=CHCON and NH and 2xPh), 7.43 (d, lH, NH), 
7.53 (s, lH, NH), 8.19 (d, lH, NH), 8.97 (t, lH, NH), 10.72 (s, 
lH, NH). MS (ESI) m/z 571 [(M+ltJ. HRMS (ESI) calcu-
lated for C27H32N60 7F: 571.2323. Observed m/z 
571.231651. Anal. Calcd. for C27H31N60 7F: C, 56.84; H, 
5.48; N, 14.73. Found: C, 56.73; H, 5.58; N, 14.68. 
Example 31 
N2 -(N-Benzy loxycarbonylalanylalany I )-N1-carbamoy1-
methyl-N 1 -trans-(3-phenethy lcarbamoy lpropenoy !)hydra-
zine (Cbz-Ala-Ala-AAsn-CH=CH-CONHCH2CH2Ph). 
This compound was obtained using the HOBt/EDC coupling 
method with minimal washing during the workup and puri-
fied by column chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent and then washed with EtOAc to 
Example 3F 50 give a white powder (12% yield). 1H-NMR (DMSO-d6): 
1.18-1.27 (m, 6H, 2xA!a-CH3), 2.74 (m, 2H, 
N--CH2CH2Ph), 3.20-3.32 (d, 2H, NCH2CO), 3.52-3.58 (m, 
2H, N--CH2CH2Ph), 4.04-4.08 (m, lH, a-H), 4.28-4.31 (m, 
lH, a-H), 4.99 (m, 2H, Cbz), 6.86-6.89 (d, lH, J=14.4 Hz, 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N1-carbamoy1-
methyl-N 1 -trans-(3-pheny lcarbamoy lpropenoy !)hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-CONHPh). This com-
pound was obtained using the HOBt/EDC coupling method 
with minimal NaHC03 washing during the workup. The 
product was isolated as a yellow solid without chromatogra-
phy by recrystallization from 10% MeOH/CH2Cl2 (21 % 
yield). 1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 2xA!a-
CH3), 3.20-3.32 (d, 2H, NCH2CO), 4.04-4.08 (m, lH, a-H), 
4.28-4.31 (m, lH, a-H), 4.99 (m, 2H, Cbz), 7.05-7.42 (m, 
llH, 2xPh, NH CH=CHCON and CH=CHCON), 7.63-
7.65 (d, 2H, Ph), 7.52 (s, lH, NH), 8.15 (d, lH, NH), 10.42 (s, 
lH, NH), 10.72 (s, lH, NH). MS (ESI) m/z 539 [(M+ltJ. 
HRMS (ESI) calculated for C26H31N60 7 : 539.2208. 65 
Observed m/z 539.2254. Anal. Calcd. for C26H30N60 7 : C, 
57.98; H, 5.61; N, 15.60. Found: C, 57.73; H, 5.58; N, 15.72. 
55 CH=CHCON), 7.04-7.08 (d, lH, J=14.8 Hz, 
CH=CHCON), 7.16-7.41 (m, 1 lH, 2xPh and NH), 7.50 (d, 
lH, NH), 8.16 (d, lH, NH), 8.53 (s, lH, NH), 10.72 (s, lH, 
NH). MS (ESI) m/z 567 [(M+lt]. HRMS (ESI) calculated 
forC28H35N60 7 : 567 .2596. Observedm/z 567 .256723.Anal. 
60 Calcd. for C28H34N60 7 .0.3H20.0.2hexane: C, 59.52; H, 
6.40; N, 14.26. Found: C, 59.71; H, 6.18; N, 13.99. 
Example 31 
N2 -(N-Benzy loxycarbonylalanylalany I )-N 1 -carbamoy l-
methyl-N1-trans-(3-(methy lpheny lcarbamoy l)propenoy I) 
hydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON(CH3)Ph). 
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This compound was obtained using the HOBt/EDC coupling 
method. The product was isolated by chromatography with 
10% MeOH/CH2Cl2 as the eluent and recrystallized from 
hexane/EtOAc to give a white powder (34% yield). 1 H-NMR 
(DMSO-d6): 1.18-1.27 (m, 6H, 2xAla-CH3), 3.20-3.32 (m, 5 
SH, NCH2CO and N--CH3), 4.02-4.07 (m, lH, a-H), 4.30 
(m, lH, a-H), 4.99 (m, 2H, Cbz), 6.56 (d, lH, 
CH=CHCON), 7.06-7.10 (d, lH, CH=CHCON), 7.14 (s, 
lH, NH), 7.29-7.46 (m, llH, 2xPh, NH), 8.14 (d, lH, NH), 
10.65 (s, lH, NH). MS (ESI)m/z 553 [(M+ltJ. HRMS (ESI) 10 
calculated for C27H33N60 7: 553.2356. Observed m/z 
553.2411. Anal. Calcd. for C27H32N60 7: C, 58.69; H. 5.84; 
N, 15.21. Found: C, 58.43; H, 5.90; N, 15.20. 
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3.52-3.58 (m, 2H, N-CH2CH2Ph), 4.04-4.08 (m, lH, a-H), 
4.28-4.31 (m, lH, a-H), 4.99 (m, 2H, Cbz), 6.86-6.89 (d, lH, 
J=14.4 Hz, CH=CHCON), 7.04-7.08 (d, lH, J=14.8 Hz, 
CH=CHCON), 7.16-7.41 (m, 1 lH, 2xPh and NH), 7.50 (d, 
lH, NH), 8.16 (d, lH, NH), 10.72 (s, lH, NH). MS (ESI) m/z 
581 [(M+ltJ. HRMS (ESI) calculated for C29H37N60 7: 
581.2717. Observed m/z 581.272373. Anal. Calcd. for 
C29H36N60 7.0.6H20.0.lhexane: C, 59.25; H, 6.48; N, 14.01. 
Found: C, 59.27; H, 6.50; N, 13.82. 
Example3N 
N2 -(N-Benzy loxycarbonylalanylalany 1 )-N1-carbamoy1-
methyl-N 1 -trans-(3-pheny lbenzy lcarbamoylpropenoy l)hy-
Example3K 15 drazine (Cbz-Ala-Ala-AAsn-CH=CH--CON(Bzl)Ph). 
This compound was obtained using the HOBt/EDC coupling 
method and purified by colunm chromatography on silica gel 
using 10% MeOHICH2Cl2 as the eluent to give a white pow-
der (14% yield). 1H-NMR (DMSO-d6): 1.20-1.21 (d, 3H, 
20 Ala-CH3), 1.26 (d, 3H, Ala-CH3), 3.31 (s, 2H, NCH2CO), 
4.04-4.08 (m, lH, a-H), 4.28-4.31 (m, lH, a-H), 4.96-4.99 
(d, 4H, N--CH2-Ph and Cbz), 6.57-6.61 (d, lH, J=15.2 Hz, 
CH=CHCON), 7.14-7.45(m, 18H,CH=CHCONand3xPh 
and 2xNH), 8.16 (d, lH, NH), 10.71 (s, lH, NH). MS (ESI) 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1-carbamoy1-
methyl-N 1 -trans-(3-benzy lmethylcarbamoy lpropenoyl )hy-
drazine (Cbz-Ala-Ala-AAsn-CH=CH--CON(CH3)Bzl). 
This compound was synthesized using the HOBt/EDC cou-
pling method and purified by colunm chromatography on 
silica gel using 10% MeOH/CH2Cl2 as the eluent and then 
recrystallized from EtOAc/hexane to give a white powder 
(54% yield). 1H-NMR (DMSO-d6): 1.18-1.27 (m, 6H, 
2xAla-CH3), 2.89 (s, 3H, N--CH3), 3.20-3.32 (d, 2H, 
NCH2CO), 4.04-4.08 (m, lH, a-H), 4.28-4.31 (m, lH, a-H), 
4.57 (m, 2H, N-CH2-Ph), 4.99 (m, 2H, Cbz), 7.05-7.41 (m, 
13H, CH=CHCON and CH=CHCON and 2xPh and NH), 
7.49 (d, lH, NH), 8.16 (d, lH, NH), 10.72 (s, lH, NH). MS 
(ESI) m/z 567 [(M+lt]. HRMS (ESI) calculated for 30 
C28H35N60 7: 567.2604. Observed m/z 567.256723. Anal. 
Calcd. forC28H34N60 7.0.9H20: C, 57.70; H. 6.19; N. 14.42. 
Found: C, 57.91; H. 6.25; N, 14.27. 
Example 3L 
25 m/z 629 [(M+lt]. HRMS (ESI) calculatedforC33H37N60 7: 
629.2691. Observed m/z 629.272373. Anal. Calcd. for 
C33H36N60 7.0.09H20.0.17hexane: C, 62.15; H, 6.05; N, 
12.83. Found: C, 62.15; H, 5.96; N, 12.66. 
Example30 
N2 -(N-Benzy loxycarbonylalanylalanyl )-N 1 -carbamoy l-
methyl-N1 -trans-(3-dibenzylcarbamoy lpropenoyl )hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-CON(Bzl)2). This com-
pound was obtained using the HOBt/EDC coupling method 
35 and purified by colunm chromatography on silica gel using 
10% MeOH/CH2Cl2 as the eluent to give-a white powder 
(34% yield). 1-NMR (DMSO-d6): 1.19 (d, 3H, Ala-CH3), 
1.26 (d, 3H,Ala-CH3), 3.31(s,2H, NCH2CO), 4.04-4.08 (m, 
lH, a-H), 4.28-4.31 (m, lH, a-H), 4.56 (s, 2H, N-CH2-Ph), 
40 4.63 (s, 2H, N-CH2-Ph), 5.00 (m, 2H, Cbz), 7.13-7.41 (m, 
17H, CH=CHCON and CH=CHCON and 3xPh and NH), 
7.48 (s, lH, NH), 8.14 (d, lH, NH), 10.71 (s, lH, NH). MS 
(ESI) m/z 643 [(M+ltJ. HRMS (ESI) calculated for 
C34H39N60 7: 643.2843. Observed m/z 643.288023. Anal. 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -carbamoy l-
methyl-N1 -trans-(3-( methy 1-1-naphthylmethy lcarbamoy 1) 
propenoyl)hydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON 
(CH3)CH2-l-Napth). This compound was obtained using the 
HOBt/FDC coupling method and purified by colunm chro-
matography on silica gel using 10% MeOH/CH2Cl2 as the 
eluent and then recrystallized from EtOAc/hexane to give a 
yellow powder (31%yield). 1 H-NMR (DMSO-d6): 1.18-1.27 
(m, 6H, 2xAla-CH3), 3.10 (s, 3H, N-CH3), 3.20-3.32 (d, 
2H, NCH2CO), 4.04-4.08 (m, lH, a-H), 4.28-4.31 (m, lH, 
a-H), 4.99 (m, 4H, Cbz and N-CH2-naphthyl), 7.07-7.61 
(m, 12H, naphthyl and Ph CH=CHCON and CH=CHCON 
and NH), 7.85-8.10 (m, 3H, naphthyl), 8.15 (d, lH, NH), 
10.42 (s, lH, NH), 10.72 (s, lH, NH). MS (ESI) m/z 617 50 
[(M+ltJ. HRMS (ESI) calculated for C32H37N60 7: 
617.265. Observed m/z 617.2724. Anal. Calcd. for 
C32H36N60 7.0.5H20: C, 61.43; H, 5.96; N, 13.43. Found: C, 
61.48; H, 6.03; N, 13.25. 
45 Calcd. for C34H38N60 7: C, 63.54; H, 5.96; N, 13.08. Found: 
C, 63.75; H, 6.02; N, 12.81. 
Example 3P 
N2 -(N-Benzy loxycarbonylalanylalany 1)-N1 -trans-(3-
benzyl-( 4-methoxybenzy 1)carbamoy1)propenoy1-N 1 -car-
bamoylmethy lhydrazine (Cbz-Ala-Ala-AAsn-CH=CH-
CON(Bzl-4-0Me )Bzl). This compound was obtained using 
the HOBt/EDC coupling method and purified by recrystalli-
Example 3M 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -carbamoy l-
methyl-N1-trans-(3-(Methy lphenethy lcarbamoy 1 )prope-
noy l)hydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON 
(CH3)CH2CH2Ph). This compound was obtained using the 
HOBt/EDC coupling method and purified by colunm chro-
matography on silica gel using 10% MeOH/CH2Cl2 as the 
eluent and then recrystallized from EtOAc/hexane to give a 
white powder (28% yield). 1H-NMR (DMSO-d6): 1.18-1.27 
(m, 6H, 2xAla-CH3), 2.74-2.82 (m, 2H, N-CH2CH2Ph), 
4.04-4.08 (m, lH, NH), CH3), 3.20-3.32 (d, 2H, NCH2CO), 
55 zation from 10% MeOH/CH2Cl2 to give a yellow powder 
(9%. yield). 1H-NMR (DMSO-d6): 1.19-1.20 (d, 3H, Ala-
CH3), 1.26-1.28 (d, 3H, Ala-CH3), 3.32 (s, 2H, NCH2CO), 
3.72 (s, 3H, OCH3), 4.04-4.09 (m, lH, a-H), 4.28-4.32 (m, 
lH, a-H), 4.48-4.54 (d, 2H, N--CH2-Ph), 4.54-4.59 (d, 2H, 
60 N--CH2-Ph), 5.00 (m, 2H, Cbz), 6.84-6.91 (2xd, 2H, Ph), 
7.06-7.08 (d, lH, J=8.8 Hz, CH=CHCON), 7.12-7.42 (m, 
14H, CH=CHCON and 3xPh and NH), 7.50 (s, lH, NH), 
8.16-8.17 (d, lH, NH), 10.71 (s, lH, NH). MS (ESI) m/z 673 
[(M+ltJ. HRMS (ESI) calculated for C35H41N60 8: 
65 673.3001. Observed m/z 673.298588. Anal. Calcd. for 
C35H40N60 8.0.5CH2Cl2: C, 59.61; H, 5.78; N, 11.75. Found: 
C, 59.76; H, 5.71; N, 11.54. 
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Example3Q 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -trans-(3-
benzyl( 4-fluoro benzyl )carbamoylpropenoy 1)-N1 -carbam-
oy lmethy lhydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON 
(Bzl-4-F)Bzl). This compound was obtained using the H 0 Bt/ 
EDC coupling method and purified by column 
chromatography using 10% MeOH/CH2Cl2 as the eluent. 
Recrystallization with hexane/EtOAc gave a white powder 
(11% yield). 1H-NMR (DMSO-d6): 1.19-1.20 (d, 3H, Ala-
CH3), 1.26-1.28 (d, 3H, Ala-CH3), 3.32 (s, 2H, NCH2CO), 
4.05-4.09 (m, lH, a-H), 4.28-4.32 (m, lH, a-H), 4.35 (s, 2H, 
CH2 Ph), 4.62-4.64 (d, 2H, N-CH2 -Ph), 5.00 (m, 2H, Cbz), 
7 .09-7 .34 (m, 17H, CH=CHCON and CH=CHCON and 
3xPh and NH), 7.40-7.42 (d, lH, NH), 7.50 (s, lH, NH), 
8.15-8.16 (d, lH, NH), 10.71 (s, lH, NH). MS (ESI) m/z 661 
[(M+ltJ. HRMS (ESI) calculated for C34H38N60 7F: 
661.2781. Observed m/z 661.278601. Anal. Calcd. for 
74 
Example 3T 
N2 -(N-Benzy loxycarbonylalanylalany I )-N 1 -trans-(3-
benzyl-1-naphthy lmethylcarbamoy lpropenoyl )-N1-carbam-
oylmethylhydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON 
(Bzl)-1-CH2 -Napth). This compound was obtained using the 
HOBt/EDC coupling method and purified by colunm chro-
matography on silica gel using 10% MeOH/CH2Cl2 as the 
10 eluent and then recrystallized from EtOAc/hexane to give a 
white powder (17% yield). 1H-NMR (DMSO-d6 ): 1.19-1.29 
(m, 6H, 2xA!a-CH3), 3.30-3.32 (d, 2H, NCH2 CO), 4.04-4.08 
(m, lH, a-H), 4.29-4.33 (m, lH, a-H), 4.64-4.67 (d, 2H, 
N--CH2 ), 4.99 (m, 2H, Cbz), 5.06-5.17 (d, 2H, N-CH2 ), 15 7.14-7.48 (m, 18H, naphthyl and 2xPh and CH=CHCON 
and CH=CHCON and 2xNH), 7 .84-7 .90 (m, 3H, naphthyl), 
8.15 (d, lH, NH), 10.72 (s, lH, NH). Anal. Calcd. for 
C33H40N60 7.0.2H2 0: C, 65.54; H, 5.85; N, 12.07. Found: C, 
C34H37N60 7F.0.35H2 0: C, 61.22; H, 5.70; N, 12.60. Found: 20 
C, 61.16; H, 5.71; N, 12.60. 
65.54; H, 5.93; N, 11.81. 
Example3U 
Example3R 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1-carbamoy1-
methyl-N 1 -trans-(3-bis-(2-furylmethy l)carbamoy lprope-
25 
N2 -(N-Benzy loxycarbonylalanylalany I )-N 1-carbamoy1-
methyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-yloxo )pro-
noy l)hydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON 
(CH2 -2-furyl)2 ). This compound was obtained using the 
HOBt/EDC coupling method. The product was isolated by 30 
chromatography with 10% MeOH/CH2 Cl2 as the eluent and 
recrystallized from hexane/EtOAc to give a white powder 
(34% yield). 1H-NMR (DMSO-d6 ): 1.18-1.27 (m, 6H, 
2xA!a-CH3), 2.92 (d, lH, fury!), 3.28-3.38 (m, 4H, N-CH2 
and NCH2 CO and fury!), 3.47-3.50 (d, lH, N-CH2 ), 3.99- 35 
4.07 (m, 2H, a-Hand N--CH2 ), 4.30-4.49 (m, 2H, a-Hand 
N-CH2 ), 4.99 (m, 2H, Cbz), 6.02 (s, lH, NH), 6.11 (s, lH, 
NH), 6.31(s, lH, CH=CHCON), 6.39 (s, lH, 
CH=CHCON), 6.55 (t, lH, fury!), 7.12 (s, lH, NH), 7.32 (m, 
40 SH, Ph), 7.41-7.59 (m, 3H, fury!), 8.21 (d, lH, NH), 10.58 (s, 
penoy !)hydrazine ( Cbz-Ala-Ala-AAsn-CH=CH-CO-tet-
rahydroquinoline). This compound was obtained using the 
HOBt/EDC coupling method and purified by colunm chro-
matography on silica gel using 10% MeOH/CH2Cl2 as the 
eluent and then recrystallized from EtOAc/hexane to give a 
yellow powder (28% yield). 1 H-NMR (DMSO-d6 ): 1.18-1.27 
(m, 6H, 2xA!a-CH3), 1.87 (m, 2H, N-CH2-CH2-CH2 ), 
2.70 (t, 2H, N--CH2-CH2-CH2 ), 3.29-3.32 (d, 2H, 
NCH2CO), 3.73 (m, 2H, N-CH2-CH2 ), 4.02-4.06 (m, lH, 
a-H), 4.31 (m, lH, a-H), 4.99 (m, 2H, Cbz), 7.02-7.07 (dd, 
2H, J=14.8 Hz, CH=CHCON), 7.15-7.41 (m, llH, quino-
line and Ph and NH and CH=CHCON), 7.49 (s, lH, NH), 
8.16 (d, lH, NH), 10.73 (s, lH, NH). MS (ESI) m/z 579 
[(M+ltJ. HRMS (ESI) calculated for C29H35N60 7: 
579.2525. Observed m/z 579.2567. Anal. Calcd. for lH, NH). MS (ESI) m/z 623 [(M+ltJ. HRMS (ESI) calcu-
lated for C30H35N60 9 : 623.2486. Observed m/z 623.2466. 
Anal. Calcd. for C30H34N60 9 .1H20: C, 56.24; H, 5.66; N, 
13.12. Found: C, 56.38; H, 5.58; N, 13.15. 
Example 3S 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -trans-(3-
benzyl-2-naphthy lmethy lcarbamoy lpropenoy 1)-N1 -carbam-
oy lmethy lhydrazine (Cbz-Ala-Ala-AAsn-CH=CH--CON 
(Bzl)-2-CH2 -Napth). This compound was obtained using the 
HOBt/EDC coupling method and purified by colunm chro-
matography on silica gel using 10% MeOH/CH2Cl2 as the 
eluent and then recrystallized from EtOAc/hexane to give a 
yellow powder (11%yield). 1 H-NMR (DMSO-d6 ): 1.18-1.28 
(m, 6H, 2xA!a-CH3), 3.29-3.32 (d, 2H, NCH2CO), 4.04-4.08 
(m, lH, a-H), 4.28-4.31 (m, lH, a-H), 4.63-4.69 (d, 2H, 
N-CH2 ), 4.73-4.80 (d, 2H, N--CH2 ), 4.99 (m, 2H, Cbz), 
7.14-7.48 (m, 18H, naphthyl and 2xPh and CH=CHCON 
and CH=CHCON and 2xNH), 7.84-7.90 (m, 3H, naphthyl), 
8.15 (d, lH, NH), 10.72 (s, lH, NH). MS (ESI) m/z 693 
[(M+ltJ. HRMS (ESI) calculated for C38H41N60 7: 
693.2998. Observed m/z 693.303673. Anal. Calcd. for 
C33H40N60 7.0.63H2 0: C, 64.82; H, 5.91; N, 11.94. Found: 
C, 64.83; H, 6.02; N, 11.83. 
45 
C29H34N60 7.0.7H2 0: C, 58.91; H, 6.03; N, 14.21. Found: C, 
58.87; H, 6.00; N, 14.24. 
Example3V 
N2 -(N-Benzy loxycarbonylalanylalany I )-N 1 -carbamoy l-
methyl-N1-trans-(3-(3 ,4-dihydro-2H-quinolin-1-y loxo )pro-
50 penoy !)hydrazine ( Cbz-Ala-Ala-AAsn-CH=CH-CO-tet-
rahydroisoquinoline ). This compound was obtained using the 
HOBt/EDC coupling method and purified by colunm chro-
matography on silica gel using 10% MeOH/CH2Cl2 as the 
eluent and then recrystallized from EtOAc/hexane to give a 
55 yellow powder (28% yield). 1 H-NMR (DMSO-d6 ): 1.18-1.27 
(m, 6H, 2xA!a-CH3), 1.87 (m, 2H, N-CH2-CH2-CH2 ), 
2.70 (t, 2H, N--CH2-CH2-CH2 ), 3.29-3.32 (d, 2H, 
NCH2CO), 3.73 (m, 2H, N-CH2-CH2 ), 4.02-4.06 (m, lH, 
60 a-H), 4.31 (m, lH, a-H), 4.99 (m, 2H, Cbz), 7.02-7.07 (dd, 
2H, J=14.8 Hz, CH=CHCON), 7.15-7.41 (m, llH, quino-
line and Ph and NH and CH=CHCON), 7.49 (s, lH, NH), 
8.16 (d, lH, NH), 10.73 (s, lH, NH). MS (ESI) m/z 579 
[(M+ltJ. HRMS (ESI) calculated for C29H35N60 7: 
65 579.2525. Observed m/z 579.2567. Anal. Calcd. for 
C29H34N60 7.0.9H2 0.0.lhexane: C, 58.92; H, 6.21; N, 13.92. 
Found: C, 58.81; H, 6.04; N, 13.79. 
US 7,482,379 B2 
75 
Example 3W 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -carbamoy l-
methyl-N1-trans-(3-(2,3-dihydroindol-1-yloxo )propenoyl) 
hydrazine ( Cbz-Ala-Ala-AAsn-CH=CH--CO-indoline ). 
This compound was obtained using the HOBt/EDC coupling 
method and purified by colunm chromatography on silica gel 
using 10% MeOH/CH2Cl2 as the eluent and then recrystal-
lized from EtOAc/hexane to give a bright yellow, flaky pow- 10 
der (IS% yield). 1H-NMR (DMSO-d6): 1.18-1.19 (d, 3H, 
Ala-CH3), 1.27-1.28 (d, 3H, Ala-CH3), 3.lS (t, 2H, 
N-CH2CH2), 3.20-3.31 (d, 2H, NCH2CO), 4.02-4.06 (m, 
lH, a-H), 4.06 (t, 2H, N-CH2--CH2), 4.31 (m, lH, a-H), 
4.99 (m, 2H, Cbz), 7.02 (t, lH, indoline-H), 7.13-7.41 (m, 15 
1 OH, indoline and Ph and NH and CH=CHCON and 
CH=CHCON), 7.S2 (s, lH, NH), 8.13 (d, lH, NH), 8.lS-
8.16 (d, lH, indoline-H), 10.76 (s, lH, NH). MS (ESI) m/z 
S6S [(M+ltJ. HRMS (ESI) calculated for C28H33N60 7: 
S6S.24l6. Observed m/z S6S.24l073. Anal. Calcd. for 20 
C23H32N60 7.0.4H20: C, S8.82; H, S.78; N, 14.70. Found: C, 
S8.87; H, S.82; N, 14.68. 
Example3X 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -carbamoy l-
methyl-N1-trans-(3-( 1,3-dihydroisoindol-2-y loxo )prope-
25 
noy l)hydrazine (Cbz-Ala-Ala-AAsn-CH=CH-CO-isoin-
doline ). This compound was obtained using the HOBt/EDC 30 
coupling method and purified by colunm chromatography on 
silica gel using 10% MeOH/CH2Cl2 as the eluent and then 
recrystallized from EtOAc/hexane to give a bright yellow, 
flaky powder (IS% yield). 1H-NMR (DMSO-d6): 1.18-1.19 
(d, 3H,Ala-CH3), 1.27-1.28 (d, 3H,Ala-CH3), 3.20-3.31 (d, 35 
2H, NCH2CO), 4.04-4.07 (m, lH, a-H), 4.29-4.33 (m, lH, 
a-H), 4.72 (s, 2H, NCH2), 4.99 (m, 2H, Cbz and NCH2), 
7.11-7.32 (m, llH, indoline and Ph and NH and 
CH=CHCON and CH=CHCON), 7.39 (d, lH, NH), 7.S2 
(s, lH, NH), 8.14 (d, lH, NH), 10.76 (s, lH, NH). MS (ESI) 40 
mlz S6S [ (M + 1 tl. HRMS (ESI) calculated for C28H33N 60 7: 
76 
Example 3Z 
N2 -(N-Benzy loxycarbonylalanylalany I )-N1 -carbamoy l-
methyl-N1-trans-(3-methyl-( 1-methylphenethy lcarbamoyl) 
pheny lethylcarbamoy lpropenoyl )hydrazine ( Cbz-Ala-Ala-
AAsn-CH=CH--CO-Phe(Me )-N(Me )(CH2)2Ph). This 
compound was obtained using the HOBt/EDC coupling 
method and purified by colunm chromatography using 10% 
MeOH/CH2Cl2 as the eluent. Recrystallization with hexane/ 
EtOAc gave a yellow powder (11%yield). 1 H-NMR (DMSO-
d6): 1.19-1.20 (d, 3H,Ala-CH3), 1.26-1.28 (d, 3H,Ala-CH3), 
2.6l-2.9S (m, !OH, Phe-CH2 and CH2Ph and 2xN-Me), 3.32 
(s, 2H, NCH2CO), 3.62 (m, 2H, N--CH2), 4.0S-4.09 (m, lH, 
a-H), 4.28-4.32 (m, lH, a-H), 4.99 (m, 2H, Cbz), S.S2 (m, 
lH, a-H), 6.93-7.32 (m, 18H, CH=CHCON and 
CH=CHCON and 3xPh and NH), 7.40-7.42 (d, lH, NH), 
7.SO (s, lH, NH), 8.lS-8.16 (d, lH, NH), 10.71 (s, lH, NH). 
MS (ESI) m/z 607 [(M-HN(CH3)CH2CH2Ph+l, lOO%tJ. 
HRMS (ESI) calculated for C39H48N70 8: 742.3S7S. 
Observed m/z 742.3S64. Anal. Calcd. for 
C39H47N70 3.1.23H20.0.3hexane: C, 62.09; H, 6.78; N, 
12.42. Found: C, 61.99; H, 6.62; N, 12.49. 
Example3AA 
trans-N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -car-
bamoy Imethyl-N 1 -trans-(3-benzoy lpropenoy !)hydrazine 
(Cbz-Ala-Ala-AAsn-CH=CH-COPh). This compound 
was obtained using the HOBt/EDC coupling method starting 
from the peptide precursor Z-Ala-Ala-NHNHCH2CONH2 
and commercially available trans-3-benzoylacrylic acid. The 
workup omitted the NaHC03 washings. The crude product 
was purified by column chromatography on silica gel using 
10% MeOH/CH2Cl2 as the eluent and then washed with 
EtOAc to give a white powder (39% yield). 1H-NMR 
(DMSO-d6): 1.18-1.27 (m, 6H, 2xA!a-CH3), 3.20-3.32 (d, 
2H, NCH2CO), 3.98-4.0S (m, lH, a-H), 4.26-4.29 (m, lH, 
a-H), 4.99 (m, 2H, Cbz), 7.14-7.21 (m, 2H, CH=CHCOPh 
and NH), 7 .32-7 .3S (m, SH, Ph), 7 .S4 (t, 2H, Ph), 7 .69 (t, lH, 
Ph), 7.76-7.80(d, 1H,J=lS.6Hz,CH=CHCOPh), 7.97-7.99 
(d, 2H, Ph), 8.14 (d, lH, NH), 10.77 (s, lH, NH). MS (ESI) 
S6S.24l4. Observed m/z S6S.24l073. Anal. Calcd. for 
C23H32N60 7.0.3H20: C, S9.00; H, S.76; N, 14.74. Found: C, 
S9.04; H, S.S4; N, l4.S6. 45 m/z S24 [(M+lt]. HRMS (ESI) calculatedforC26H30N50 7: S24.20S6. Observed m/z S24.2l4S. Anal. Calcd. for 
C26H29N5 0 7: C, S9.6S; H, S.S8; N, 13.38. Found: C, S9.42; 
H, S.SO; N, 13.16. 
Example3Y 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -carbamoy l-
methyl-N1-trans-(3-( 4-phenyl-S,6-dihydro-2H-pyridin-1- 50 
yloxo )propenoyl)hydrazine (Cbz-Ala-Ala-AAsn-
CH=CH-C0-( 4-Ph-Py)). This compound was obtained 
using the HOBt/EDC coupling method and purified by col-
unm chromatography using 10% MeOH/CH2Cl2 as the elu-
ent to give a white solid (11%yield). 1H-NMR (DMSO-d6): 55 
l.lS-1.26 (m, 6H, 2xA!a-CH3), 2.S6 (s, 2H, pyridyl-CH2), 
3.30-3.32 (d, 2H, NCH2CO), 3.74 (t, 2H, pyridyl-CH2), 4.02-
4.07 (m, lH, a-H), 4.17 (s, 2H, pyridyl-CH2), 4.27-4.3S (m, 
lH, a-H), 4.99 (m, 2H, Cbz), 6.16 (s, lH, pyridyl-CH=), 60 
7.02-7.06 (d, lH, J=lS.2 Hz, CH=CHCON), 7.19 (s, lH, 
NH), 7.23-7.42 (m, llH, CH=CHCON and 2xPh), 7.Sl (d, 
lH, NH), 8.14-8.lS (d, lH, NH), 10.72 (s, lH, NH). MS (ESI) 
mlz 60S [(M+ltJ. HRMS (ESI) calculated forC31 H37N60 7: 
60S.27S7. Observed m/z 60S.272373. Anal. Calcd. for 65 
C31H36N60 7.1H20: C, S9.80; H, 6.lS; N, 13.SO. Found: C, 
S9.7l; H, 6.02; N, 13.27. 
Example3BB 
N2 -(N-Benzy loxycarbonylalanylalany I )-N1 -carbamoy l-
methyl-N 1-trans-trans-hexa-2,4-dienoy lhydrazine (Cbz-
Ala-Ala-AAsn-CH=CHCH=CHCH3). This compound 
was synthesized by coupling the peptide precursor Z-Ala-
Ala-NHNHCH2CONH2 and commercially available 2,4-
hexadienoic acid using HOBt/EDC and was purified by col-
unm chromatography on silica gel using 10% MeOH/CH2Cl2 
as the eluent and then recrystallized from CH2Cl2/hexane to 
give a white powder (14% yield). 1H-NMR (DMSO-d6): 
1.18-1.24 (m, 6H, 2xA!a-CH3), 1.79 (d, 3H, CH3-
CH=CH-), 3.30-3.32 (d, 2H, NCH2CO), 4.06 (m, lH, 
a-H), 4.2S (m, lH, a-H), 4.98 (m, 2H, Cbz), 6.19 (m, 3H, 
CH3-CH=CH-CH), 7.21 (m, 2H, NH and CH=CH-
CO), 7.33 (m, SH, Ph), 7.S (d, lH, NH), 8.19 (d, lH, NH), 
l0.S3 (s, lH, NH). MS (ESI)m/z460 [(M+lt]. HRMS (ESI) 
calculated for C22H30N50 6: 460.21S7. Observed m/z 
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460.219609. Anal. Calcd. for C22H29N50 6.0.3Et0Ac: C, 
S7.39; H, 6.44; N, 14.42. Found: C, S7.14; H, 6.72; N, 14.44. 
Example3CC 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N 1 -carbamoy l-
methyl-N1-trans-(3-(2-fury l )propenoy l)hydrazine (Cbz-Ala-
Ala-AAsn-CH=CH-2-furyl). This compound was obtained 
using the HOBt/EDC coupling method starting with the pep-
tide precursor Cbz-Ala-Ala-NHNHCH2CONH2 and com- 10 
mercially available 2-furylacrylic acid and purified by col-
unm chromatography on silica gel using 10% MeOH/CH2Cl2 
as the eluent. Recrystallization from hexane/EtOAc gave a 
whitepowder(23%yield). 1H-NMR((CD3)CO): 1.37 (d, 3H, 
Ala-CH3), 1.44 (d, 3H, Ala-CH3), 2.88 (s, 2H, NCH2CO), 15 
4.24 (m, lH, a-H), 4.S2 (m, lH, a-H), S.10 (m, 2H, Cbz), 
6.41 (m, lH, furyl-H), 6.SS (m, lH, furyl-H), 6.68 (m, lH, 
CH=CH-CON), 6.88 (s, 2H, NH2), 7.31-7.36 (m, SH, Ph), 
7.39-7.43 (d, lH, J=lS.6 Hz, CH=CHCON), 7.48 (s, lH, 
NH), 7.6S (s, lH, furyl-H), 7.81 (s, lH, NH), 9.83 (s, lH, 20 
NH). MS (ESI) m/z 486 [(M+lt]. HRMS (ESI) calculated 
forC23H28N50 7 : 486.19S7. Observedm/z486.198874.Anal. 
Calcd. for C23H27N50 7 .0.3H20.0.lhexane: C, S6.l4; H, 
S.91; N, 13.87. Found: C, S6.09; H, S.8S; N, 13.78. 
25 
Example3DD 
78 
C21 H27N30 8: 449.1798; Observed m/z: 449.1876. Anal. 
Calcd. forC21 H27N30 8.0.29H20: C, SS.47; H, 6.13; N, 9.26. 
Found: C, SS.47; H, 6.11; N, 9.24. 
Example4B 
N2 -(N-Benzyloxycarbonylvalyl)-N1-trans-(but-2-
enoyl)-N1-carboxymethylhydrazine (Cbz-Val-AAsp-
CH=CHCH3). HRMS (ESI) Calcd. for C19H25N30 6; 
391.1822; Observed m/z: 391.1797. 
Example4C 
N2 -(N-Benzy loxyearbonylvalyl )-N1 -carboxymethy l-
N1-trans-(hexa-2,4-dienoy l)hydrazine (Cbz-Val-AAsp-
CH=CHCH=CHCH3). 1 H NMR (DMSO-d6): 0.90 ( d, 6H, 
Val), 1.78 (d, 3H, CH3), 1.97 (m, lH, Val), 3.87 (t, lH, a-H), 
S.OS (q, 2H, Cbz), 6.14 (m, 2H, db), 6.38 (m, lH, db), 7.09 
(dd, 2H, db), 7.33 (m, SH, Ph), 7.S9 (d, lH, NH), 10.81 (s, lH, 
NH-N). HRMS (ESI) Calcd. for C21 H27N30 6: 417.1978; 
Observed m/z: 417.1974. Anal. Calcd. for 
C21 H27N30 6.l.43H20.0.0STFA: C, S6.4S; H, 6.72; N, 9.36. 
Found: C, S6.36; H, 6.43; N, 9.66. 
Example4D 
N2 -(N-Benzy loxycarbonylvalyl )-N 1 -carboxymethy l-
N1-trans-(3-phenethy lpropenoy l )hydrazine (Cbz-Val-AAsp-
CH=CHCH2CH2Ph). HRMS (ESI) Calcd. forC26H31 N30 6: 
30 482.2291; Observed m/z: 482.2301. Anal. Calcd. for 
C26H31N30 6.0.84H20: C, 62.87; H, 6.63; N, 8.46. Found: C, 
62.87; H, 6.Sl; N, 8.28. 
N2 -(N-Benzy loxycarbony lalanylalanyl )-N1 -carbamoy l-
methyl-N1-trans-(3-(3-pyridy l )propenoy l)hydrazine (Cbz-
Ala-Ala-AAsn-CH=CH-3-Py). This compound was 
obtained using the H 0 Bt/EDC coupling method starting from 
the peptide precursor Z-Ala-Ala-NHNHCH2CONH2 and 
commercially available 3-pyridyl acrylic acid. Upon comple-
tion of the reaction sat. NaHC03 was added, and the volatiles 
were evaporated. Without further workup, the crude product 35 
was chromatographed on silica gel using 10% to 20% MeOH/ 
CH2Cl2 as the eluent and recrystallized from hexane/EtOAc 
togiveawhitepowder(7%yield). 1H-NMR((CD3)CO): 1.37 
Example4E 
N2 -(N-Benzy loxycarbonylvalyl )-N 1 -carboxymethy I-
(d, 3H, Ala-CH3), 1.44 (d, 3H, Ala-CH3), 2.91 (s, 2H, 
NCH2CO), 4.24 (m, lH, a-H), 4.42 (m, lH, a-H), S.10 (m, 40 
2H, Cbz), 6.S3 (m, lH, pyridine-H), 6.68 (d, lH, 
CH=CHCON), 7.31-7.36 (m, SH, Ph), 7.S9-7.64 (m, lH, 
NH and CH=CHCON), 7.98 (s, lH, pyridine-H), 8.32 (s, 
lH, NH), 7.S3 (s, lH, pyridine-H), 8.90 (s, lH, pyridine-H), 
10.08 (s, lH, NH). MS (ESI)m/z497 [(M+lt]. HRMS (ESI) 45 
calculated for C24H29N60 6: 497.2078. Observed m/z 
497.2149. Anal. Calcd. for C24H28N60 6.1H20: C, S6.02; H, 
S.88; N, 16.33. Found: C, S6.2l; H, S.77; N, 16.93. 
N 1 -cis-(3-chloropropenoy I )hydrazine ( Cbz-Val-AAsp-cis-
CH=CH-Cl). 1 H NMR (DMSO-d6): 0.86 ( d, 6H, Val), 1.93 
(m, lH, Val), 3.84 (t, lH, a-H), S.Ol (s, 2H, Cbz), 6.S7 (s, lH, 
db), 6.76 (d, lH, db), 7.29-7.34 (m, SH, Ph), 7.S3 (d, lH, NH), 
10.80 (s, lH, NH-N). HRMS (ESI) Calcd. for 
C18H22N30 6Cl: 411.127S; Observed m/z: 411.119S. Anal. 
Calcd. for C18H22N30 6Cl.0.04H20: C, S2.40; H, S.39; N, 
1019. Found: C, S2.40; H, S.46; N, 10.30. 
Example 4F 
N2 -(N-Benzy loxycarbonylvalyl )-N 1 -carboxymethy l-
Example 4 
Deb locking of the t-Buty I Protecting Group in the Aza-Asp 
Peptide Inhibitors. The aza-peptide inhibitors were treated 
with 1:1 TFA: CH2Cl2 at0° C. for 1 hand at room temperature 
for 2 h. TFA and CH2Cl2 were removed under vacuum and the 
final products were recrystallized from ether/hexanes mostly 
as white solids. 
Example4A 
N2 -(N-Benzy loxycarbony lvalyl )-N1-carboxymethy1-
N 1 -trans-(3-ethoxycarbonylpropenoyl)hydrazine (Cbz-Val-
AAsp-CH=CH-COOEt ). 1H NMR (DMSO-d6): 0.87 (d, 
6H, Val), 1.lS-1.23 (m, 3H, OCH2CH3), 1.98 (m, lH, Val), 
3.89 (t, lH, a-H), 4.13 (q, 2H, OCH2CH3), S.03 (s, 2H, Cbz), 
6.6S (d, lH, db), 7.28-7.34 (m, 6H, db and Ph), 7.S4 (d, lH, 
NH), 11.00 (s, lH, NH). HRMS (FAB) Calcd. for 
N1-trans-(3-( 4-chloropheny l)propenoy !)hydrazine ( Cbz-
50 Val-AAsp-CH=CH-Ph-4-Cl). 1H NMR (DMSO-d6): 0.86-
0.9S (dd, 6H, Val), 1.94 (m, lH, Val), 3.84 (t, lH, a-H), S.03 
(q, 2H, Cbz), 7.27-7.32 (m, SH, Ph), 7.42 (d, lH, db), 7.SS (d, 
lH, db), 7.77 (m, 4H, Ph-Cl), 10.97 (s, lH, NH-N). HRMS 
(ESI) Calcd. for C24H26N30 6Cl: 488.1S88; Observed m/z: 
55 488.1S63. Anal. Calcd. for C24H26N30 6Cl.0.29H20: C, 
S8.4S; H, S.43; N, 8.Sl. Found: C, S8.46; H, S.43; N, 8.Sl. 
Example4G 
60 N2 -(N-Benzyloxycarbonylvalyl)-N1-trans-(3-butylcar-
bamoylpropenoyl)-N1-carboxymethylhydrazine (Cbz-Val-
AAsp-CH=CH--CONH-nBu). 1HNMR(DMSO-d6): 0.83-
0.87 (m, 9H, Val and NHCH2CH2CH2CH3), 1.27 (m, 2H, 
NHCH2CH2CH2CH3), 1.37-1.41 (m, 2H, 
65 NHCH2CH2CH2CH3), 1.97 (m, lH, Val), 3.12 (dd, 2H, 
NHCH2CH2CH2C3), 3.93 (t, lH, a-H), S.03 (q, 2H, Cbz), 
6.91 (d, lH, db), 7.08 (d, lH, db), 7.28-7.34 (m, SH, Ph), 7.47 
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(d, lH, NH), 8.37 (t, lH, NHCH2CH2CH2CH3), 10.93 (s, lH, 
NH-N). HRMS (ESI) Calcd. for C23H32N40 7 : 477.2349; 
Observed m/z: 477.23S7. Anal. Calcd. for 
C23H32N40 7 .0.46H20: C, S6.98; H, 6.84; N, 11.S6. Found: 
C, S6.99; H, 6.8S; N, l l.S6. 
Example4H 
N 1 -trans-(3-Benzy lcarbamoy lpropenoy l)-N2 -(N-benzy-
loxycarbony lvalyl )-N 1 -carboxymethy !hydrazine ( Cbz-Val-
AAsp-CH=CH-CONHCH2Ph ). 1H NMR (DMSO-d6): 
0.8S (d, 6H, Val), 1.97 (m, lH, Val), 3.96 (t, lH, a-H), 4.3S (d, 
2H, NHCH2Ph), S.01(s,2H, Cbz), 6.97 (d, lH, db), 7.lS (d, 
lH, db), 7.19-7.32 (m, lOH, Ph), 7.47 (d, lH, NH), 8.91 (t, 
lH, NHCH2Ph), 10.94 (s, lH, NH-N). HRMS (ESI) Calcd. 
for C26H30N40 7 : Sl0.2193; Observed m/z: Sl0.2208. Anal. 
Calcd. for C26H30N40 7 .0.S6H20: C, S9.98; H, 6.02; N, 
10.79. Found: C, S9.99; H, 6.08; N, 10.76. 
Example 41 
N2 -(N-Benzy loxycarbony lglutamy lvalyl )-N 1 -car-
boxymethyl-N1 -trans-(3-ethoxycarbony lpropenoy I )hydra-
zine (Cbz-Glu-Val-AAsp-CH=CH-COOEt). 1H NMR 
(DMSO-d6): 0.84 (m, 6H, Val), 1.20-1.21(t,3H, OCH2CH3), 
1.70-2.10 (m, 3H, Val, Glu), 2.21 (m, 2H, Glu), 2.40 
(CH=CH--COOEt) 4.0S-4.22 (m, 4H, NCH2COOH and 
OCH2CH3), 4.S0-4.60 (m, 2H, a-H), S.OS (m, 2H, Cbz), 7.12 
(CO--CH=CH-COOEt) 7.20-7.40 (m, SH, Ph), 7.60 (lH, 
NH), 7.8S (m, 2H, NH), 11.00 (m, COOH). HRMS (FAB) 
Calcd. forC26H35N40 11 : S79.2302; Observedm/z S79.2342. 
Anal. Calcd. for C26H34N40 11 : C, S3.97; H, S.92; N, 9.68. 
Found: C, S4.30; H, 6.12; N, 9.47. 
Example 41 
80 
Observed m/z: 693.2S16. Anal. Calcd. for 
C30H39N50wlH20: C, S0.63; H, S.81; N, 9.67. Found: C, 
S0.61; H, S.82; N, 9.67. 
Example4L 
N 1 -trans-(3-Benzy loxycarbonylpropenoy l)-N2 -(N-ben-
zyloxycarbony laspartylglutamylvaly l )-N1-carboxymethyl-
hydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH-
10 COOCH2Ph). 1H NMR (DMSO-d6): 0.81 (d, 6H, Val), 1.74 
(m, lH, Glu), 1.86 (m, lH, Glu), l.9S (m, lH, Val), 2.18 (m, 
2H, Glu), 2.4S (dd, lH,Asp), 2.61 (dd, lH,Asp), 4.13 (t, lH, 
a-H), 4.29 (m, 2H, a-H), 4.99 (s, 2H, Cbz), S.18 (s, 2H, Bzl), 
6.69 (d, lH, db), 7.2S-7.37 (m, 1 lH, Ph, and db), 7.60 (d, lH, 
15 NH), 7.93 (t, 2H, NH), 11.02 (s, lH, NH-N). HRMS (ESI) 
Calcd. for C35H41N50 14: 7SS.2728; Observed m/z: 
7SS.263 l. Anal. Calcd. for C35H41 N50w0.S9H20: C, S4.86; 
H, S.SS; N, 9.14. Found: C, S4.86; H, S.67; N, 9.11. 
20 Example4M 
N1 -trans-(3-Benzylcarbamoylpropenoyl)-N2 -(N-benzy-
loxycarbonylasparty lglutamy lvaly 1)-N 1 -carboxymethy !hy-
drazine (Cbz-Asp-Glu-Val-AAsp-CH=CH-
25 CONHCH2Ph). 1 H NMR (DMSO-d6): 0.8S (t, 6H, Val), l.7S 
(m, lH, Glu), 1.88 (m, lH, Glu), 2.01 (m, lH, Val), 2.19 (m, 
2H, Glu), 2.48 (dd, lH, Asp), 2.61 (dd, lH, Asp), 4.17 (t, lH, 
a-H), 4.30 (m, 2H, a-H), 4.3S (d, 2H, NHCH2Ph), S.00 (s, 
2H, Cbz), 6.96 (d, lH, db), 7.12 (d, lH, db), 7.21-7.32 (m, 
30 lOH, Ph), 7.S8 (d, lH, NH), 7.90 (d, lH, NH), 7.96 (d, lH, 
NH), 8.92 (t, lH, NHCH2Ph), 10.97 (s, lH, NH-N). HRMS 
(ESI) Calcd. for C35H42N60 13: 7S4.2888; Observed m/z: 
7S4.28S3.Anal. Calcd. forC35H42N60 13 .l.63H20: C, S3.6l; 
H, S.82; N, 10.72. Found: C, S3.82; H, S.74; N, 10.42. 
35 
Example4Q 
N2 -(N-Benzy loxycarbony !asp arty lglutamy lthreony I)- 40 
N2 -(N-Benzy loxycarbonylasparty lglutamy lvaly l)-N1-
carboxymethy I-N 1 -trans-(3-phenethy lcarbamoy lpropenoyl) 
hydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH-
CONHCH2CH2Ph). 1H NMR (DMSO-d6): 0.87 (t, 6H, Val), 
l.7S (m, lH, Glu), 1.89 (m, lH, Glu), 2.01 (m, lH, Val), 2.21 
(m, 2H, Glu), 2.46 (dd, lH,Asp), 2.62 (dd, lH,Asp), 2.73 (t, 
2H, NHCH2CH2Ph), 3.73 (d, 2H, NHCH2CH2Ph), 4.18 (t, 
lH, a-H), 4.32 (m, 2H, a-H), S.Ol (s, 2H, Cbz), 6.89 (d, lH, 
db), 7.08 (d, lH, db), 7.16-7.32 (m, lOH, Ph), 7.S9 (d, lH, 
NH), 7.89 (d, lH, NH), 7.98 (d, lH, NH), 8.S2 (t, lH, 
NHCH2CH2Ph), 10.97 (s, lH, NH-N). HRMS (ESI) Calcd. 
forC36H44N60 13 : 768.3044; Observedm/z: 768.2949.Anal. 
Calcd. for C36H44N60 13 .l.22H20: C, S4.68; H, S.92; N, 
10.63. Found: C, S4.86; H, S.91; N, 10.33. 
N 1 -carboxy lmethyl-N 1 -trans-(3-ethoxycarbony lpropenoyl) 
hydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH--COOEt). 
1H NMR (DMSO-d6): 0.86 (d, 6H, Val CH3), 1.21 (t, 3H, 
OEt), 1.7S and 1.98 ( d of m, 2H, Glu CH2), 1.8S (m, lH, Val 45 
CH), 2.18 (m, 2H, Glu CH2), 2.47 and 2.60 (d ofm, 2H, Asp 
CH2), 3.32 (s, 2H, AAsp CH2), 4.lS (q, 2H, OEt), 4.31 (m, 
3H, a-H), S.00 (s, 2H, Z), 6.S8 (d, lH, CH=CH), 7.20-7.3S 
(m, 7H, CH=CH, Ph and NH), 7.S8 (d, lH, NH), 7.97 (m, 
2H, NH), l0.9S (b, 3H, COOH). HRMS (FAB) calcd. for 50 
C30H40N50 14: 694.2S72; Observed m/z 694.2S99. Anal. 
Calcd. forC30H39N50 14: C, Sl.9S; H, S.67; N, 10.10. Found: 
C, Sl.6S; H, S.71; N, 10.03. 
Example4K 55 
Example4R 
N1 -trans-(3-Benzy lmethy lcarbamoy lpropenoy 1)-N2 -(N-
benzyloxycarbony laspartylglutamylvalyl )-N 1 -carboxym-
ethy lhydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH--CON 
(CH3)CH2Ph). 1H NMR (DMSO-d6): 0.8S (d, 6H, Val), 1.73 
N2 -(N-Benzy loxycarbony !asp arty lglutamy lvaly l)-N1 -
car boxy lmethyl-N 1 -cis-(3-ethoxycarbony lpropenoy I )hydra-
zine (Cbz-Asp-Glu-Val-AAsp-cis-CH=CH--COOEt). 1H 
NMR (DMSO-d6): 0.8S ( d, 6H, Val), 1.18 (t, 3H, OCH2CH3), 
1.74 (m, lH, Glu), 1.86 (m, lH, Glu), l.9S (m, lH, Val), 2.18 
(m, 2H, Glu), 2.4S (dd, lH,Asp), 2.61 (dd, lH,Asp), 4.09 (t, 
lH, a-H), 4.16 (q, 2H, OCH2CH3), 4.33 (m, 2H, a-H), S.01 
(s, 2H, Cbz), 6.61 (d, lH, db), 7.2S (d, lH, db), 7.33 (s, SH, 
Ph), 7.62 (d, lH, NH), 7.93 (t, 2H, NH), 11.0S (s, lH, 
NH-N). HRMS (ESI) Calcd. for C30H39N50 14: 693.2S66; 
60 (m, lH, Glu), 1.87 (m, lH, Glu), 1.97 (m, lH, Val), 2.20 (m, 
2H, Glu), 2.48 ( dd, lH, Asp), 2.63 ( dd, lH, Asp), 2.88-2.98 
( d, 3H, N(CH3)CH2Ph), 4.17 (t, lH, a-H), 4.32 (m, 2H, a-H), 
4.47-4.S8 (q, lH, N(CH3)CH2Ph), 4.66 (s, lH, N(CH3) 
CH2Ph), S.00 (s, 2H, Cbz), 7.14 (d, lH, db), 7.20 (d, lH, db), 
65 7.28-7.36 (m, lOH, Ph), 7.S7 (d, lH, NH), 7.91-7.9S (m, 2H, 
NH), 10.99 (s, lH, NH-N). HRMS (ESI) Calcd. for 
C36H44N60 13 : 768.304S; Observed m/z: 768.3039. Anal. 
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Calcd. for C36H44N60 13 .Et0Ac: C, 55.44; H, 6.20 N, 9.95. 
Found: C, 55.32; H, 6.20; N, 9.95. 
Example 4S 
N2 -(N-Benzy loxycarbony !asp arty lglutamy lvaly l)-N1 -
carboxymethy I-N1 -trans-(3-phenethy lmethylcarbamoy lpro-
penoy l )hydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH-
CON(CH3)CH2CH2Ph). 1H NMR (DMSO-d6): 0.86 (t, 6H, 
Val), 1.75 (m, lH, Glu), 1.89 (m, lH, Glu), 2.01 (m, lH, Val), 10 
2.21 (m, 2H, Glu), 2.46 (dd, lH, Asp), 2.62 (dd, lH, Asp), 
2.SO(t, 2H, N(CH3)CH2CH2Ph), 2.85-2.98 (d, 3H, N(CH3) 
CH2CH2Ph), 3.73 (d, 2H, N(CH3)CH2CH2Ph), 4.18 (t, lH, 
a-H), 4.32 (m, 2H, a-H), 5.00 (s, 2H, Cbz), 6.94 (d, lH, db), 
7.05 (dd, lH, db), 7.15-7.32 (m, !OH, Ph), 7.59 (d, lH, NH), 15 
7.91 (d, lH, NH), 7.97 (d, lH, NH), 10.93 (d, lH, NH-N). 
HRMS (ESI) Calcd. for C37H46N60 13 : 783.3196; Observed 
m/z: 783.3182. Anal. Calcd. for 
C37H46N60 13 .l.09H20.0.24TFA: C, 54.32; H, 5.77; N, 
10.14. Found: C, 54.32; H, 5.91; N, 9.92. 20 
Example4T 
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HRMS (ESI) Calcd. for C37H44N60 13 : 780.3039; Observed 
m/z: 780.2954. Anal. Calcd. for 
C37H44N60 13 .0.48H20.0.47TFA: C, 54.06; H, 5.43 N, 9.97. 
Found: C, 54.16; H, 5.72; N, 9.67. 
Example 4W 
N2 -(N-Benzy loxycarbonylasparty lglutamy lvaly l)-N1 -
trans-(3-benzoylpropenoyl)-N1-carboxymethylhydrazine 
(Cbz-Asp-Glu-Val-AAsp-CH=CH--COPh). 1H NMR 
(DMSO-d6): 0.82 (d, 6H, Val), 1.73 (m, lH, Glu), 1.85 (m, 
lH, Glu), 1.98 (m, lH, Val), 2.20 (m, 2H, Glu), 2.48 (dd, lH, 
Asp), 2.62 (dd, lH, Asp), 4.16 (t, lH, a-H), 4.33 (m, 2H, 
a-H), 5.01 (s, 2H, Cbz), 7.24 (d, lH, db), 7.32 (s, SH, Ph), 
7.54 (t, 3H, Ph), 7.67 (t, lH, NH), 7.79 (d, lH, NH), 7.93 (t, 
lH, NH), 7.97 (d, 2H, Ph), 11.06 (s, lH, NH-N). HRMS 
(ESI) Calcd. for C34H39N50 13 : 725.2623; Observed m/z: 
725.2543. Anal. Calcd. for C34H39N50 13 .H20.0.61TFA: C, 
52.02; H, 5.16; N, 8.61. Found: C, 52.01; H, 5.10; N, 8.54. 
Example4X 
N2 -(N-Benzy loxycarbonylisoleucy lglutamy lthreony I)-
N 1 -carboxymethy I-N 1 -trans-(3-ethoxycarbonylpropenoy I) N2 -(N-Benzy loxycarbony !asp arty lglutamy lvaly l)-N1 -
carboxymethy I-N 1 -trans-(3-dibenzy lcarbamoy lpropenoy I) 
hydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH--CON 
(CH2Ph)2). 1 H NMR (DMSO-d6): 0.87 (t, 6H, Val), 1.73 (m, 
lH, Glu), 1.87 (m, lH, Glu), 2.02 (m, lH, Val), 2.23 (m, 2H, 
Glu), 2.48 (dd, lH, Asp), 2.65 (dd, lH, Asp), 4.19 (t, lH, 
a-H), 4.33 (m, 2H, a-H), 4.55 (d, 2H, N(CH2Ph)2), 4.63 (s, 
2H, N(CH2Ph)2), 5.00 (s, 2H, Cbz), 7.14 (d, lH, db), 7.21-
7.34 (m, 16H, db, Cbz-Ph, and N(CH2Ph)2), 7.60 (d, lH, 
NH), 7.91-7.98 (dd, 2H, NH), 11.00 (s, lH, NH-N). HRMS 
(ESI) Calcd. for C42H48N60 13 : 844.3352; Observed m/z: 
844.3210.Anal. Calcd. forC42H48N60 1y0.53H20.0.40TFA: 
25 hydrazine (Cbz-Ile-Glu-Thr-AAsp-CH=CH--COOEt). 1H 
NMR (DMSO-d6): 0.8 (m, 6H, Ile CH3), 1-1.2 (m, 4H, Thr 
CH3 and Ile CH2), 1.2-1.3 (t, 3H, OCH2CH3), 1.4 (m, lH, Ile 
CH2), 1.6-1.8 (m, 2H, CH Ile and Glu CH2), 1.8-2.0 (m, lH, 
Glu CH2), 2.15-2.35 (m, 2H, Glu CH2), 3.85-4.05 (m, 3H, 
30 NCH2COOH and CH-OH), 4.1-4.3 (m, 3H, OCH2CH3 and 
a-H), 4.4 (m, 2H, a-H), 5.05 (m, 2H, Cbz), 6.6-6.65 (d, lH, 
CH=CH), 7 .20-7.40 (m, 6H, Ph and CH=CH), 7 .80 (m, lH, 
NH), 8.1 (m, lH, NH). HRMS (FAB) Calcd. for 
C31 H44N50 13 : 694.29356; Observed m/z 694.29979. Anal. 
35 Calcd. for C31 H43N50 13.H20: C, 52.32; H, 6.33; N, 9.84. 
C, 57.12; H, 5.54 N, 9.34. Found: C, 57.12; H, 5.64; N, 9.11. 
Example4U 
N2 -(N-Benzy loxycarbony !asp arty lglutamy lvaly l)-N1- 40 
carboxymethy I-N 1 -trans-(3-( 4-fluoro benzy l)carbamoy lpro-
penoy l )hydrazine (Cbz-Asp-Glu-Val-AAsp-CH=CH-
CONHCH2-4-F-Ph). 1 H NMR (DMSO-d6): 0.86 (t, 6H, Val), 
1.75 (m, lH, Glu), 1.88 (m, lH, Glu), 2.01 (m, lH, Val), 2.20 
(m, 2H, Glu), 2.48 (dd, lH,Asp), 2.65 (dd, lH,Asp), 4.18 (t, 45 
lH, a-H), 4.34 (m, 4H, a-HandNHCH2Ph-4-F), 5.01(s,2H, 
Cbz), 6.93 (d, lH, db), 7.12 (d, 2H, NHCH2Ph-4-F), 7.25-
7.32 (m, SH, Cbz-Ph, NHCH2Ph-4-F, and db), 7.59 (d, lH, 
NH), 7.90-7.99 (dd, 2H, NH), 8.94 (t, lH, NHCH2Ph-4-F), 
10.98 (s, lH, NH-N). HRMS (ESI) Calcd. for 50 
C35H41N60 13F: 772.2788; Observed m/z: 772.2747. Anal. 
Calcd. for C35H41N60 13F.2.08H20: C, 51.92; H, 5.62; N, 
10.38. Found: C, 51.92; H, 5.40; N, 10.21. 
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Found: C, 52.38; H, 6.35; N, 9.83. 
Example4Y 
N1 -trans-(3-Benzy loxycarbonylpropenoy l)-N2 -(N-ben-
zyloxycarbony lisoleucylglutamylthreony 1)-N 1 -carboxylm-
ethy lhydrazine (Cbz-Ile-Glu-Thr-AAsp-CH=CH-
COOCH2Ph). 1H NMR (DMSO-d6): 0.80 (m, 6H, Ile CH3), 
1.02 (m, 3H, ThrCH3), 1.lO(m, 2H, IleCH2), 1.65 (m, lH, Ile 
CH), 1.75 and 1.85 (d ofm, 2H, Glu CH2), 2.25 (m, 2H, Glu 
CH2), 3.30 (s, 2H, AAsp CH2), 3.90 (m, 2H, a-H), 4.25 (m, 
lH, a-H), 4.39 (m, lH, Tur CH), 5.00 (s, 2H, Z), 5.20 (s, 2H, 
CH2Ph), 6.70 (d, lH, NH), 7.20-7.40 (m, 12H, Ph and 
CH=CH), 7.90 (b, lH, NH), 8.10 (b, lH, NH), 8.60 (m, lH, 
NH), 10.70 (b, 2H, COOH). HRMS (FAB) Calcd. for 
C36H46N50 13 : 756.3092; Observed m/z 756.3037. Anal. 
Calcd; for C36H45N50 13 .2H20: C, 54.61; H, 6.24; N, 8.84. 
Found: C, 54.82; H, 6.64; N, 9.08. 
Example4Z 
N2 -(N-Benzy loxycarbonylisoleucy lglutamy lthreony I)-
N 1 -carboxylmethyl-N1 -trans-(3-phenylcarbamoylprope-
noyl)hydrazine (Cbz-Ile-Glu-Thr-AAsp-CH=CH-CON-
N2 -(N-Benzy loxycarbony !asp arty lglutamy lvaly l)-N1 -
carboxymethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-yl-
carbony l)propenoy !)hydrazine ( Cbz-Asp-Glu-Val-AAsp-
CH=CH-CO-tetrahydroquinoline ). 1 H NMR (DMSO-d6): 
0.89 (t, 6H, Val), 1.75 (m, lH, Glu), 1.87 (m, 3H, Glu and 
NCH2CH2CH2), 2.02 (m, lH, Val), 2.20 (m, 2H, Glu), 2.48 
(dd, lH, Asp), 2.65 (dd, lH, Asp), 2.70 (t, 2H, 
NCH2CH2CH2), 3.73 (t, 2H, NCH2CH2CH2), 4.19 (t, lH, 
a-H), 4.33 (m, 2H, a-H), 5.01(s,2H, Cbz), 6.95 (m, lH, db), 
7.04 (d, lH, db), 7.14-7.33 (m, 9H, Cbz-Ph, and quinoline), 
7.60 (d, lH, NH), 7.96 (dd, 2H, NH), 11.02 (s, lH, NH-N). 
60 HPh). 1 H NMR (DMSO-d6): 0.84 (t, 6H, Ile CH3), 1.06 (m, 
3H, Thr CH3), 1.45 (m, 2H, Ile CH2), 1.70 (m, lH, Ile CH), 
1.80 and 1.90 ( d of m, 2H, Glu CH2), 2.25 (m, 2H, Glu CH2), 
3.33 (s, 2H,AAsp CH2), 3.88 (t, lH, a-H), 4.00 (m, lH, a-H), 
4.25 (m, lH, a-H), 4.39 (m, lH, Thr CH), 5.00 (s, 2H, Z), 
65 7.00-7.10 (m, 4H, CH=CH and Ph), 7.30 (m, 7H, Ph and 
NH), 7.64 (d, 2H, Ph), 7.85 (b, lH, NH), 8.05 (d, lH, NH), 
8.35 (m, lH, NH), 8.60 (m, lH, NH), 10.45 (b, 2H, COOH). 
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HRMS (FAB) Calcd. for C35H45N60 12: 741.3095; Observed 
m/z 741.3106. Anal. Calcd. for C35H44N60 12.2H20: C, 
54.12; H, 6.23; N, 10.82. Found: C, 53.07; H, 5.88: N, 10.98. 
84 
7.10-7.40 (m, 13H, CH=CH, NH and Ph), 7.65 (b, lH, NH), 
7.90 (b, lH, NH). HRMS (FAB) Calcd. for C38H51N60 12: 
783.3565; Observed m/z 783.3569. Anal. Calcd. for 
C33H50N60 12.2H20: C, 55.74; H, 6.65; N, 10.26. Found: C, 
Example4AA 5 55.59; H, 6.23; N, 10.07. 
N1-trans-(3-Benzylcarbamoylpropenoyl)-N2-(N-benzy-
loxycarbony lisoleucy lglutamy lthreonyl )-N 1 -carboxylmeth-
y lhydrazine (Cbz-Ile-Glu-Thr-AAsp-CH=CH-
Example4EE 
N2 -(N-Benzy loxycarbonylisoleucy lglutamy lthreony I)-
N 1 -carboxylmethyl-N1 -trans-(3-dibenzylcarbamoylprope-
noyl)hydrazine (Cbz-Ile-Glu-Thr-AAsp-CH=CH--CON 
(CH2Ph)2). 1H NMR (DMSO-d6): 0.80 (m, 6H, Ile CH3), 
1.06 (m, 3H, ThrCH3), 1.50 (m, 2H, Ile CH2), 1.65 (m, lH, Ile 
CH), 1.78 and 1.90 ( d of m, 2H, Glu CH2), 2.25 (m, 2H, Glu 
CH2), 3.32 (s, 2H, AAsp CH2), 4.00 (m, 2H, a-H), 4.25 (m, 
lH, a-H), 4.40 (m, lH, ThrCH), 4.60 (d, 4H, CH2Ph), 5.00 (s, 
2H, Z), 7.00-7.35 (m, 13H, CH=CH, Ph and NH), 7.85 (b, 
lH, NH), 8.10 (d, lH, NH), 8.60 (b, lH, NH), 10.75 (b, 2H, 
COOH). HRMS (FAB) Calcd. for C43H53N60 12 : 845.3721; 
CONHCH2Ph). 1H NMR (DMSO-d6): 0.75-0.87 (m, 6H, Ile 10 
CH3), 1.02 (m, 3H, Thr CH3), 1.49 (m, 2H, Ile CH2), 1.65 (m, 
lH, Ile CH), 1.74 and 1.85 (d ofm, 2H, Glu CH2), 2.25 (m, 
2H, Glu CH2), 3.32 (s, 2H, AAsp CH2), 4.00 (m, 2H, a-H), 
4.25 (m, lH, a-H), 4.40 (m, 3H, ThrCH andCH2Ph), 5.00 (s, 
2H,Z), 7.00(d, lH, CH=CH), 7.40-7.40(m, 13H,CH=CH, 15 
Ph and NH), 7 .90 (b, lH, NH), 8.05 (b, lH, NH), 8.90 (b, lH, 
NH), 10.60 (b, 2H, COOH). HRMS (FAB) Calcd. for 
C36H47N60 12: 755.3252; Observed m/z 755.3200. Anal. 
Calcd. for C36H46N60 12.2H20: C, 54.68; H, 6.37; N, 10.63. 
Found: C, 55.02; H, 6.32; N, 10.70. 20 Observed m/z 845.3731. Anal. Calcd. for 
Example4BB 
N2 -(N-Benzy loxycarbony lisoleucy lglutamy I threonyl )-
N 1 -carboxylmethyl-N1 -trans-(3-phenyethylcarbamoylpro- 25 
penoy I )hydrazine ( Cbz-Ile-Glu-Thr-AAsp-CH=CH-
CONHCH2CH2Ph ). 1H NMR (DMSO-d6): 0.82 (m, 6H, Ile 
CH3), 1.04 (m, 3H, Thr CH3), 1.45 (m, 2H, Ile CH2), 1.65 (m, 
lH, Ile CH), 1.75 and 1.90 (d ofm, 2H, Glu CH2), 2.24 (m, 
2H, Glu CH2), 2.73 (t, 2H, CH2Ph), 3.32 (m, 4H, AAsp CH2 30 
and NCH2), 3.95 (m, 2H, a-H), 4.22 (m, lH, a-H), 4.40 (m, 
lH, Thr CH), 5.00 (s, 2H, Z), 6.88 (d, lH, CH=CH), 7.10-
7.45 (m, 13H, CH=CH, Ph and NH), 7.90 (b, 2H, NH), 8.05 
(b, lH, NH), 8.52 (b, lH, NH), 10.73 (b, 2H, COOH). HRMS 
(FAB) Calcd. for C37H49N60 12: 769.3408; Observed m/z 35 
769.3332. Anal. Calcd. forC37H48N60 12.2H20: C, 55.22; H, 
6.51; N, 10.44. Found: C, 55.34; H, 6.46; N, 10.55. 
Example4CC 
40 
N 1 -trans-(3-Benzy lmethy lcarbamoylpropenoy l)-N2 -(N-
benzyloxycarbony lisoleucylglutamy lthreony l)-N1-carboxy-
lmethylhydrazine (Cbz-Ile-Glu-Thr-AAsp-CH=CH--CON 
(CH3)CH2Ph). 1 H NMR (DMSO-d6): 0.80 (m, 6H, Ile CH3), 
1.06 (m, 3H, ThrCH3), 1.49 (m, 2H, Ile CH2), 1.65 (m, lH, Ile 45 
CH), 1.80 and 1.92 ( d of m, 2H, Glu CH2), 2.24 (m, 2H, Glu 
CH2), 2.88 and 2.99 ( d, 3H, NCH3), 3.32 (s, 2H, AAsp CH2), 
4.02 (m, 2H, a-H), 4.20 (m, lH, a-H), 4.40 (m, lH, ThrCH), 
4.55 (m, 2H, CH2Ph), 5.00 (s, 2H, Z), 7.10-7.45 (m, 14H, 
CH=CH, Ph and NH), 7.80 (m, lH, NH), 8.05 (m, lH, 50 
NH),10.90 (b, 2H, COOH). HRMS (FAB) Calcd. for 
C37H49N60 12: 769.3408; Observed m/z 769.3394. Anal. 
Calcd. forC37H48N60 12.2H20: C, 55.22; H, 6.51; N, 10.44. 
Found: C, 55.02; H, 6.03; N, 10.26. 
C43H52N60 12.2H20: C, 58.63; H, 6.41; N, 9.54. Found: C, 
58.40; H, 6.14; N, 9.68. 
Example 4FF 
N2 -(N-Berzy loxycarbony lleucy lglutamy lthreonyl )-N1 -
carboxymethy I-N 1 -trans-(3-ethoxycarbonylpropenoy !)hy-
drazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-COOEt). 1 H 
NMR (DMSO-d6): 0.85 (t, 6H, Leu CH3), 1.05 (d, 3H, Thr 
CH3), 1.25 (t, 3H, OCH2CH3), 1.4 (m, 2H, Leu CH2), 1.6 (m, 
lH, CH Leu), 1.75 (m, lH, Glu CH2), 1.9 (m, lH, Glu CH2), 
2.25 (m, 2H, Glu CH2), 3.9-4.1 (m, 3H, NCH2COOH and 
a-H), 4.1-4.3 (m, 3H, OCH2CH3 and CH-OH), 4.3-4.4 (m, 
2H, a-H), 5.02 (m, 2H, Cbz), 6.6-6.65 (d, lH, CH=CH), 
7.20-7.40 (m, 6H, Ph and CH=CH), 7.50 (d, lH, NH), 7.78 
(m, lH, NH), 8.05 (m, lH, NH). HRMS (FAB) Calcd. for 
C31 H44N50 13 : 694.29356; Observed m/z 694.29963. Anal. 
Calcd. for C31 H43N50 13.H20: C, 52.32; H, 6.33; N, 9.84. 
Found: C, 52.54; H, 6.28; N, 9.69. 
Example4GG 
N 1 -trans-(3-Benzy loxycarbonylpropenoy l)-N2 -(N-ben-
zyloxycarbony lleucy lglutamy lthreony 1)-N 1 -carboxymethy !-
hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-
COOCH2Ph). 1H NMR (DMSO-d6): 0.84 (t, 6H, Leu), 1.02 
(d, 3H, Thr), 1.40 (m, 2H, Leu), 1.60 (m, lH, Glu), 1.73 (m, 
lH, Glu), 1.90 (m, lH, Leu), 2.22 (m, 2H, Glu), 3.94 (m, lH, 
a-H), 4.03 (m, lH, a-H), 4.20 (m, lH, a-H), 4.37 (m, lH, 
Thr), 4.99 (s, 2H, Cbz), 5.19 (s, 2H, Bzl), 6.65 (d, lH, db), 
7.32-7.36 (m, lOH, Ph), 7.42 (d, lH, db), 7.76 (d, lH, NH), 
8.03 ( d, lH, NH), 10.84 (s, lH, NH-N). HRMS (ESI) Calcd. 
forC36H45N50 13 : 755.3092; Observedm/z: 755.3150.Anal. 
Calcd. for C36H45N50 13.0.27H20.0.28TFA: C, 55.41; H, 
55 5.83; N, 8.84. Found: C, 55.41; H, 5.77; N, 8.77. 
Example4DD 
N2 -(N-Benzy loxycarbony lisoleucy lglutamy lthreonyl )-
N1-carboxy lmethyl-N1-trans-(3-methylpheny lethylcarbam-
oylpropenoyl)hydrazine (Cbz-Ile-Glu-Thr-AAsp- 60 
CH=CH-CON(CH3)CH2CH2Ph). 1H NMR (acetone-d6): 
0.88 (m, 3H, Ile CH3), 0.97 (m, 3H, Ile CH3), 0.97 (m, 3H, Ile 
CH3), 1.21 (m, 3H, Thr CH3), 1.60 (m, 3H, Ile CH and CH2), 
2.00 (m, 2H, Glu CH2), 2.47 (m, 2H, Glu CH2), 2.88 (m, 4H, 
CH2PhandAAsp CH2), 2.98 and3.10 (d, 3H, CH3), 3.67 (m, 65 
2H, CH2N), 4.13 (m, lH, a-H), 4.32 (m, lH, a-H), 4.50 (m, 
2H, a-H and Thr CH), 5.09 (m, 2H, Z), 6.62 (b, lH, NH), 
Example4HH 
N2 -(N-Benzy loxycarbonylleucylglutamylthreonyl )-N1 -
carboxylmethyl-N 1 -trans-(3-pheny lcarbamoylpropenoy I) 
hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-CONHPh). 
1H NMR (DMSO-d6): 0.85 (t, 6H, Leu CH3), 1.06 (m, 3H, 
ThrCH3), 1.49 (m, 2H, LeuCH2), 1.61 (m, lH, Leu CH), 1.80 
and 1.95 (dofm, 2H, Glu CH2), 2.26 (m, 2H, Glu CH2), 3.32 
(s, 2H, AAsp CH2), 4.03 (m, 2H, a-H), 4.25 (m, lH, a-H), 
4.40 (m, lH, Thr CH), 5.00 (s, 2H, Z), 7.00-7.10 (m, 4H, 
CH=CH and Ph), 7 .30 (m, 7H, Ph and NH), 7 .64 ( d, 2H, Ph), 
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(d, 3H, NCH3), 3.68 (m, 2H, NCH2), 4.30 (m, 2H, a-H), 4.50 
(m, 2H, a-Hand Thr CH), 5 .09 (m, 2H, Z), 5 .65 (b, 1 H, NH), 
6.75 (b, lH, NH), 7.10-7.40 (m, 12H, CH=CH and Ph), 7.85 
(b, lH, NH), 7.95 (b, lH, NH). HRMS (FAB) Calcd. for 
7.85 (m, lH, NH), 8.05 (b, lH, NH), 8.20 (m, lH, NH), 8.75 
(b, lH, NH), 10.45 (s, 2H, COOH). HRMS (FAB) Calcd. for 
C35H45N60 12: 741.3095; Observed m/z 741.3064. Anal. 
Calcd. for C35H44N60 12.2H20: C, 54.12; H, 6.23; N, 10.82. 
Found: C, 53.86; H, 5.81; N, 10.85. 5 C33H51N60 12: 783.3565; Observed m/z 783.3493. Anal. 
Example4II 
N1-trans-(3-Benzylcarbamoylpropenoyl)-N2-(N-benzy-
loxycarbony lleucylglutamy lthreony 1)-N 1 -car boxy !methyl- 1 o 
hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CONHCH2Ph). 1 H NMR (DMSO-d6): 0.85 (t, 6H, Leu CH3), 
1.06 (m, 3H, Thr CH3), 1.49 (m, 2H, Leu CH2), 1.61 (m, lH, 
Leu CH), 1.80 and 1.90 ( d of m, 2H, Glu CH2), 2.26 (m, 2H, 
Glu CH2), 3.32 (s, 2H, AAsp CH2), 4.03 (m, 2H, a-H), 4.25 15 
(m, lH, a-H), 4.45 (m, 3H, Thr CH and CH2Ph), 5.00 (s, 2H, 
Z), 7.00 (d, lH, CH=CH), 7.20-7.40 (m, 13H, CH=CH, Ph 
and NH), 7.80 (b, lH, NH), 8.05 (d, lH, NH), 8.90 (d, lH, 
NH), 10.65 (b, 2H, COOH). HRMS (FAB) Calcd. for 
C36H47N60 12: 755.3252; Observed m/z 755.3184. Anal. 20 
Calcd. for C36H46N60 12.2H20: C, 54.68; H, 6.37; N, 10.63. 
Found: C, 54.96; H, 6.72; N, 10.85. 
Example 4JJ 
25 
N2 -(N-Benzy loxycarbony lleucylglutamylthreony 1)-N1 -
car boxy lmethyl-N 1 -trans-(3-pheny lethy lcarbamoylprope-
Calcd. for C38H50N60 12.2H20: C, 55.74; H, 6.65; N, 10.26. 
Found: C, 55.60; H, 6.84; N, 9.99. 
Example4MM 
N2 -(N-Benzyloxycarbonylleucylglutamylthreonyl)-N1 -
carboxylmethyl-N1 -trans-(3-dibenzylcarbamoy lpropenoyl) 
hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH--CON 
(CH2Ph)2). 1H NMR (DMSO-d6): 0.85 (t, 6H, Leu CH3), 
1.06 (m, 3H, Thr CH3), 1.45 (m, 2H, Leu CH2), 1.60 (m, lH, 
Leu CH), 1.80 and 1.90 ( d of m, 2H, Glu CH2), 2.25 (m, 2H, 
Glu CH2), 3.32 (s, 2H, AAsp CH2), 4.03 (m, 2H, a-H), 4.25 
(m, lH, a-H), 4.40 (m, lH, Thr CH), 4.60 (d, 4H, CH2Ph), 
5.00(s, 2H, Z), 7.10-7.35 (m, 12H, CH=CHandPh), 7.40(b, 
lH, NH), 7.80 (b, lH, NH), 8.07 (b, lH, NH), 8.65 (m, lH, 
NH), 10.75 (b, 2H, COOH). HRMS (FAB) Calcd. for 
C43H53N60w 845.3721; Observed m/z 845.3777. Anal. 
Calcd. for C43H52N60 12.2H20: C, 58.63; H, 6.41; N, 9.54. 
Found: C, 58.50; H, 6.00; N, 9.45. 
Example4NN 
N2 -(N-Benzy loxycarbonylleucylglutamylthreonyl )-N1 -
carboxylmethyl-N1 -trans-(3-( 4-fluorobenzyl)carbamoylpro-
penoyl)hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CONHCH2-4-F-Ph). 1H NMR (DMSO-d6): 0.85 (t, 6H, Leu 
CH3), 1.04 (m, 3H, Thr CH3), 1.60 (m, 2H, Leu CH2), 1.75 
(m, lH, Leu CH), 1.90 (m, 2H, Glu CH2), 2.24 (m, 2H, Glu 
CH2), 3.32 (s, 2H, AAsp CH2), 4.03 (m, 2H, a-H), 4.25 (m, 
lH, a-H), 4.40 (m, 3H, Thr CH and CH2Ph), 5.00 (s, 2H, Z), 
6.93 (d, lH, CH=CH), 7.10-7.40 (m, lOH, CH=CH and 
Ph), 7.85 (b, lH, NH), 8.05 (d, lH, NH), 8.70 (b, lH, NH), 
8.94 (m, 2H, NH), 10.60 (b, 2H, COOH). HRMS (FAB) 
Calcd. for C36H46N60 12F: 773.3153; Observed m/z 
noy l)hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CONHCH2CH2Ph). 1H NMR (DMSO-d6): 0.85 (t, 6H, Leu 
CH3), 1.06 (m, 3H, Thr CH3), 1.45 (m, 2H, Leu CH2), 1.60 30 
(m, lH, Leu CH), 1.75 and 1.88 (d ofm, 2H, Glu CH2), 2.25 
(m, 2H, Glu CH2), 2.75 (t, 2H, CH2Ph), 3.30-3.35 (m, 4H, 
CH2N andAAsp CH2), 4.00 (m, 2H, a-H), 4.20 (m, lH, a-H), 
4.38 (m, lH, ThrCH), 5.00 (s, 2H, Z), 6.90-7.15 (dofd, 2H, 
CH=CH), 7.20-7.40 (m, 12H, Ph and NH), 7.86 (m, lH, 35 
NH), 8.06 (d, lH, NH), 8.50 (b, lH, NH), 10.60 (b, 2H, 
COOH). HRMS (FAB) Calcd. for C37H49N60 12: 769.3408; 
Observed m/z 769.3201. Anal. Calcd. for 
C37H48N60 12.2H20: C, 55.22; H, 6.51; N, 10.44. Found: C, 
55.78; H, 6.15; N, 10.61. 40 773.3061. Anal. Calcd. for C36H45N60 12F.2H20: C, 53.46; 
H, 6.11; N, 10.39. Found: C, 53.62; H, 6.05; N, 10.16. 
Example4KK 
N 1 -trans-(3-Benzy lmethy lcarbamoylpropenoy l)-N2 -(N-
benzyloxycarbony lleucy lglutamy lthreony l)-N1-carboxy lm- 45 
ethylhydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH--CON 
(CH3)CH2Ph). 1 H NMR (DMSO-d6): 0.83 (t, 6H, Leu CH3), 
1.06 (m, 3H, Thr CH3), 1.49 (m, 2H, Leu CH2), 1.65 (m, lH, 
Leu CH), 1.80 and 1.92 ( d of m, 2H, Glu CH2), 2.24 (m, 2H, 
Glu CH2), 2.88 and 2.99 (d, 2H, CH3), 3.32 (s, 2H, AAsp 50 
CH2), 4.02 (m, 2H, a-H), 4.20 (m, lH, a-H), 4.40 (m, lH, Thr 
CH), 4.55 (m, 2H, CH2Ph), 5.00 (s, 2H, Z), 7.10-7.45 (m, 
14H, CH=CH, Ph and NH), 7.80 (m, lH, NH), 8.05 (m, lH, 
NH),10.85 (b, 2H, COOH). HRMS (FAB) Calcd. for 
C37H49N60 12: 769.3408; Observed m/z 769.3320. Anal. 55 
Calcd. forC37H48N60 12.2H20: C, 55.22; H, 6.51; N, 10.44. 
Found: C, 55.02; H, 6.03; N, 10.26. 
Example4LL 
60 
N2 -(N-Benzy loxycarbony lleucylglutamylthreony 1)-N1 -
carboxylmethyl-N1-trans-(3-methylphenylethylcarbamoyl-
propenoyl)hydrazine (Cbz-Leu-Glu-Thr-AAsp-CH=CH-
CON(CH3)CH2CH2Ph). 1 H NMR (acetone-d6): 0.94 (m, 6H, 
Leu CH3), 1.20 (m, 3H, Thr CH3), 1.65 (m, 2H, Leu CH2), 65 
1.75 (m, lH, Leu CH), 2.00 (m, 2H, Glu CH2), 2.46 (m, 2H, 
Glu CH2), 2.88 (m, 4H, CH2Ph andAAsp CH2), 2.98 and 3.11 
Example400 
N2 -(N-Benzy loxycarbonylleucylglutamylthreonyl )-N1 -
carboxylmethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-
yloxo )propenoyl)hydrazinee (Cbz-Leu-Glu-Thr-AAsp-
CH=CH-CO-tetrahydroquinoline ). 1H NMR (acetone-
d6): 0.94 (m, 6H, Leu CH3), 1.22 (m, 3H, Thr CH3), 1.66 (m, 
2H, Leu CH2), 1.78 (m, lH, Leu CH), 1.98 (m, 2H, quinoline 
CH2), 2.00 (m, 2H, Glu CH2), 2.46 (m, 2H, Glu CH2), 2.80 
(m, 4H, quinoline CH2 and Asp CH2), 3.81 (m, 2H, NCH2), 
4.28 (m, lH, a-H), 4.38 (m, lH, a-H), 4.50 (m, 2H, a-Hand 
Thr CH), 5.09 (m, 2H, Z), 6.75 (b, lH, NH), 7.10-7.40 (m, 
lOH, CH=CH and Ph), 7.48 (d, lH, Ph), 7.60 (d, lH, NH), 
7.90 (d, lH, NH), 9.00 (s, lH, NH). HRMS (FAB) Calcd. for 
C38H49N60 12: 781.3408; Observed m/z 781.3367. Anal. 
Calcd. for C38H48N60 12.2H20: C, 55.87; H, 6.42; N, 10.29. 
Found: C, 55.98; H, 6.02; N, 10.32. 
Example 4PP 
N2 -(N-Benzy loxycarbonylleucylglutamylthreonyl )-N1 -
carboxylmethyl-N1-trans-(3-(methyl-1-naphthylmethyl)car-
bamoylpropenoyl)hydrazine (Cbz-Leu-Glu-Thr-AAsp-
CH=CH-CON(CH3)CH2-l-Napth). 1H NMR (acetone-
d6): 0.92 (m, 6H, Leu CH3), 1.22 (m, 3H, Thr CH3), 1.65 (m, 
US 7,482,379 B2 
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2H, Leu CH2), 1.75 (m, lH, Leu CH), 2.00 (m, 2H, Glu CH2), 
2.47 (m, 2H, Glu CH2), 3.08 (d, 4H, AAsp CH2 and NCH3), 
4.25 (m, lH, a-H), 4.35 (m, 2H, a-H), 4.50 (m, lH, ThrCH), 
5.07 (m, 2H, Z), 5.15 (m, 2H, CH2-napth), 6.75 (b, lH, NH), 
7.20-7.35 (m, 6H, CH=CH and Ph), 7.40-7.60 (m, 7H, Ph 
and NH), 7.90 (m, 2H, napth), 7.80 (b, lH, NH), 8.10 (b, lH, 
NH). HRMS (FAB) Calcd. for C41 H51N60 12, 819.3565; 
Observed m/z 819.3521. Anal. Calcd. for 
C41H50N60 12.2H20: C, 57.60; H, 6.37; N, 9.83. Found: C, 
57.63; H, 6.07; N, 9.78. 
Example4QQ 
N2 -(N-Benzyloxycarbonylvalylglutamylvalyl)-N1 -car-
boxymethyl-N1 -trans-(3-ethoxycarbony lpropenoy 1 )hydra-
zine ( Cbz-Val-Glu-Val-AAsp-CH=CH--COO Et). 1HNMR 
(DMSO-d6): 0.80-0.87 (dd, 12H, Val), 1.21 (t, 3H, 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 5 
<212 > TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
10 
88 
OCH2CH3), 1.74 (m, lH, Glu), 1.89 (m, lH, Glu), 1.94 (m, 
lH, Val), 2.20 (m, 2H, Glu), 3.87 (t, lH, a-H), 4.16 (m, 3H, 
a-H and OCH2CH3), 4.33 (t, lH, a-H), 5.01 (s, 2H, Cbz), 
6.63 (d, lH, db), 7.20 (d, lH, db), 7.33 (m, SH, Ph), 7.97 (t, 
2H, NH), 11.02 (s, lH, NH-N). HRMS (ESI) Calcd. for 
C31 H43N50 12 : 677.2986; Observed m/z: 677.2978. Anal. 
Calcd. for C31H43N50 12.l.41H20.0.51hex: C, 54.84; H, 
7.02: N, 9.39. Found: C, 54.84; H, 6.73; N, 9.16. 
The above specification and Examples fully disclose how 
to make and use the compounds of the present disclosure. 
However, the present disclosure is not limited to the particular 
embodiments described hereinabove, but includes all modi-
fications thereof within the scope of the following claims. The 
15 various references to journals, patents, and other publications 
which are cited herein comprise the state of the art and are 
incorporated herein by reference. 
<223> OTHER INFORMATION, conserved active site of caspase 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, X~R, Q, G 
<400> SEQUENCE, 1 
Gln Ala Cys Xaa Gly 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH, 4 
<212 > TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, group I caspase recognition site 
<400> SEQUENCE, 2 
Trp Glu His Asp 
1 
<210> SEQ ID NO 3 
<211> LENGTH, 4 
<212 > TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, group II caspase recognition site 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 3 
Asp Glu Xaa Asp 
1 
<210> SEQ ID NO 4 
<211> LENGTH, 4 
<212 > TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, group III caspase recognition site 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, x~v or L 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 4 
Xaa Glu Xaa Asp 
1 
What is claimed is: 
1. A compound of the formula: 
wherein, 
or 
R1 is selected from the group cons1stmg of M1-AA1, 
20 
25 
30 
M1-AA2-AA1, and M1-AA3-AA2-AA1; 35 
Wis selected from the group consisting of halogen, cyano, 
and hydrogen; 
M1 is selected from the group consisting of H, NH2-
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, 
X2N--CO-, X-NH--CS-, X2N-CS-, 40 
X-NH-S02-, X2N-S02-, X-CO-, X-CS-, 
X-, Y-S02-, Y---0-CO-, Y---0---CS-, mor-
pholine-CO-, and biotinyl; 
X is selected from the group consisting of H, C1_10 alkyl, 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl sub- 45 
stituted with J, cl-10 fluoroalkyl substituted with J, 1-ad-
mantyl, 9-fluorenyl, phenyl, pentafluorophenyl, phenyl 
monosubstituted with K, phenyl disubstituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl mono-
substituted with K, naphthyl disubstituted with K, naph- 50 
thy! trisubstituted with K, C1_10 fluoroalkyl with an 
attached phenyl group, C1_10 alkyl with an attached phe-
nyl group, cl-10 alkyl with two attached phenyl groups, 
C1_10 alkyl with an attached phenyl group substituted 
with K, C1_10 alkyl with two attached phenyl groups 55 
substituted withK, C1_10 alkyl withanattachednaphthyl 
group, C1_10 alkyl with an attached naphthyl group sub-
stituted with K, C1_10 alkyl with an attached phenoxy 
group, and C1_10 alkyl with an attached phenoxy group 
substituted with Kon the phenoxy group; 60 
Y is selected from the group consisting ofC1_10 alkyl, C3_15 
cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl monosubstituted with K, 
phenyl disubstituted with K, phenyl trisubstituted with 65 
K, naphthyl, naphthyl monosubstituted withK, naphthyl 
disubstituted with K, naphthyl trisubstituted with K, 
cl-10 fluoroalkyl with an attached phenyl group, cl-10 
alkyl with an attached phenyl group, C1_10 alkyl with two 
attached phenyl groups, cl-10 alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with two 
attached phenyl groups substituted with K, C1_10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the phe-
noxy group; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, amino, C1_10 alkoxy, C1_10 alkylamino, 
C2_12 dialkylamino, C1_10 alkyl-0---CO-, C1_10 alkyl-
0---CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, 
CN, OH, C02H, CONH2, amino, C1_10 alkylamino, 
C2_12 dialkylamino, C1_10 acyl, and C1_10 alkoxy-CO-, 
and C1_10 alkyl-S-; 
AA1, AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the alpha-carbon selected from the 
group consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenylala-
nine, tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine, norvaline, alpha-aminobutanoic acid, 
epsilon-aminocaproic acid, citrulline, hydroxyproline, 
ornithine, homoarginine, sarcosine, indoline 2-carboxy-
lic acid, 2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2--CH(CH2CHEt2)--C02H, alpha-ami-
noheptanoic acid, NH2--CH(CH2-l-naphthyl)-C02H, 
NH2-CH(CH2-2-naphthyl)-C02H, NH2--CH 
(CH2CH2CH2-phenyl)-C02H, NH2-CH(CH2-cyclo-
hexyl)-C02H, NH2-CH(CH2-cyclopentyl)-C02H, 
NH2-CH(CH2-cyclobutyl)-C02H, NH2-CH(CH2-
cyclopropyl)-C02H, trifluoroleucine, 4-fluorophenyla-
lanine, lysine substituted on the epsilon nitrogen with a 
biotinyl group, hexafluoroleucine, 
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R5 is selected from the group consisting ofC1 _10 alkyl and 
cl-10 alkyl substituted with phenyl; 
Q is selected independently from the group consisting of 
C1_10 alkoxy, C1 _10 alkyl-S-, C1 _10 alkoxy substituted 
with phenyl, and C1_10 alkyl-S-substituted with phenyl; 
G is selected from the group consisting of cyano, amidino 
(-C( NH)NH2 ), guanidino (-NHC( NH)NH2 ), 
isothiureido (-S--C( NH)NH2 ), amino, C1_6 alky-
10 !amino, c2-12 dialkylamino, and imidazyl; 
R3 is selected independently from the group consisting of 
H, R6 , halogen, CN, CO-C6H5 , benzoyl substituted 
with K on the phenyl, C02 H, C02 R7 , CONHR8 , 
15 CONR8R9 , CO-AA4 -T, 
20 
25 
and 30 
35 
R2 is selected from the group consisting of C1 _10 alkyl, 
cl-10 perfluoroalkyl, cl-10 alkyl substituted with Q, 
cl-10 alkyl substituted with phenyl, cl-10 alkyl with an 
attached phenyl substituted with K, C1 _10 alkyl substi- 40 
tuted with naphthyl, C1 _10 alkyl with an attached naph-
thyl substituted with K, phenyl, phenyl substituted with 
K, naphthyl, naphthyl substituted with K, C1_10 alkyl 
substituted with CONH2 , C1 _10 alkyl substituted with 
CONHR5 , C1 _10 alkyl substituted with C02 H, C1_10 45 
alkyl substituted with S02 NH2 , C1_10 alkyl substituted 
with S03H, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-furyl 
substituted with K, 3-furyl substituted with K, 2-thienyl 
substituted with K, 3-thienyl substituted with K, 2-furyl 
substituted with G, 3-furyl substituted with G, 2-thienyl 50 
substituted with G, 3-thienyl substituted with G, C1_10 
alkyl substituted with C02R5 , CH2 CH2 SCH3 , CH2 -3-
indolyl, cl-2 alkyl with an attached 2-furyl, cl-2 alkyl 
with an attached 3-furyl, C1 _2 alkyl with an attached 
2-thienyl, cl-2 alkyl with an attached 3-thienyl, cl-2 55 
alkyl with an attached 2-furyl substituted with K, C1_2 
alkyl with an attached 3-furyl substituted with K, C1_2 
alkyl with an attached 2-thienyl substituted with K, C1 _2 
alkyl with an attached 3-thienyl substituted with K, C1 _2 
alkyl with an attached 2-furyl substituted with G, C1_2 60 
alkyl with an attached 3-furyl substituted with G, C1_2 
alkyl with an attached 2-thienyl substituted with G, C1 _2 
alkyl with an attached 3-thienyl substituted with G, 
CH2 -2-imidazyl, C1 _10 alkyl substituted with G, C1_10 
alkyl with an attached phenyl substituted with G, C1_10 65 
alkyl with an attached naphthyl substituted with G, phe-
nyl substituted with G, and naphthyl substituted with G; 
0 0 )lco )le 
~I, I~ , 
~ ,,,::::; 
and 
R4 is selected from the group consisting of R6 , halogen, 
CN, CO-C6H5 , benzoyl substituted with Kon the phe-
nyl, C02H, C02 R7 , CONHR8 , CONR8R9 , CO-AA4 -T, 
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0 0 Aco A& ~I, I~ , 
~ ,,,;:::; 
0 
AD 
l) 
and 
10 
15 
R6 is selected independently from the group consisting of 20 
phenyl, phenyl monosubstituted with K, phenyl disub-
stituted with K, phenyl trisubstituted with K, naphthyl, 
naphthyl monosubstituted with K, naphthyl disubsti-
tuted with K, naphthyl trisubstituted with K, C1_10 alk-
enyl, c3-15 cyclized alkyl, cl-10 alkyl with a phenyl 25 
group attached to the cl-10 alkyl, c3-15 cyclized alkyl 
with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group monosubstituted with K, C1_10 
alkyl with an attached phenyl group disubstituted with 
K, C1 _10 alkyl with an attached phenyl group trisubsti- 30 
tuted with K, C3 _15 cyclized alkyl with an attached phe-
nyl group substituted with K, C1 _10 alkyl with a naphthyl 
group attached to the cl-10 alkyl, c3-15 cyclized alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group monosubstituted with K, C1_10 35 
alkyl with an attachednaphthyl group di substituted with 
K, C 1 _10 alky 1 with an attached naphthyl group trisubsti-
tuted with K, C3 _ 15 cyclized alky 1 with an attached naph-
thy l group substituted with K, C1 _10 alkyl with an 
attached2-furyl group, cl-10 alkyl withanattached3-fu- 40 
ryl group, cl-10 alkyl with an attached 2-pyridyl group, 
cl-10 alkyl with an attached 3-pyridyl group, cl-10 alkyl 
with an attached 4-pyridyl group, 2-furyl, 3-furyl, 2-py-
ridyl, 3-pyridyl, and 4-pyridyl; 
R7 is selected independently from the group consisting of 45 
phenyl, phenyl monosubstituted with K, phenyl disub-
stituted with K, phenyl trisubstituted with K, naphthyl, 
naphthyl monosubstituted with K, naphthyl disubsti-
tuted with K, naphthyl trisubstituted with K, C1 _10 alkyl, 
cl-10 alkenyl, c3-15 cyclized alkyl, cl-10 alkyl with a 50 
phenyl group attached to the cl-10 alkyl, c3-15 cyclized 
alkyl with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 
with an attached phenyl group disubstituted with K, 
cl-10 alkyl with an attached phenyl group trisubstituted 55 
with K, C3 _15 cyclized alkyl with an attached phenyl 
groupmonosubstituted withK, C3 _15 cyclizedalkyl with 
an attached phenyl group disubstituted with K, C3 _15 
cyclized alkyl with an attached phenyl group trisubsti-
tuted with K, C1 _10 alkyl with a naphthyl group attached 60 
to the cl-10 alkyl, c3-15 cyclized alkyl with an attached 
naphthyl group, C1_10 alkyl with an attached naphthyl 
group monosubstituted with K, C1_10 alkyl with an 
attached naphthyl group disubstituted with K, C1_10 
alkyl with an attached naphthyl group trisubstituted with 65 
K, C3 _15 cyclized alkyl with an attached naphthyl group 
monosubstituted with K, C3 _15 cyclized alkyl with an 
94 
attached naphthyl group disubstituted with K, C3 _15 
cyclized alkyl with an attached naphthyl group trisub-
stituted with K, C1_10 alkyl with an attached 2-furyl 
group, cl-10 alkyl with an attached 3-furyl group, cl-10 
alkyl with an attached 2-pyridyl group, C1 _10 alkyl with 
an attached 3-pyridyl group, and C1_10 alkyl with an 
attached 4-pyridyl group; 
T is selected independently from the group consisting of 
OH, OR10, NHR1 u and NR10R11 ; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the alpha-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, beta-alanine, norleucine, nor-
valine, alpha-aminobutanoic acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-C02H, alpha-aminoheptanoic 
acid, NH2-CH(CH2-l-naphthyl)-C02H, NH2---CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2CH2CH2-
phenyl)-C02H, NH2-CH(CH2-cyclohexyl)-C02H, 
NH2-CH(CH2-cyclopentyl)-C02H, NH2-CH(CH2-
cyclobutyl)-C02H, NH2---CH(CH2-cyclopropyl)-
C02H, trifluoroleucine, 4-fluorophenylalanine, lysine 
substituted on the epsilon nitrogen with a biotinyl group, 
hexafluoroleucine, and 
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and 
10 
R8 and R9 are selected independently from the group con-
sisting of H, C1 _10 alkyl, C1_10 alkenyl, C3_20 cyclized 
alkyl, cl-10 alkyl with a phenyl group attached to the 15 
cl-10 alkyl, cl-10 alkyl with two phenyl groups attached 
to the cl-10 alkyl, c3-20 cyclized alkyl with an attached 
phenyl group, phenyl, phenyl substituted with K, C1_10 
alkyl with an attached phenyl group substituted with K, 
cl-10 alkyl with an attached phenyl group disubstituted 20 
with K, C1 _10 alkyl with an attached phenyl group trisub-
stituted with K, C1_10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and substituted with Kon the 
phenyl group, cl-10 alkyl with two phenyl groups 
attached to the C1 _10 alkyl and disubstituted with K on 25 
the phenyl groups, c3-20 cyclized alkyl with an attached 
phenyl group substituted with K, C1 _10 alkyl with a mor-
pholine [-N(CH2CH2)0] ring attached through nitro-
gen to the alkyl, cl-10 alkyl with a piperidine ring 
attached through nitrogen to the alkyl, C1 _10 alkyl with a 30 
pyrrolidine ring attached through nitrogen to the alkyl, 
C1_20 alkyl with an OH group attached to the alkyl, 
--CH2CH2CH20CH3, C1_10 alkyl substituted by 
1-naphthyl, cl-10 alkyl substituted by 2-naphthyl, cl-10 
alkyl with an attached cyclohexyl group, -NH- 35 
CH2CH2-( 4-hydroxyphenyl), -NH-CH2CH2-(3-in-
dolyl), cl-10 alkyl with an attached 2-furyl group, cl-10 
alkyl with an attached 3-furyl group, C1 _10 alkyl with an 
attached 2-pyridyl group, C1 _10 alkyl with an attached 
3-pyridyl group, cl-10 alkyl with an attached 4-pyridyl 40 
group, and C1_5 alkyl with an attached phenyl and a 
hydroxyl attached to the cl-5 alkyl; 
R10 and R11 are selected independently from the group 
consisting of H, C1 _10 alkyl, phenyl, nitrophenyl, and 
cl-10 alkyl substituted with phenyl; 45 
or a pharmaceutically acceptable salt, pharmaceutically 
derivative, hydrate or solvate thereof. 
2. A compound according to claim 1 wherein: 
W is selected from the group consisting of hydrogen and 
halogen. 50 
3. A compound according to claim 2 wherein: 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the alpha-carbon selected from the 
group consisting of alanine, valine, leucine, isoleucine, 55 
praline, methionine, methionine sulfoxide, phenylala-
nine, tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine, norvaline, alpha-aminobutanoic acid, 60 
epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxy-
lic acid, 2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 0-eth-
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl- 65 
cysteine, NH2--CH(CH2CHEt2)-C02H, alpha-amino-
heptanoic acid, NH2--CH(CH2-l-naphthyl)-C02H, 
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NH2-CH(CH2-2-naphthyl)-C02H, NH2--CH 
(CH2CH2CH2-phenyl)-C02H, NH2-CH(CH2-cyclo-
hexyl)-C02H, NH2-CH(CH2-cyclopentyl)-C02H, 
NH2-CH(CH2-cyclobutyl)-C02H, NH2-CH(CH2-
cyclopropyl)-C02H, trifluoroleucine, 4-fluorophenyla-
lanine, lysine substituted on the epsilon nitrogen with a 
biotinyl group, hexafluoroleucine; 
R2 is selected from the group consisting of C1 _10 alkyl, 
cl-10 perfluoroalkyl, cl-10 alkyl substituted with Q, 
cl-10 alkyl substituted with phenyl, cl-10 alkyl with an 
attached phenyl substituted with K, C1_10 alkyl substi-
tuted with naphthyl, C1 _10 alkyl with an attached naph-
thyl substituted with K, phenyl, phenyl substituted with 
K, naphthyl, naphthyl substituted with K, C1 _10 alkyl 
substituted with CONH2, C1 _10 alkyl substituted with 
CONHR5, C1 _10 alkyl substituted with C02H, C1_10 
alkyl substituted with S02NH2, C1 _10 alkyl substituted-
with S03H, C1_10 alkyl substituted with C02R5, 
CH2CH2SCH3, CH2-3-indolyl, C1 _2 alkyl with an 
attached2-furyl, cl-2 alkyl withanattached3-furyl, cl-2 
alkyl with an attached 2-thienyl, C1 _2 alkyl with an 
attached 3-thienyl, cl-2 alkyl with an attached 2-furyl 
substituted with K, C1 _2 alkyl with an attached 3-furyl 
substituted with K, C1 _2 alkyl with an attached 2-thienyl 
substituted with K, C1 _2 alkyl with an attached 3-thienyl 
substituted with K, C1 _2 alkyl with an attached 2-furyl 
substituted with G, C1 _2 alkyl with an attached 3-furyl 
substituted with G, C1 _2 alkyl with an attached 2-thienyl 
substituted with G, C1 _2 alkyl with an attached 3-thienyl 
substituted with G, CH2-2-imidazyl, C1 _10 alkyl substi-
tuted with G, C1 _10 alkyl with an attached phenyl substi-
tuted with G, C1 _10 alkyl with an attached naphthyl sub-
stituted with G, phenyl substituted with G, and naphthyl 
substituted with G; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the alpha-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, beta-alanine, norleucine, nor-
valine, alpha-aminobutanoic acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-C02H, alpha-aminoheptanoic 
acid, NH2-CH(CH2-l-naphthyl)-C02H, NH2--CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2CH2CH2-
phenyl)-C02H, NH2-CH(CH2-cyclohexyl)-C02H, 
NH2-CH(CH2-cyclopentyl)-C02H, NH2-CH(CH2-
cyclobutyl)-C02H, NH2--CH(CH2-cyclopropyl)-
C02H, trifluoroleucine, 4-fluorophenylalanine, lysine 
substituted on the epsilon nitrogen with a biotinyl group, 
hexafluoroleucine. 
4. A compound according to claim 1 wherein: 
W is selected from the group consisting of hydrogen and 
halogen; 
R2 is selected from the group consisting of C1 _10 alkyl, 
cl-10 perfluoroalkyl, cl-10 alkyl substituted with Q, 
cl-10 alkyl substituted with phenyl, cl-10 alkyl with an 
attached phenyl substituted with K, C1_10 alkyl substi-
tuted with naphthyl, C1 _10 alkyl with an attached naph-
thyl substituted with K, phenyl, phenyl substituted with 
K, naphthyl, naphthyl substituted with K, C1 _10 alkyl 
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substituted with CONH2, C1 _10 alkyl substituted with 
CONHR5 , C1 _10 alkyl substituted with C02H, C1_10 
alkyl substituted with S02NH2, C1_10 alkyl substituted 
with S03 H, 2-furyl substituted with G, 3-furyl substi-
tuted with G, 2-thienyl substituted with G, 3-thienyl 5 
substituted with G, C1 _10 alkyl substituted with C02R5 , 
CH2CH2SCH3 , CH2-3-indolyl, C1 _2 alkyl with an 
attached 2-furyl substituted with K, C1_2 alkyl with an 
attached 3-furyl substituted with K, C1_2 alkyl with an 
attached 2-thienyl substituted with K, C1 _2 alkyl with an 10 
attached 3-thienyl substituted with K, C1 _2 alkyl with an 
attached 2-furyl substituted with G, C1_2 alkyl with an 
attached 3-furyl substituted with G, C1_2 alkyl with an 
attached 2-thienyl substituted with G, C1 _2 alkyl with an 
attached 3-thienyl substituted with G, CH2-2-imidazyl, 15 
C1_10 alkyl substituted with G, C1 _10 alkyl with an 
attached phenyl substituted with G, C1_10 alkyl with an 
attachednaphthyl substituted with G, phenyl substituted 
with G, and naphthyl substituted with G. 
5. A compound according to claim 4 wherein: 
AAv AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
20 
or no chirality at the alpha-carbon selected from the 
group consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenylala- 25 
nine, tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine, norvaline, alpha-aminobutanoic acid, 
epsilon-aminocaproic acid, citrulline, hydroxyproline, 30 
omithine, homoarginine, sarcosine, indoline 2-carboxy-
lic acid, 2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 0-eth-
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NH2-CH(CH2-cyclobutyl)-C02H, NH2-CH(CH2-
cyclopropyl)-C02H, trifluoroleucine, 4-fluorophenyla-
lanine, lysine substituted on the epsilon nitrogen with a 
biotinyl group, hexafluoroleucine; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the alpha-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, gly-
cine, serine, threonine, cysteine, tyrosine, asparagine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, beta-alanine, norleucine, nor-
valine, alpha-aminobutanoic acid, epsilon-aminocap-
roic acid, citrulline, hydroxyproline, omithine, 
homoarginine, sarcosine, indoline 2-carboxylic acid, 
2-azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylserine, 
S-methylcysteine, S-ethylcysteine, S-benzylcysteine, 
NH2-CH(CH2CHEt2)-C02H, alpha-aminoheptanoic 
acid, NH2-CH(CH2-l-naphthyl)-C02H, NH2---CH 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2CH2CH2-
phenyl)-C02H, NH2-CH(CH2-cyclohexyl)-C02H, 
NH2-CH(CH2-cyclopentyl)-C02H, NH2-CH(CH2-
cyclobutyl)-C02H, NH2---CH(CH2-cyclopropyl)-
C02H, trifluoroleucine, 4-fluorophenylalanine, lysine 
substituted on the epsilon nitrogen with a biotinyl group, 
hexafluoroleucine. 
6. The compound of claim 1, wherein each of the double 
bond carbons stereochemistry selected from the group con-
sisting of cis, trans, E, and Z. 
7. The composition of claim 1, wherein said composition is 
substantially sterochemically pure at each of the double 
bonds. 
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl- 8. The composition of claim 1, wherein said composition is 
cysteine, NH2---CH(CH2CHEt2)-C02H, alpha-amino- 35 a mixture of double bond isomers. 
heptanoic acid, NH2---CH(CH2-l-naphthyl)-C02H, 
NH2---CH(CH2-2-naphthyl)-C02H, NH2---CH 
(CH2CH2CH2-phenyl)-C02H, NH2-CH(CH2-cyclo-
hexyl)-C02H, NH2---CH(CH2-cyclopentyl)-C02H, 
9. The composition of claim 1, wherein said composition 
substantially comprises a single optical isomer. 
* * * * * 
